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Abstract
14-3-3 proteins are a family of small, acidic, scaffolding and adapter proteins, which have
been implicated in cell cycle regulation, apoptosis and signal transduction mechanisms.
There are seven isoforms of 14-3-3 (P, rp y, e, x/0, o and 'Q that form hetero- and
homodimers in vivo. Recently, 14-3-3 has been shown to associate with members of the
heptahelical, plasma membrane spanning G-protein coupled receptor (GPCR) superfamily.
GPCRs mediate neurotransmitter and other extracellular agonist-evoked activation of
intracellular effectors and signalling cascades. Some of these effector mechanisms lead to
the activation of phospholipase D (PLD). Mammalian PLD isoforms catalyse the hydrolysis
of phosphatidylcholine, forming choline and phosphatidic acid, a novel second messenger
molecule. 14-3-3 dimers associate with other proteins containing specific target motifs,
including an RSxpSxP motif (where pS is phosphoserine), or an unphosphorylated
WLDLE/DALDL motif. We recognised that the former motif is present in mammalian
PLD1 at residues 712-717 and therefore have investigated whether 14-3-3 isoforms
associate with PLD and GPCRs to provide a functional role in intracellular signalling. It was
shown, using in vitro GST-fusion protein pull-downs and co-immunoprecipitation that in
COS 7 cells, 14-3-3 associates with the M3 muscarinic receptor. 14-3-3 was also
demonstrated to associate with PLD1, and to a lesser extent PLD2, in an isoform-dependent
manner. The effect of PLD activation by protein kinase C (PKC) on this interaction was
investigated using the aforementioned techniques and confocal microscopy. Furthermore, in
whole cell signalling assays, the overexpression of different 14-3-3 isoforms selectively
modified PKC or GPCR-mediated activation of PLD. In addition, PLD was found to
physically associate with the M3 receptor. The implications of these interactions for
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Regulation of many biological processes depends on cellular recognition of the external
environment and the generation of an appropriate response. Cell surface receptors play an
important role in transducing this external information into intracellular signals. The cell
surface receptors can be divided into superfamilies, depending on the mechanism of signal
transduction. Amongst these are ionotropic ligand-gated ion channels, G protein-coupled
receptors and receptor tyrosine kinases. Over 50% of current therapeutic drugs act on
members of the G protein-coupled receptor superfamily (Archer et al., 2003; Karnik et al.,
2003) and they remain a very important pharmacological target.
The G protein-coupled receptor
The G protein-coupled receptor (GPCR) superfamily is the largest family of the cell surface
receptors and amongst the largest families of proteins in the human genome, comprising of
more than 700 gene products (Lander et al., 2001; Venter et al., 2001). The G protein-
coupled receptor itself remains one of the most important pharmacological targets for drug
design, however the continual process of elucidating novel effectors has yielded ever more
complexity for understanding the full range of specific signalling events that can be
regulated by these receptors. All GPCRs are integral membrane proteins that have a similar
architecture consisting of an extracellular amino terminal domain, a seven a-helix plasma
membrane-spanning domain, three extracellular and three intracellular loops and
terminating at an intracellular carboxy-tail domain (Figure 1.1) (Dohlman et al., 1987;
Baldwin, 1993). The template for determining the structural aspects of G protein-coupled
receptor topology was originally based on nuclear magnetic resonance (NMR) data, electron
cryo-microscopy and crystal structure of the transmembrane spanning archaebacterial
proton pump, bacteriorhodopsin, from Halobacterium halobium (Henderson and Unwin,
1975; Hayward and Stroud, 1981; Spohn and Kimmich, 1983; Frankel and Forsyth, 1985;
Lewis etal., 1985; Pebay-Peyroula et al., 1997). Areas of sequence similarity between
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bacteriorhodopsin and other GPCRs were found to exist within the seven transmembrane
spanning a-helices of bacteriorhodopsin and suggested that GPCRs probably had a similar
structural topology, with the presence of a seven transmembrane spanning domain (Findlay
and Eliopoulos, 1990; Henderson and Schertler, 1990; Pardo et al., 1992). Refinements in
the structural analysis of GPCR topology were made using the abundant photoreceptor of
the rod cells in the eye, rhodopsin (Daemen, 1978; Findlay et al., 1981; Argos etal., 1982;
Findlay et al., 1984; Dratz et al., 1985; Longstaff et al., 1986). Rhodopsin, used as a
prototypical GPCR, coupled with further developments allowed by the increasing power of
computational modelling and continuing biochemical and molecular biology studies,
yielded a high level of information regarding the structural characteristics and possible
structure-function relationships that exist with signalling mechanisms of other GPCRs
(Dixon et al., 1986; Kubo et al., 1986; Peralta et al., 1987b; Henderson and Schertler, 1990;
Hollenberg, 1991; Hargrave and McDowell, 1992; Baldwin, 1993; Donnelly et al., 1994;
Unger et al., 1997). The inactivated (11 -cA-retinal) rhodopsin photoreceptor was solved by
X-ray crystallography in 2000 (Palczewski et al., 2000) and the structure appeared to verify
alternative experimental and modelling methods that had been used to determine the nature
of GPCR structure-function relationships (Baldwin, 1993; Farahbakhsh et al., 1995; Unger
et al., 1997; Karnik et al., 2003). The seven transmembrane spanning a-helices are
organised in an anticlockwise bundle (visualised from the extracellular side), the third
transmembrane spanning helix is almost central to the bundle and changes orientation from
the extracellular to the intracellular side of the membrane. Furthermore, an amphipathic a-
helix, parallel to the plane of the membrane was identified distal to the seventh
transmembrane spanning a-helix (and correlates to the i4 region), which may be important






The topology of a typical G protein-coupled receptor.
A two dimensional diagram of the topology of a generic G protein-coupled receptor (GPCR)
(purple) bounded by lipid groups of the plasma membrane (red). The extracellular amino-
terminal domain, seven transmembrane spanning domain and intracellular carboxy-terminal
tail domain are shown, along with the three intracellular (il-3) and extracellular (el-3) loops
(with disulphide bridge between the third membrane spanning helix and the second
extracellular loop). The palmitoylation of the tail (present on most GPCRs) causes a pseudo
fourth intracellular loop (sometimes referred to as i4), which is made up of a short a-helix,
orientated parallel to the plasma membrane in rhodopsin. In the folded protein, the




The crystal structure of rhodopsin, a template for the G-protein coupled receptor.
The solved crystal structure for the seven transmembrane spanning helices of the rhodopsin
hepatahelical receptor at 2.6 A resolution shown in ribbon form, from the side (A) and from
the extracellular (B) views (Berman et al., 2000; Okada et al., 2002). The peptide chain is
rainbow colour coded, from the blue N-terminus to the red C-terminus. The seven
transmembrane anticlockwise a-helix bundle is apparent (with helices labelled HI-7), as is
the extracellular amino- and intracellular carboxy-terminal domains (with the additional
amphipathic a-helix (H8) parallel to the plane of the membrane). The change of orientation
of the third transmembrane helix (from the extracellular (top) to the intracellular (bottom)
surface) is also apparent.
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Classification of the GPCR superfamily has been attempted using a number of
different phylogenetic and structural categorisations (Donnelly et al., 1994; Kolakowski,
1994; Fredriksson et al., 2003). This task has been made more efficient with the sequencing
of the human genome, as all the gene products encoding GPCRs have been determined
(Lander et al., 2001; Venter et al., 2001). The original nomenclature of receptor classes (A-
F) includes those receptors from many different types of organisms (Kolakowski, 1994). An
alternative, recent classification is based on the GRAFS family system (Fredriksson et al.,
2003; Karnik et al., 2003). This system includes only those GPCRs from the human genome
and, like the class categorisations, compares homology of the transmembrane spanning
domains of the GPCRs to determine a dendrogram of the most related receptors. This yields
five main families of GPCRs within the human genome and these are discussed below.
Although all of the families have a similar structural topology and nearly all of the receptors
within each class have been shown to couple to heterotrimeric G proteins, they each share
relatively little sequence similarity to each of the other families of GPCRs (Foord, 2002).
For convenience, both the original mammalian classes and the human GRAFS family
nomenclature are provided.
The rhodopsin-like receptors
The rhodopsin-like (family R, or class A) receptors are closely related in homology to the
photon receptor, rhodopsin (Dixon et al., 1986), they are the largest class of GPCRs
(Fredriksson et al., 2003) and have been the most widely studied. The rhodopsin-like
receptors number around 700 (241 non-olfactory) in humans, have been further subdivided
into four major groups and comprise of many subfamilies including the olfactory (group 6),
biogenic amine, prostanoid and cannabinoid receptors (group a), endothelin and
neuropeptide Y (group |3) and opioid and somatostatin receptors (group y) (Dixon et al.,
1986; Kubo et al., 1986; Strange, 1993;Drutel et al., 1995; Narumiya and FitzGerald, 2001;
Foord, 2002; Ronnett and Moon, 2002; Fredriksson et al., 2003). The bovine rhodopsin
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receptor was fully sequenced and cloned in 1983 (Nathans and Hogness, 1983), following
previous sequence analysis of parts of the protein (Hargrave, 1977; Hargrave and Fong,
1977; Pellicone et al., 1981). The sequence of the human form of the rhodopsin receptor
followed in the following year (Nathans and Hogness, 1984). The ligand-activated (3-
adrenergic receptor was cloned in 1986 by Dixon and colleagues and it appeared to bear
structural homology with the rhodopsin photoreceptor (and implied that a number of other
cell surface receptors may also have similar features) (Dixon et al., 1986). Since the cloning
of the rhodopsin and p-adrenergic receptor, many GPCRs and their splice variants have
been characterised from their gene products. The most extensively studied of the rhodopsin-
like GPCRs are the subfamilies of the biogenic amine receptors - the adrenergic receptor (a
and p adrenenoceptors) (Lefkowitz et al., 1976; Lefkowitz et al., 1981; Dixon et al., 1986),
the muscarinic acetylcholine receptors (M receptors) (Kubo et al., 1986; Bonner et al.,
1987), the dopamine receptors (D receptors) (Strange, 1993) and the 5-hydroxytryptamine
(5-HT) receptors (Hoyer et al., 1994; Hoyer et al., 2002).
All rhodopsin-like receptors contain highly conserved regions within their structure.
These include a disulphide bridge, found in nearly all GPCRs, formed by cysteine residues
that link the second extracellular loop to the third transmembrane spanning helix (Pedersen
and Ross, 1985; Dixon et al., 1987; Karnik and Khorana, 1990; Schertler et al., 1993).
There is a conserved Asp-Arg-Tyr (DRY) motif at the intracellular junction of the third
transmembrane helix, which has been proposed to be involved in the efficient coupling of
the GPCR to the heterotrimeric G proteins. Mutations in these residues have been shown to
constitutively activate the signalling by the a,- and p2-adrenergic receptor (Scheer et al.,
1996; Rasmussen et al., 1999), the A3 adenosine receptor (Chen et al., 2001) and the GnRH
receptor (Arora et al., 1997). However, a conflicting report has indicated that mutation of
the arginine in the DRY motif of the p2-adrenergic receptor does not affect activity (Seibold
et al., 1998). In addition a conserved NPxxY motif at the distal end of the seventh
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transmembrane spanning helix has been shown to be involved with the GPCR activation of
the small G proteins ARF and Rho (Mitchell et al., 1998) and may be necessary for the
activation of the Gq heterotrimeric G proteins in the stimulation of PLC activity (Gales et
al., 2000). The NPxxY domain has also been demonstrated to be important for efficient
internalisation of some GPCRs such as the 6-opioid receptor (Kramer et al., 2000), the type
II vasopressin receptor (Bouley et al., 2003), the bradykinin receptor (Kalatskaya et al.,
2004) and the formyl-peptide receptor (Gripentrog et al., 2000; He et al., 2001), but not for
others such as the angiotensin II type 1 receptor (Thomas et al., 1995; Hunyady et al.,
2000). Furthermore, the side chains of the amino acids on the internal face of the
transmembrane spanning domain have been shown to be important for providing selectivity
of ligand binding. Amongst these is an aspartate residue in the third transmembrane
spanning helix (at position 113 in the p2-adrenergic receptor and position 148 in the M3
receptor) that is conserved within the biogenic amine liganded GPCRs and which is thought
to coordinate an important ionic interaction with the nitrogen of the ligands (Dixon et al.,
1987; Strader et al., 1987; Strader et al., 1988;Matsui et al., 1989; Strader et al., 1989b).
Moreover, amine GPCRs also have conserved serine or threonine residues in the helix
barrel, which potentially coordinate the hydroxyl groups of the aromatic ring of the ligand
(Strader et al., 1989a; Wess et al., 1991). There is a conserved proline residue, present in the
fourth transmembrane spanning helix, which has also been demonstrated to be important for
high affinity ligand binding of the M3 receptor (Wess et al., 1993). Antagonists are thought
to coordinate to some of the residues involved in agonist binding, but not to some critical
residues involved in receptor activation (Wess et al., 1991). The peptide receptors have a
larger extracellular amino-terminal domain, which is thought to coordinate additional
interactions with the larger peptide agonists (especially on the third extracellular loop),
however the residues within the transmembrane domain remain very important for ligand
binding (Bhogal et al., 1994; Schwartz, 1994).
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It has been demonstrated that the second and third intracellular loop and carboxy-
terminal tail domains in many GPCRs are necessary for coupling to the specific
heterotrimeric G proteins (Strader et al., 1989b; Wess et al., 1990; Wu et al., 2000) and
small G proteins (Robertson et al., 2001). Regions of the third intracellular loop and
carboxy-terminal tail domains have also been shown to be phosphorylated (and
desensitised) by G protein receptor kinases and bind the internalising arrestin proteins (see
below) (Lohse et al., 1990; Freedman and Lefkowitz, 1996; Krupnick et al., 1997b; Wu et
al., 1997; Pitcher et al., 1998). In addition, there is a cysteine residue in the carboxy-
terminal domain of many GPCRs that is palmitoylated and which may thereby cause the
formation of a pseudo fourth intracellular loop (involving the amphipathic a-helix that was
determined by X-ray crystallography) (Wess, 1998; Palczewski et al., 2000).
The secretin-like receptors
The secretin-like (family S, or class B) G protein-coupled receptors have 15 members that
all bind large peptides and include the families of the secretin, corticotrophin releasing
factor (CRF), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating
polypeptide (PACAP) receptors (Christophe et al., 1988; Lutz et al., 1993; Morrow et al.,
1993; Spengler et al., 1993; Foord et al., 2002). The receptors are characterised by a large
extracellular amino-terminal domain, which contains a number of conserved residues
including a series of cysteine residues thought to form important structurally stabilising
disulphide bonds with the extracellular loop domains (Gaudin et al., 1995). Site-directed
mutagenesis and chimaeric receptor studies have demonstrated that regions involving both
the transmembrane spanning domain (similarly to the rhodopsin-like GPCRs) and the
extracellular loop domains contribute to coordinating high affinity ligand binding to the
larger peptide agonists (Di Paolo et al., 1999; Unson et al., 2002). Most members of the
secretin family have a basic residue followed by a conserved aspartate at the junction
between the second transmembrane spanning helix and the proximal region of the first
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extracellular loop region and these residues have been shown to be important for ligand
binding to the VPAC receptors (Solano et al., 2001; Vertongen et al., 2001; Langer et al.,
2003). In addition, some of the conserved cysteine residues of the extracellular domains
have also been shown to be important for ligand binding (Gaudin et al., 1995; Harmar,
2001; Unson et al., 2002). A model of the peptide agonist binding mechanism has been
proposed in the case of the glucagon and glucagon-like peptide 1 receptor (GLP-1) that
identifies the GPCR transmembrane spanning regions as important for coordinating the
amino-terminal domain of the peptide agonist, with the amino-terminal domain and
extracellular loops of the receptor being responsible for coordinating the central and
carboxy-terminal regions of the peptide (Gourlet et al., 1996; Al-Sabah and Donnelly, 2003;
Runge et al., 2003). This has been further substantiated by NMR spectrometry data from the
N-terminal domain of the corticotrophin-releasing factor (CRF) receptor (Grace et al.,
2004).
The regions of the receptor involved in coupling to the heterotrimeric G proteins
have been demonstrated to involve the intracellular loop and carboxy-terminal tail domains
in a similar way to the rhodopsin-like GPCRs, however the second intracellular loop may be
more important then the third (Chicchi et al., 1997; Cypess et al., 1999). There is also
proposed to be an equivalent motif to the DRY region, the conserved YL residues,
mutations of which were shown to alter G protein activation by the VPAC1 receptor (Tarns
et al., 2001). One interesting aspect of the secretin-like GPCRs' signalling mechanisms is
that all the receptors appear to preferentially couple to the Gs heterotrimeric G protein
family to activate adenylate cyclase and increase intracellular cAMP, however many can
also couple to other family heterotrimeric G proteins (to activate phospholipase C, for
example) (Harmar, 2001). Furthermore, the receptors recruit G protein-receptor kinases and
arrestin proteins in a similar way to rhodopsin-like GPCRs to desensitise the agonist-
stimulated signalling (Shetzline et al., 1998).
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The metabotropic glutamate-like receptors
The glutamate-like (family G, or class C) receptors have 15 members and include the
metabotropic glutamate receptor (mGluR) family, the metabotropic GABAb receptors, Ca2+
sensing receptors, pheromone and group-1 taste receptors (Houamed et al., 1991; Masu et
al., 1991; Conn and Pin, 1997; Kaupmann et al., 1997; Couve et al., 2000; Pin et al., 2003).
These GPCRs are characterised by a very large extracellular amino-terminal (Desai et al.,
1995). The amino-terminal contains a conserved Venus Flytrap Module (VFTM) used for
ligand recognition (O'Hara et al., 1993; Takahashi et al., 1993; Tones et al., 1995) and (in
all except the GABAb receptor) a conserved cysteine rich domain that connects the VFTM
to the transmembrane spanning domain (Pin et al., 2003). The VFTM domain shares
sequence similarity with a family of small molecule-binding bacterial periplasmic transport
proteins (O'Hara et al., 1993), and it has been proposed that the family G GPCRs may have
evolved from the fusion of an ancestral seven transmembrane receptor with one of these
periplasmic proteins (Felder et al., 1999; Pin et al., 2003). The Venus Flytrap Module is so
called because it is composed of two regions (or lobes) each composed of a p-sheet
surrounded by two a-helices, separated by three linkers, which form a cleft into which the
ligand binds (Sack et al., 1989; Galvez et al., 1999; Kunishima et al., 2000). These lobes
can be found in an open or closed conformation with an equilibrium constant that favours
the open state when the receptor is unliganded and therefore the closed state is stabilised
when ligand is bound (Parmentier et al., 2002). It is thought that part of the mechanism of
competitive antagonist ligands may be due to the interference with efficient closure of the
VFTM lobes (Costantino and Pellicciari, 1996).
The family G receptors were the first GPCRs to be shown to form functional dimers
in vivo (which has been reproduced subsequently for a number of other family GPCRs)
(Romano et al., 1996; Robbins et al., 1999; Milligan et al., 2003). Whilst mGluR and Ca2+
sensing receptors form homodimers, GABAb and taste receptors form heterodimers for full
agonist activation (Romano et al., 1996; Kuner et al., 1999; Kunishima et al., 2000; Pin et
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al., 2003). Dimerisation of the receptors has been shown to involve the VFTM domains
(formed by a disulphide bridge and a hydrophobic interaction), a putative transmembrane
interaction and the carboxy-terminal tail domains (Bai et al., 1998; Ray et al., 1999;
Robbins et al., 1999; Ray and Hauschild, 2000; Tsuji et al., 2000). It has been determined
that the receptors do not require two agonist molecules to bind to elicit activation (Galvez et
al., 2000), however X-ray crystallography data of the N-terminal domain suggests that the
active state of the receptor may be more stable when the VFTM lobes of both receptors in
the dimer are closed (Kunishima et al., 2000; Pin et al., 2003). Furthermore, the GPCR
dimer does not appear to activate more than one heterotrimeric G protein at any time
(however, the functional dimer is still required for G protein coupling) (Galvez et al., 2001;
Pin et al., 2003).
The frizzled, adhesion and other G protein-coupled receptors
The family F receptors have 24 members and are comprised of the frizzled/smoothened
receptors and the group-2 taste receptors. These receptors have short conserved sequences in
transmembrane helices 2, 5 and 7 (Fredriksson et al., 2003). The frizzled receptors control
cell proliferation and polarity during metazoan development by binding secreted
glycoproteins known as Wnts (Fredriksson et al., 2003). Although they may all be GPCRs,
only a few of the members have been shown to couple to heterotrimeric G proteins and they
may be constitutively active (Foord et al., 2002). These receptors, along with the family A
receptors, were previously classified as belonging to the secretin-like receptors (Harmar,
2001; Foord et al., 2002), however the GRAFS system determines that they have their own
functional classification (Fredriksson et al., 2003).
The family A receptors (24 members) are made up of the adhesion receptors (or
latrophilins), which are receptors that have the typical transmembrane spanning domain
coupled to an amino-terminal domain that contains a functional adhesion-like motif, such as
the EGF repeat motif or a mucin-like motif (Fredriksson et al., 2003). The amino-terminal
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domains are vastly different in size, ranging from 200 residues up to 2800 residues in the
case of the very large G protein coupled receptors (VLGRs) (Foord et al., 2002). Functional
activities associated with these receptors include the definition of cell polarity, inhibition of
angiogenesis and regulation of the immune system. In addition, some members are allosteric
receptors for a-latrotoxin (venom from the black widow spider Latrodectus mactans), a
powerful secretagogue for insulin (Holz et al., 2000).
Heterotrimeric G protein signalling cascades
The signalling by GPCRs has traditionally focused on the heterotrimeric G protein
signalling pathway as the main mechanism for intracellular second messenger activation.
The mechanism of a guanine nucleotide dependent protein acting as an intermediary
transducer between the GPCR and the activation of intracellular effectors was originally
proposed by Rodbell and colleagues (Rodbell et al., 1971). The involvement of a signal
transducing GTPase was verified by Limbird and colleagues when they demonstrated that
cholera toxin could specifically ADP-ribosylate (and thereby block) a GTPase activity
required for the (3-adrenergic receptor-dependent activation of adenylate cyclase (Limbird et
al., 1979; Limbird et al., 1980; Stadel et al., 1981). It is now accepted that nearly all GPCRs
(except for some orphan or family F receptors, see above) couple directly through a
heterotrimeric G protein to activate or modulate intracellular effectors (Stadel et al., 1981;
Blackmore et al., 1985; Bourne and Sullivan, 1986; Sullivan et al., 1986; Bourne et al.,
1987).
The G proteins are made up of a trimer of Ga (~41 kDa), G|3 (~35 kDa) and Gy
(~10 kDa) subunits (Baehr et al., 1982; Northup et al., 1983; Gilman, 1984). The py
subunits are tightly bound, extremely stable and are consequently regarded as a single
functional unit. Currently there are thought to be around twenty gene products encoding Ga
subunits, five encoding Gp and thirteen encoding Gy (Venter et al., 2001). The number of
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various possible subunit combinations is potentially very large and this combinatorial
characteristic may yield part of the regulation that is necessary for the specificity of second
messenger coupling and activation. The Gy subunit displays the lowest homology between
the isoforms and is acylated at the carboxy-terminal to provide interaction with the lipid
membrane. The G(3 subunit structure is dominated by the presence of a p-propeller domain
and associates with the Gy subunit via a coiled-coil interaction (Morris and Malbon, 1999).
The Ga subunits are composed of two main domains - a Ras-like GTPase domain that is
important for GTPase activity, connected to a helical domain that may be important for
effector coupling (Liu and Northup, 1998). The GDP/GTP is bound at the interface of the
two domains and a change in conformation at three additional switch regions, which are
contacted by the Gpy subunit, allows GTP/GDP exchange (Morris and Malbon, 1999).
The heterotrimeric G protein family nomenclature is based upon the types of second
messenger pathways that the Ga subunits of the G proteins couple to and they can be
classified (at least in part) into four main families; Gs, Gi, Gq and G12 (see below). It was
traditionally thought that the a-subunits of the G protein could exclusively regulate their
downstream effectors and the original family nomenclature arose with this caveat. However,
in 1987, Logothetis and colleagues demonstrated that exogenous application of the G|3y
subunit to excised patch clamped atrial membranes caused activation of the muscarinic K+
current, which is present in the heart (Logothetis et al., 1987). Subsequently G|3y subunits
have been shown to couple to other intracellular effectors such as PLC(f2-3 (Smrcka and
Sternweis, 1993; Haga et al., 1994; Luttrell et al., 1995; Pumiglia et al., 1995) as well as to
many ion channels (Penington et al., 1993; Krapivinsky et al., 1995; Herlitze et al., 1996;
Ikeda, 1996), demonstrating the importance of both the Ga and G|3y subunits for signal
transduction. Furthermore, specificity of Gf5y coupling to the G protein-coupled inwardly-
rectifying K+ channels has been shown to be dependent on the Gp subunit type, with pi-4
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being able to activate the K channel and (35 (and Ga subunits) coupling to inhibit the
channel (Lei et al., 2003).
The Gs heterotrimeric G protein family includes the Gas and Gaolf G proteins. The
Gs G protein was the first one characterised by Limbird and colleagues and has been
demonstrated to stimulate adenylate cyclase, which catalyses the formation of the second
messenger, cAMP, from ATP (Lefkowitz et al., 1976; Limbird et al., 1980; Sullivan et al.,
1986). An increase in cAMP levels subsequently activates protein kinase A to mediate other
intracellular effects (Miyamoto et al., 1968; Robison et al., 1968; Walsh et al., 1968).
Furthermore, the Gs family G proteins have been shown to close K+ channels (probably via
a cAMP-dependent mechanism) (Madison and Nicoll, 1986; Pedarzani and Storm, 1995)
and open cardiac L-type Ca2+ channels (mediated by a direct coupling of G(3y subunits to the
channel) (Fisher and Johnston, 1990). The hydrolysis of GTP to GDP by the dissociated
Gas subunit can be specifically blocked by ADP-ribosylation of the subunit by the bacterial
cholera toxin from Vibrio cholerae. Cholera toxin transfers the ADP-ribose group from
nicotinamide adenine dinucleotide (NAD+) to an arginine residue at position 178 on the Ga
subunit (Hsia et al., 1985). This permanently activates the G protein and it cannot hydrolyse
the bound GTP.
The Gi/o family comprises the Gai,.3, the brain specific Gaoa_b, Gaz and the
photoreceptor Gat (transducin) G proteins (Morris and Malbon, 1999). The Gai/o subunits
act to inhibit adenylate cyclase and reduce the intracellular cAMP levels (Sullivan et al.,
1986; Yatani et al., 1988). The Gi/o family act to open the G protein-coupled inwardly-
rectifying K+ channels (GIRK) and close neuronal N-type Ca2+ channels by direct G(3y
coupling (Logothetis et al., 1987; Penington et al., 1993; Krapivinsky et al., 1995; Oh et al.,
1995; Herlitze et al., 1996; Ikeda, 1996). Transducin (Gat) acts to activate cGMP
phosphodiesterase, which is the main effector mechanism in photoreceptor transduction
(Morris and Malbon, 1999). With the exception of Gz (about which very little is known),
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Gai/o subunits can be specifically inhibited by the action of pertussis toxin from Bordatella
pertussis, which transfers the ADP-ribose group from NAD+ to a cysteine residue at position
350 on the Ga subunit to prevent the GDP/GTP exchange upon G protein activation (Hsia
etal., 1985).
The pertussis toxin insensitive Gq/11 family is comprised of the Gaq, Gal 1 and
Gal4-16 G proteins (Morris and Malbon, 1999). They can activate the beta isozymes of
phospholipase C (PLCpi-4), which hydrolyse phosphatidylinositol bisphosphate (PIP2) to
form the second messengers diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3
activates intracellular ionotropic IP3 receptors on the endoplasmic reticulum to release the
intracellular store of Ca2+ (Mak et al., 1998). DAG directly activates protein kinase C, which
phosphorylates many intracellular targets and can activate phospholipase D (Merritt et al.,
1986; Gierschik and Jakobs, 1987; Taylor et al., 1991;Hammond etal., 1997).
Furthermore, the Gq/11 G protein family has been shown to modulate a novel K+ current
(Shi et al., 2004) in addition to inhibiting the established GIRK current (Hill and Peralta,
2001).
The G12/13 family (G12 and G13) has been shown to couple to small G proteins
via interactions with the Rho guanine nucleotide exchange factor (p 115RhoGEF), a GTPase
activating protein (GAP) for the small G protein Rho (Jiang et al., 1998; Kozasa et al.,
1998). G12 G proteins can couple to (and activate) PLD, which may be dependent on Rho
activity (Rumenapp et al., 2001). They interact with the cytoskeletal proteins HSP90 and
radixin (Vaiskunaite et al., 2000; Waheed and Jones, 2002) and they have been shown to
activate the non-receptor Bruton's tyrosine kinase (Jiang et al., 1998; Kurose, 2003).
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GPCR-mediated activation ofheterotrimeric G proteins
One popular (and probably oversimplified) model for GPCR mediated stimulation is that an
agonist binds to the receptor, within the pocket formed by the transmembrane domain
(rhodopsin-like) or at the extracellular amino terminal domain (for other family GPCRs)
(Dixon et al., 1987; Strader et al., 1987; Matsui et al., 1989; Strader et al., 1989b). The
binding of agonist appears to elicit a conformational change within the receptor, probably
involving movement of the second, third or sixth transmembrane helices relative to the other
helices within the bundle (Farahbakhsh et al., 1995; Karnik et al., 2003; Miura et al., 2003).
Prevention of the helical movement in rhodopsin by artificial disulphide linkage and Zn2+
cross linkage has been demonstrated to inhibit activation of the receptor (Farrens et al.,
1996; Sheikh et al., 1996). The helix movement is thought to involve an opening and
unmasking of important residues on the intracellular surface, probably at the base of the
third, sixth or seventh transmembrane helices (Abdulaev and Ridge, 1998; Ballesteros et al.,
2001). This allows the amino-terminal helix and carboxy-terminal domains of the Ga
protein subunit (Blahos et al., 2001), to bind the agonist occupied activated receptor at the
third intracellular loop or tail domains (Limbird et al., 1980; Strader et al., 1989b; Wu et al.,
1998; El Far et al., 2001). The Ga subunit of the G protein undergoes a conformational
change, probably involving the switch region or a destabilisation of the amino-terminal
helix (Lambright et al., 1996; Remmers et al., 1999; Yeagle and Albert, 2003) and the GDP
that is bound to the trimer is exchanged for GTP. This GTP exchange in the switch region
(which contacts the G(3y subunits) causes the G protein to dissociate into the a and Py forms
that couple to intracellular effectors to activate or modulate signalling pathways (Limbird et
al., 1980; Stadel et al., 1981; Logothetis et al., 1987). The a-subunit, which has an intrinsic
GTPase activity, hydrolyses GTP back to GDP, the G protein is inactivated and it re-
associates (Bohm et al., 1997; Strange, 1999). This simple view of the transient activation
of the heterotrimeric G protein by GPCRs has been complicated somewhat by the
demonstration that heterotrimeric G proteins can bind unliganded GPCRs and that
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intracellular effectors can be co-immunoprecipitated with GPCRs as a complex (Chidiac,
1998; Lachance et al., 1999). It is apparent, therefore, that the activation mechanism of G
proteins by GPCRs is a subtle and complex process that deserves continuing attention.
The M3 muscarinic G protein-coupled receptor
The parasympathetic nervous system utilises the endogenous neurotransmitter acetylcholine
to elicit various effects in the central nervous system and peripheral tissues. Examples of
parasympathetic stimulation include a reduction in heart rate and force of contraction, the
stimulation of gastric acid and glandular secretion, the contraction of visceral smooth
muscle, the contraction of the ciliary body within the eye and an indirect relaxation of
vascular smooth muscle tone (due to the co-transmission of nitric oxide) (Kayaalp and
Turker, 1969; Carrow et al., 1975; Kowalewski et al., 1975; Lonnerholm and Widerlov,
1975; Sarna and Daniel, 1975).
The physiological effects of the muscarinic agonist muscarine (from the mushroom
Amanita muscaria) and antagonist atropine (from the Deadly Nightshade Atropa
belladonna) have been recognised for many years (Ford, 1909; Dale, 1914). More recent
pharmacological studies on the mechanism of muscarinic receptor signalling indicated that
there were a number of different subtypes within the family, as the inhibition of adenylate
cyclase and the hydrolysis of phosphoinositides, coupled with different ligand dissociation
constants, were observed in the activation of various muscarinic-type receptors (Haga et al.,
1985; Kubo et al., 1986; Bonner et al., 1987; Fukuda et al., 1987; Peralta et al., 1987a). The
muscarinic receptor family was subsequently determined to comprise of five subtypes,
which were named according to their chronological characterisation (Kubo et al., 1986;
Bonner et al., 1987; Bonner, 1989). The M1; M3 and M5 receptors all couple to Gq/11 family
G proteins and elicit activation of phospholipase C leading to downstream activation of
protein kinase C (PKC) and an increase in intracellular Ca2+ concentration (Jones and
Michel], 1974; Bonner, 1989; Buckley et al., 1989). The M2 and M4 receptors couple
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through Gi/o family G proteins to inhibit adenylate cylase (Haga et al., 1985; Bonner,
1989). They also elicit an inward rectifying K+ current, activated by the G(3y subunits
(Bunemann and Hosey, 2001). The M3 receptor can also signal to activate phospholipase D
via an additional pertussis toxin insensitive G12 activation in some cell types, rather than
the Gq dependent PKC-mediated PLD activation (Singer et al., 1996; Mitchell et al., 1998;
Rumenapp et al., 2001).
The M3 muscarinic G protein-coupled receptor was first cloned in 1987 (Bonner et
al., 1987; Peralta et al., 1987a). It is found widely distributed in neuronal cells and in the
central nervous system (CNS), as well as in the peripheral ganglia, in visceral and vascular
smooth muscle, exocrine glands and the ciliary body of the eye (Doods et al., 1994; Levey
etal., 1994; de la Vega et al., 1996; Zhang, 1996; Hoglund and Baghdoyan, 1997; Lau and
Pennefather, 1998; Masuda et al., 1998). The human M3 receptor is 590 amino acids in
length (approximately 66 kDa in size) and, like most rhodopsin-like GPCRs, contains a
number of N-linked glycosylation sites on asparagine residues at positions 5, 6, 15 and 41 in
the extracellular amino-terminal domain. Cysteine residues at positions 141 and 221 form
the disulphide bridge present in nearly all GPCRs and the receptor is palmitoylated on
cysteine residues 561 and 563 in the intracellular carboxy-terminal tail domain (Peralta et
al., 1987b; Bonner, 1989). Mutagenesis and modelling studies have demonstrated that the
acetylcholine ligand binding site is probably formed by multiple tyrosine and threonine
residues within the transmembrane domain a-helices (TM), which coordinate to provide a
binding pocket on the internal face of the a-helix barrel. This ligand binding domain
involves the conserved Asp-148, which coordinates the protonated nitrogen of acetyl¬
choline, Tyr-149 in TM3, Thr-232 and Thr-235 in TM5, Tyr-507 in TM6 and Tyr-530 and
Tyr-534 in TM7, mutations of which were not shown to appreciably affect receptor
expression or G protein coupling, but reduced the agonist binding affinity (Wess et al.,
1991; Wess, 1993). A proline residue (201) in TM4, which does not appear to interact with
the ligand, is also thought to be necessary for binding (Wess et al., 1991; Wess, 1993). The
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M3 receptor has an unusually long third intracellular loop (i3) of approximately 239 amino
acids (R253-Q491). The heterotrimeric G protein subunit GPy interacts at a domain
determined to be in the i3 region at residues 289-330 and the phosphorylation by G protein-
coupled receptor kinase (GRK) putatively occurs at residues 331-333 and 348-352 (Wu et
al., 2000), although this phosphorylation may not be necessary for intemalisation (Shockley
et al., 1999; Budd et al., 2000). The small G protein ADP-ribosylation factor (ARF) also
associates with the muscarinic receptor at the third intracellular loop (Robertson et al., 2001;
Mitchell et al., 2003).
Receptor desensitisation and endocytosis
The stimulation of intracellular effectors by G protein-coupled receptors can often be
measured within seconds (Yang et al., 1967; Mukherjee et al., 1975; Cockcroft, 1984). So
that the activation of effectors by the receptors is attenuated despite the continued presence
of agonist, a number of negative feedback mechanisms exist to 'switch off' the signal
provided by the activation of the GPCR and G protein.
One of the most important mechanisms by which the receptor signalling is
attenuated is by the agonist-dependent uncoupling of the G protein (desensitisation) and
subsequent endocytosis of the receptor away from the plasma membrane (internalisation or
sequestration). This process often begins with the specific phosphorylation of the receptor,
at a site rich in serine and threonine residues, often within the carboxy-terminal tail domain
or the third intracellular loop on most GPCR types (Dohlman et al., 1987; Leeb-Lundberg et
al., 1987; Krupnick and Benovic, 1998). This phosphorylation can be mediated by a
member of the G protein receptor kinase (GRK) family in response to agonist stimulation of
the receptor (Kuhn, 1974; Sibley et al., 1984; Bunemann and Hosey, 1999). In the case of
the M3 receptor, the GRK that is involved may be GRK6 (Willets et al., 2003) or GRK2
(Wu et al., 1998). Some GRKs may be activated by the G|3y subunits of the heterotrimeric
G protein as a consequence of agonist activation (Haga et al., 1994) and some
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phosphorylate the receptor in the presence of PIP2 (Pitcher et al., 1995; Willars et al., 1996).
Because the phosphorylation by GRKs only affects the activated receptor, the term
homologous desensitisation has been applied to this process (Sibley et al., 1985). Other
effector kinases such as casein kinase la (Tobin et al., 1997; Budd et al., 2000) and protein
kinases A and C (Benovic et al., 1985; Bouvier et al., 1987; Hausdorff et al., 1989) can also
mediate phosphorylation of the GPCR and interrupt signalling to G proteins. In this latter
instance, the receptor does not necessarily have to be agonist occupied and phosphorylation
of other non activated (and different liganded) receptors also takes place - the term
heterologous desensitisation has been applied to this type of mechanism.
Homologous desensitisation of the receptor, following GRK phosphorylation, often
involves the recruitment of proteins known as arrestins that act to uncouple the G protein
from the receptor by binding to regions on the receptor to occlude them from G protein
interaction (Wu et al., 1997; Krupnick and Benovic, 1998; Wu et al., 2000). There are four
types of known arrestin (Freedman and Lefkowitz, 1996); visual arrestin and cone arrestin
are localised to the visual system (Shinohara et al., 1987; Yamaki et al., 1987; Murakami et
al., 1993; Craft et al., 1994), (3-arrestin 1 (or arrestin-2) and |3-arrestin 2 (or arrestin-3) are
expressed ubiquitously and act as adapter proteins for the clathrin-mediated endocytosis of
many GPCRs (Lohse et al., 1990; Attramadal et al., 1992; Goodman et al., 1996; Lin et al.,
1997). The carboxy-terminal region of the (3-arrestins (residues 371-377 in (3-arrestin 2), but
not the visual arrestins, can bind to the amino-terminal domain of the clathrin heavy chain
(Goodman et al., 1996; Krupnick et al., 1997a; Krupnick et al., 1997b) and can additionally
bind the AP-2 clathrin adapter complex to facilitate the clathrin coated pit-mediated
endocytosis of GPCRs (Laporte et al., 1999; Laporte et al., 2000). In addition, the large
GTPase, dynamin, which is involved in vesicle budding from the plasma membrane, may
facilitate receptor endocytosis for different GPCR types (Ahn et al., 1999; Claing et al.,
2002). Interestingly, some recent studies have suggested that phospholipase D (PLD)
activity may also be implicated in the endocytosis of certain G protein-coupled receptors.
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The PLD2 isoform has been proposed to be important for the endocytosis of both the
angiotensin II type 1 GPCR (Du et al., 2004) and the p-opioid GPCR (Koch et al., 2003;
Koch et al., 2004). This process may be mediated by phosphatidic acid (the product of PLD
activation) as PA has been shown to be important in other membrane trafficking events and
may influence the physical characteristics of the phospholipid membrane to allow efficient
vesicle budding (Andresen et al., 2002). Following sequestration, the receptors are
processed by early endosomes where the ligand is dissociated and the receptor is
dephosphorylated and recycled back to the plasma membrane swiftly (resensitised).
Alternatively the receptor is held in a subcellular pool or transported to lysosomes for
degradation (Claing et al., 2002). The particular fate of the GPCRs may be dependent on
specific serine residues within the carboxy-terminal tail domains of the receptors, which
appear to modulate the recycling kinetics of the receptors (Innamorati et al., 1998; Oakley et
al., 1999; von Zastrow, 2003).
Another of the mechanisms that modulate GPCR signalling is the regulation of
heterotrimeric G protein activity by the regulator of G protein signalling (RGS) proteins.
These are cofactors that belong to the family of GTPase-activating proteins (GAPs) that act
to accelerate hydrolysis of GTP back to GDP by G proteins; RGS proteins act specifically
on the Ga subunit of the heterotrimeric G protein to drive the G protein (and subsequently
the GPCR) back into an inactive conformation (Berman and Gilman, 1998). This is distinct
from desensitisation, as the mechanism effectively acts to recycle the signalling properties
provided by the receptor faster than the receptor/G protein complex could under normal
conditions. The RGS family consists of more than twenty proteins (some with splice
variants), which range in size from 159 amino acids (~19 kDa) (RGS 13) to 1447 amino
acids (~156 kDa) (RGS 12) (Chatterjee and Fisher, 2000; Strausberg et al., 2002). All RGS
proteins have a conserved domain (the RGS domain) of 117 residues and many have other
homologous domains including a PDZ domain (RGS 12), a G protein gamma-like subunit
(GGL) domain (RGS6, RGS7, RGS9 and RGS11) and a Rapl/2 binding (RBD) domain
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(RGS12 and RGS14) (Hollinger and Hepler, 2002). The RGS proteins directly bind, with
high affinity, the GTP-bound Ga subunit of the heterotrimeric G protein and overexpression
of RGS4, for example, has been shown to inhibit both the Gi/o and Gq coupled signalling in
mammalian cells (Druey et al., 1996). However, at lower physiological levels, RGS4 has
been shown to interact transiently with Gq, to facilitate an oscillation of Ca2+ release within
the cell (Luo et al., 2001; Hollinger and Hepler, 2002). RGS proteins may additionally
function as molecular switches, which may modulate the signalling characteristics of a G
protein. Rumenapp and colleagues demonstrated that overexpression of RGS4 (which is
specific for Gq) could inhibit M3 receptor-activated Gq-mediated PLC activation, without
affecting G12/13-mediated PLD responses, whilst expression of the RGS homology domain
of Lsc (which is specific for G12/13) could specifically inhibit PLD but not PLC responses
(Rumenapp et al., 2001). RGS proteins may therefore be important and useful targets for
elucidating important GPCR mediated signalling pathways.
Signal crosstalk and convergence
The signalling by G protein-coupled receptors is complicated and diverse. The simple
notion of a single GPCR coupling to a single specific type of G protein to activate a single
type of downstream effector is becoming increasingly inaccurate. Many hundreds of
different types of GPCRs, many with vastly different sequences exist in mammals and these
all couple through a similar subset of G proteins to regulate effectors. There is increasing
evidence that many of the receptor/G protein pathways can amplify and influence other
separate but parallel signalling pathways. This is known as signal crosstalk and can occur at
various levels of the signalling cascade.
At the level of receptor/G protein signalling, there are many reports suggesting that
various heterotrimeric G proteins can influence and even regulate the signals from another
GPCR and G protein. An example of this is the agonist stimulated Gi/o coupled 6-opioid
receptor synergistically potentiating the Gq coupled M3 muscarinic receptor activated intra-
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cellular Ca2+ release in SH-SY5Y cells (Yeo et al., 2001). This Gi/o enhancement of Gq
modulated signalling is repeated in many other findings (Megson et al., 1995; Selbie et al.,
1995; Dickenson and Hill, 1997) and is probably due to the Gpy subunit interacting directly
with PLC(3 (Selbie et al., 1997). In addition, stimulation of protein kinase C by phorbol
esters has been shown to potentiate the accumulation of cAMP in cells by Gs stimulation
(which may be dependent on the isoforms of adenylate cyclase involved) (Karbon et al.,
1986).
It has also been shown that GPCRs can modulate the signalling of other GPCR/G
protein independent signalling pathways and vice-versa. The p-adrenergic receptor has been
shown to be phosphorylated in vitro and in vivo by the insulin and insulin-like growth factor
tyrosine kinase receptors and although no functional consequences were observed, the
implication was that the adrenergic receptors may be heterologously desensitised and cease
signalling (Baltensperger et al., 1996; Karoor and Malbon, 1996). It has been demonstrated
that G protein Gpy subunits can mediate the signalling to the MAPK pathway of the insulin¬
like growth factor tyrosine kinase receptor (Luttrell et al., 1995) and GPy subunits have
been shown to directly associate with c-Raf in a yeast two-hybrid assay and in vitro
(Pumiglia et al., 1995), however any potential functional role of this association was not
addressed. Many GPCRs have been shown to activate the MAP kinase pathway and the
phosphorylation, arrestin recruitment and internalisation of GPCRs have all been implicated
in the activation of MAPK to some extent, depending on the receptor type (Hawes et al.,
1995; Pierce et al., 2000). The heterologous phosphorylation of the p-adrenergic receptor by
protein kinase A leads to an arrestin mediated recruitment of c-Src to the receptor and
subsequent endocytosis-dependent activation of the MAPK pathway (Daaka et al., 1997;
Luttrell et al., 1999). The similar activation of MAPK by the M, muscarinic, formyl peptide
and the k-, 8- and q-opioid receptors has been shown to be dependent upon receptor
endocytosis (Ignatova et al., 1999; Vogler et al., 1999; He et al., 2001). However, the
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necessity of GPCR internalisation has been disputed in the case of the opioid receptors, as
agonist activation has also been shown to activate MAPK without endocytosis (Kramer and
Simon, 2000). In addition, the heterologous phosphorylation of the M3 muscarinic receptor
by PKC can activate the MAPK pathway without involving receptor endocytosis (Budd et
al., 1999; Budd et al., 2001) and internalisation-independent MAPK activation by other
GPCRs such as the a2-adrenergic and cannabinoid receptors has been demonstrated
(DeGraff et al., 1999; Roche et al., 1999; Schramm and Limbird, 1999). The functional
significance of receptor internalisation for the activation of the MAPK pathway remains
elusive, however the evidence remains that co-activation of other signalling pathways by
GPCRs is an important mechanism of signal transduction.
Key signalling pathways of the M3 receptor: Phospholipase C
A novel enzymatic activity was described in the 1950s, which resulted in the incorporation
of 32P into phospholipids upon carbachol stimulation of pigeon pancreatic slices (Hokin and
Hokin, 1953). Subsequent work done by Michell and colleagues, resulted in the
characterisation of a membrane-associated enzyme, phospholipase C. This enzyme was
shown to catalyse the formation of 1,2-diacylglycerol and inositol phosphate from the
membrane lipid phosphatidylinositol, which was intriguingly coupled to a concomitant
increase in intracellular Ca2+ levels (Lapetina and Michell, 1972; Lapetina and Michell,
1973a; Lapetina and Michell, 1973b; Jones and Michell, 1974; Allan and Michell, 1975;
Akhtar and Abdel-Latif, 1980).
Mammalian PLC isoforms are generally phosphatidylinositol specific (PI-PLC) and
preferentially hydrolyse the phospholipid phosphatidylinositol (4,5)-bisphosphate (PIP2)
into sn 1,2-diacylglycerol (DAG) and myo-inositol (l,4,5)-trisphosphate (IP3) (Griffin and
Hawthorne, 1978; Ryu et al., 1987; Berridge, 1993). DAG and IP3 then mediate the
activation of protein kinase C (PKC) and the release of Ca2+ from intracellular reserves
respectively (Streb et al., 1983; Nishizuka, 1984; Putney et al., 1986). There are eleven
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mammalian isoforms of PLC, grouped into four main PLC families; there are four subtypes
of PLC(3 (~145-155 kDa), two subtypes ofPLCy (~145-155 kDa) four of PLCS (~85 kDa)
and a novel PLCe isoform (~86 kDa) (Suh et al., 1988; Thomas et al., 1991; Cockcroft and
Thomas, 1992; Rhee and Choi, 1992; Berridge, 1993; Rhee and Bae, 1997; Wing et al.,
2003). PLC activity in response to agonist stimulated GPCRs was determined to act via a
heterotrimeric G protein mechanism by Taylor and Merritt (Merritt et al., 1986) and
subsequent analysis revealed that the PLC activity was due to the PLC|3 isoform (Blank et
al., 1991; Taylor et al., 1991;Shawand Exton, 1992;Exton, 1993). PLC(3 isoforms are
activated by the Gq family of heterotrimeric G proteins (Blank et al., 1991; Taylor et al.,
1991; Lee et al., 1992; Wu et al., 1992). Purified PLC|31 is more potently activated than
PLC(32 and PLC|33 (which showed little difference in activation) by purified Gaq and Gal 1
subunits (Hepler et al., 1993; Smrcka and Sternweis, 1993). It has been determined that both
the Ga and G|3y subunits can activate members of the PLC|3 family with different potencies
- the activation of PLC by the G|3y subunits is of approximately 50-100 fold lower potency
than that by the Ga subunits (Morris and Scarlata, 1997). However, as the PLC|3 isoform
has a GTPase activating protein (GAP) effect for the Ga subunit (Berstein et al., 1992;
Paulssen et al., 1996), the use of the non-hydrolysable GTP analogue (GTPyS) would negate
the GAP effect of PLC and may account for the higher potency of Ga activation in vitro
(Morris and Scarlata, 1997). The potency of PLC(3 activation by G(3y subunits is also
isoform dependent, with PLC|32 and PLC(33 being more sensitive than PLC[31 and PLC(34
(Smrcka and Sternweis, 1993; Ueda et al., 1994).
PLC|3 is the only isoform subfamily that is directly activated by the Gq/11 hetero¬
trimeric G protein family (Rhee and Choi, 1992) and this is thought to be due to PLCp
having an extended carboxy-terminal domain compared to PLC6 and PLCy (Lee et al.,
1992; Park et al., 1993). Truncations of this tail portion abolished the enzymes ability to be
activated by Gaq (although not by G|3y) (Park et al., 1993; Wu et al., 1993) suggesting that
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this region contains a Gaq binding site. The G|3y binding site is thought to be in the N-
terminal pleckstrin homology (PH) domain, necessary for phosphatidylinositol bisphosphate
(PIP2) binding (Kuang et al., 1996). There are recent reports that PLCe can be activated in
response to G protein-coupled receptor stimulation, which could be mediated by the
Gal2/13 heterotrimeric G protein family (Wing et al., 2003; Kelley et al., 2004) and which
may also be mediated by an elevated level of intracellular cAMP (Evellin et al., 2002). The
PLC family have a common main structure consisting of an amino-terminal pleckstrin
homology (PH) domain, an EF hand domain that acts as a flexible linking domain to the
conserved catalytic core of the enzyme (the X/Y box) and a C2 region at the carboxy-
terminal of the protein (Figure 1.3) (Rhee and Choi, 1992). The PH domain is
approximately 120 amino acid residues long and is necessary for the association of PLC
with phospholipid head groups in the membrane and specifically with PIP2 (Paterson et al.,
1995; Lomasney et al., 1996; Yagisawa et al., 1998). The conserved catalytic core of the
enzyme begins at approximately residue 300 and consists of two parts - the X region is
approximately 147 residues and is connected to the Y region, which is approximately 118
residues in length. In PLC|3 and PLC6, this X/Y box is separated by 50-70 amino acids,
however PLCy has over 400 residues between the two regions, containing three src-
homology (SH) domains (two SH2 domains and one SH3 domain) (Rhee and Choi, 1992;
Essen et al., 1996). The catalytic domain contains residues that are important for phospho-
inositol hydrolysis (Lys-438, Lys-440, Ser-522 and Arg-549 in PLC6) and also other
residues that are important for catalysis (His-311 in PLC6) (Ellis et al., 1998). The C2
domain is similar to that found in the protein kinase C superfamily (where it is necessary for
allosterically binding Ca2+ ions for activity), however it may primarily function as a
stabilising domain, as mutations to prevent Ca2+ binding do not significantly alter the
activity of the enzyme (James and Downes, 1997). The carboxy-terminal domain of the
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PH I II Loop PIP2 III IV CT
The domain structure of the phospholipases C and D, and protein kinase C.
The domain structures of the major GPCR pathway-coupled isozymes of PLC, PKC and
PLD. The catalytic domains in each are indicated in red. The pleckstrin homology (PH)
domains in PLC and PLD (blue) are important for associating with lipid membranes. The
EF-hand and C2 regions in PLC and C2 region in PKC are important for Ca2+ ion binding.
The P-box in PLC0 is important for interaction with the heterotrimeric G proteins. PKC
contains an additional conserved CI domain, where diacylglycerol and phorbol esters bind.
PLD contains a phox homology (PX) domain and the conserved regions J-IV include the
catalytic HKD domains. PLD contains an additional loop region, an allosteric PIP2 site and
the carboxy-terminal tail domain (CT) is important for regulating activity of the enzyme.
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like (GAP-like) activity, which accelerates hydrolysis of the GTP on the active Gaq subunit
back to the inactive GDP form (Paulssen et al., 1996).
Key signalling pathways of the M3 receptor: Phospholipase D
Phospholipase D (PLD) activity was originally described in plants (Hanahan and Chaikoff,
1947). Originally thought to be present only in simple eukaryotes such as Dictyostelium
discoideum (Ellingson and Dischinger, 1984; Cubitt et al., 1993) and plants (Dawson, 1967;
Long et al., 1967a), it was characterised in mammals only in the 1970s (Saito and Kanfer,
1973). PLD uniquely hydrolyses phospholipids at the terminal phosphodiester bond to
produce phosphatidic acid (PA) and the free polar head group. The preferred substrate for
PLD, phosphatidylcholine (PtdCho), is the most abundant phospholipid constituent of
mammalian membranes, providing around 50% of the total phospholipid content and as
much as 60% of the intracellular membrane phospholipid content (Owen et al., 1981;
Lagarde et al., 1982; Patton et al., 1982). The phosphatidyl transferase ability of PLD has
been utilised as an unequivocal indication of PLD activity (Dawson, 1967; Long et al.,
1967b; Long et al., 1967a; Yang et al., 1967). In the presence of a primary alcohol such as
butan-l-ol, activated PLD transfers the phosphatidyl moiety of the phospholipid to the
alcohol and produces phosphatidylbutanol. The phosphatidylbutanol product is not
metabolised further by the action of phosphatidic acid phosphohydrolase (see below). Thus
PLD activity can be assayed by monitoring the production of [3H]phosphatidylbutanol
([3H]PtdBut) when [3H]palmitate labelled cells are stimulated in the presence of 0.1-0.5%
(v/v) butan-l-ol. This transphosphatidylation assay is a specific way of measuring
phospholipase D activity within whole cells and a scheme is shown in Figure 1.4.
The function of PLD activity has remained somewhat elusive; it was originally
postulated that the release of the choline group by PLD is an essential step in the synthesis
of the neurotransmitter acetylcholine (Hattori and Kanfer, 1984; Blusztajn et al., 1987; Zhao
et al., 2001) and whilst this may be the case in many neuronal cells, the currently favoured
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hypothesis is that the PA group released during hydrolysis may function as an additional
second messenger in peripheral tissues (Exton, 1990; English, 1996).
Phosphatidic acid (PA) has been implicated in a variety of cellular functions and
includes possible calcium mobilisation independent to that caused by the action of IP3
(English, 1996), cellular proliferation (Knauss et al., 1990) and as a substrate for
downstream prostaglandin synthesis (Marshall et al., 1981). It has also been implicated in
the activation of certain kinases (Ohguchi et al., 1997). Furthermore, phosphatidic acid has
been shown to have a critical role in activation of the regulatory kinase mTOR (target of
rapamycin), a phosphatidylinositol 3-kinase related kinase (PIKK), which is a potentially
oncogenic protein that is involved in cell cycle regulation and proliferation (Fang et al.,
2001). Moreover, phosphatidic acid is an important regulator of the mitogen activated
protein kinase (MAPK) signalling mechanism (Ghosh et al., 1996; Rizzo et al., 1999). PA
appears to directly bind to the serine-threonine kinase c-Raf (residues 389-423) to facilitate
14-3-3-mediated translocation of c-Raf to the plasma membrane in vivo and is possibly a
cofactor for full activation of c-Raf (Ghosh et al., 1996; Rizzo et al., 1999; Andresen et al.,
2002; Ghosh et al., 2003).
Phosphatidic acid is further metabolised by phosphatidic acid phosphohydrolase
(PAP) to produce diacylglycerol (DAG) (Brown et al., 1990; Sciorra and Morris, 1999). A
second period of elevation of DAG following GPCR activation is thought to be more
sustained than the original PLC-mediated release and probably arises due to the rate limiting
action of PAP on phosphatidic acid (Martinson et al., 1990). Initial reports indicated that the
DAG derived from PAP action on PA was not efficient at activating PKC (Martin et al.,
1989; Kiley et al., 1991), however, more recent reports have indicated that DAG derived
from PA is effective at activating PKC isoforms (although it may be more effective at
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The unique phospholipase D catalysed transphosphatidylation reaction.
The in vivo scheme of PLD activity is shown (top), with PLD hydrolysing the terminal
phosphodiester head group of phosphatidylcholine (PtdCho) to produce phosphatidic acid
(PA) and choline (not shown, for clarity). The PA is then further metabolised to
diacylglycerol (DAG) by the action of phosphatidic acid phosphohydrolase (PAP). PLD has
a higher affinity for primary alcohols than H20, so in the presence of a primary alcohol, the
catalysis proceeds with the alcohol as the substrate (bottom). This results in an accumulation
of phosphatidyl-alcohol that cannot be metabolised further. The phosphatidyl-alcohol levels
can be assayed if the fatty acid moiety of phosphatidylcholine has been radiolabelled.
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PA can also be metabolised to lysophosphatidic acid (lysoPA) by the actions of
phospholipase A! or A2 (Gerrard and Robinson, 1989; Gaits et al., 1997). LysoPA is
bioactive and it has also been shown to mobilise Ca2+, activate PKC and inhibit cAMP
formation by acting on Edg family G protein coupled receptors (van Corven et al., 1989;
Jalink etal., 1990; van der Bend et al., 1992;Hecht et al., 1996; An et al., 1997;Bandoh et
al., 1999). It has been shown to display the properties of a growth factor and causes cellular
proliferation (van Corven et al., 1989; Moolenaar et al., 1992). Following the release of
lysoPA from activated platelets, which cause aggregation, there are high levels of lysoPA
found in serum (Eichholtz et al., 1993; Sano et al., 2002). LysoPA has also been shown to
be important in the activation of the PKCp (PKD) isoform (Kam and Exton, 2004).
PLD has additionally been proposed to be important in mediating anti-apoptotic
signalling in a number of different cell types - glutamate induced cell death in PC 12 cells
was attenuated by overexpression of PLD isoforms (Kim et al., 2003) and an increased PLD
activity could protect against hydrogen peroxide (H202) and hypoxia induced cell death in
PC12 cells (Lee et al., 2000a; Yamakawa et al., 2000). Furthermore, elevated PLD activity
could also protect against apoptosis in human neutrophils and vascular smooth muscle cells
with the protection possibly being mediated by phosphatidic acid and microtubule
stabilisation (Park et al., 2002; Zheng et al., 2004). There are conflicting reports from some
groups however, suggesting that enhanced PLD activity can sensitise a cell to promote
apoptosis rather than protect it (Kang et al., 1998; Zhong et al., 2002). The role of PLD in





The two mammalian phosphatidylcholine specific phospholipase D isoforms, the 124 kDa
PLD1 and 106 kDa PLD2 were cloned in 1995 and 1997 (Hammond et al., 1995; Colley et
al., 1997b; Kodaki and Yamashita, 1997; Lopez et al., 1998). PLDlb, a splice variant of
PLD1 lacking the 38 internal amino acids 565-624, has been cloned and is apparently
regulated in the same way as PLD la (Hammond et al., 1997). Other PLD activities distinct
from these isoforms have also been described, such as the phosphatidylinositol-glycan
specific PLD isolated from human and bovine sera (Davitz et al., 1987; Scallon et al., 1991)
and a phosphatidylcholine specific PLD activity isolated in porcine lung, which had a
molecular mass of 190 kDa (Okamura and Yamashita, 1994). This oleate-sensitive PLD
activity has been proposed as being due to a novel isozyme (Kawabe et al., 1998; Lee et al.,
1998), however other groups believe it is likely to be due to PLD2 activity (Kim et al.,
1999b; Sarri et al., 2003)
Protein Kinase C stimulated PLD activity
The activation of PLD as a consequence of GPCR agonist-stimulated PLC activity, leading
to downstream activation of protein kinase C (PKC) by diacylglycerol (DAG) (a product of
the PLC mediated hydrolysis of PIP2) has been recognised for some time (Cockcroft, 1984;
Martinson et al., 1989; Brown et al., 1990). The tumour-promoting phorbol esters, which
activate protein kinase C (Castagna et al., 1982; Nishizuka, 1984), were known to indirectly
stimulate PLD activity and therefore implicated PKC in the direct activation of PLD (Billah
et al., 1989; Gelas et al., 1989; Huang and Cabot, 1990). In 1992 Conricode and colleagues
demonstrated that PKC could indeed stimulate PLD activity (Conricode et al., 1992) and in
1996, recombinant PKCa and purified PKCa from porcine brain were shown to interact
with and activate PLD1 synergistically with ARF and in a kinase-independent manner
(Singer et al., 1996). Moreover, the conventional PKC|3 isoform, but not the PKCy isoform,
was shown to stimulate PLD activity, but with a lower potency than PKCa, whilst PKC8,
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PKCe and PKC^ failed to stimulate PLD activity (Conricode et al., 1994). However, the use
of PKC inhibitors, such as staurosporine and bisindoylmaleimide has yielded information
that agonist-dependent GPCR-stimulated PLD activity is dependent on catalytic activation
of PKC in many cell types (Cook et al., 1991; Plevin et al., 1994; Ahmed et al., 1995;
Martinson et al., 1995; Meacci et al., 1995; Yeo and Exton, 1995; Rumenapp et al., 1997).
It has been demonstrated that both PLD 1 and PLD2 isozymes are activated by PKC
isoforms with similar potencies and in a direct manner (Xie et al., 2002; Chen and Exton,
2004). In PC 12 cells, bradykinin and hydrogen peroxide stimulated PLD2 activity is
potentially mediated by PKCS and PKCe as well as by PKCa (Lee et al., 2000b; Oh et al.,
2000).
The protein kinase C superfamily consists of five main subfamilies, each with
different isozymes. The classical or conventional PKC (cPKC) subfamily consists of the
isoforms PKCa, PKC|3 and PKCy. These three isoforms (the first to be cloned) were
elucidated originally due to their dependence on Ca2+ for activation by diacylglycerol and
their activation by the tumour promoting phorbol esters (Takai et al., 1977; Takai et al.,
1979; Kikkawa et al., 1982; Coussens et al., 1986; Parker et al., 1986). Soon three more
PKC isoforms were discovered - PKC8, PKCe and PKC^ (Ono et al., 1987). The isoforms
PKC8 and PKCe, together with PKCr) (Osada et al., 1990) and PKC0 (Osada et al., 1992),
make up the novel PKC subfamily (nPKC). These four PKCs are still activated by
diacylglycerol, and are also stimulated by phorbol esters, however they lack the Ca2+
dependent C2 region found in the conventional PKCs, so are not dependent on Ca2+ for
kinase activity (Osada et al., 1990). The isoforms PKC^ and PKCi (Ono et al., 1989b) make
up the atypical PKCs (aPKC), which are both Ca2+ and DAG insensitive (Ono et al., 1989b).
There are also PKCv and PKCp (or PKD) isoforms, which may comprise another PKC
subfamily. These PKCs are insensitive to Ca2+, DAG and are not activated by phorbol esters
(Johannes et al., 1994; Hayashi et al., 1999). Three other gene products make up the protein
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kinase C related kinase (PRK) subfamily, which consists of PRK1-3 (Mellor and Parker,
1998). These proteins are like the atypical PKCs in regulation, but can also bind the
activated small G protein RhoA to increase their kinase activity (Mellor and Parker, 1998).
With the exception of the PRK subfamily, all PKCs contain a conserved CI domain region
that contains one or two zinc finger motifs rich in cysteine and histidine residues (the CI
region is slightly altered in the atypical PKCs) (Mellor and Parker, 1998). The CI domain is
also the region responsible for binding of phorbol ester and phospholipids (Ono et al.,
1989a; Zhang et al., 1995) and in the absence of activators acts as an autoinhibitory domain,
which associates with the catalytic domain C4 to inactivate the enzyme (Orr et al., 1992).
The C2 region found in the conventional PKCs has homologous structure to the conserved
region V0 found in the other PKCs, however it is the only region that is dependent upon
allosteric binding of Ca2+ ions for activity (due to a number of aspartate residues that are not
present in the V0 region) (Ono et al., 1989a; Shao et al., 1996; Mellor and Parker, 1998).
The catalytically active kinase domain is conserved in all of the PKC superfamily and
consists of two regions - C3 and C4. The C3 region is thought to coordinate ATP as the
phosphate donor and C4 is thought to bind the substrate to be phosphorylated (Figure 1.3)
(Ron and Kazanietz, 1999).
The region that is thought to interact with PLD is the amino-terminal regulatory
domain of PKCa and this direct interaction-dependent activation of PLD may not be
dependent upon the kinase activity of PKC (Singer et al., 1996). Studies utilising
truncations of the amino terminal of rat and human PLD1 yielded information that the
region involved with PKCa activation was present in the first 325 residues of the PLD1
isozyme (within the PX domain - see below) (Park et al., 1998; Sung et al., 1999). Further
studies revealed that the insertion of the residues GVPLE at position 87 of human PLD1




Furthermore, the interaction of PKC with PLD isozymes has been shown to increase
phosphorylation of PLD, which may negatively regulate PLD activity (Hu and Exton, 2003;
Chen and Exton, 2004). In addition to stimulation of PLD by the conventional PKCa, recent
reports have demonstrated a negative regulation of PLD1 by the competitive association of
the novel PKC6 with PLD 1. There is even evidence to suggest that PLD is basally
negatively regulated by PKC6 in vivo, as cells containing both PKCa and PKC6 isoforms
elicited a lower PLD response and attenuated PKCa and PLD association compared to those
containing PKCa alone (Hornia et al., 1999; Oka et al., 2003). However, another group has
reported that PKC8 activates PLD1 as effectively as PKCa (Hodgkin et al., 1999). These
conflicting reports indicate that there may be potential PKC isoform-dependent mechanisms
involved in the regulation of PLD.
Regulation ofPLD by small G proteins ARF and Rho
PLD regulation by small G proteins was originally discovered when a cytosolic factor of
approximately 16 kDa could reconstitute GTPyS evoked PLD activity in permeabilised
(cytosol-depleted) and isolated membranes from HL-60 cells (Anthes et al., 1991; Geny and
Cockcroft, 1992; Geny et al., 1993). The cytosolic factor was purified and identified as
ADP-ribosylation factor (ARF) (Brown et al., 1993; Cockcroft et al., 1994). ARFs are small
molecular weight G proteins that were originally characterised as cytosolic cofactors
involved in the ADP-ribosylation of the Gas heterotrimeric G protein subunit by cholera
toxin (Kahn and Gilman, 1984). They have subsequently been implicated in the coatomer-
mediated formation and fusion of Golgi vesicles (Serafini et al., 1991; Donaldson et al.,
1992a; Palmer et al., 1993) and in the binding of the clathrin adapter protein AP-1 to Golgi
membranes (Stamnes and Rothman, 1993; Traub et al., 1993; Zhu et al., 1998). The ARF-
dependent PLD activity present within the Golgi apparatus is thought to be important for
vesicle trafficking, which is potentially mediated by the product of PLD activity -
36
Chapter 1: introduction
phosphatidic acid (Ktistakis et al., 1995; Ktistakis et al., 1996; Chen et al., 1997).
Phosphatidic acid may influence the physical characteristics of the lipid bilayer to facilitate
a change in the curvature of the membrane and, subsequently, facilitate efficient vesicle
budding (Siddhanta and Shields, 1998; Huttner and Schmidt, 2000). PLD1 activity on
internal lysosomal membranes has been shown to increase with the assembly of the AP-2
clathrin proteins (Arneson et al., 1999) and as a consequence of ARF-mediated coatomer
formation (Jones et al., 1999). The activation of PLD by ARF is markedly increased with
fatty acid modification of ARF, with myristoylated ARF being able to activate PLD much
more effectively than unmodified ARF (Massenburg et al., 1994; Brown et al., 1995). The
site of ARF interaction on PLD currently remains unidentified.
The involvement of the small G protein Rho in the activation of PLD in neutrophils
was discovered by Bowman and colleagues (Bowman et al., 1993). After some contention
as to whether Rho could indeed activate PLD in some cell types (Ohguchi et al., 1995;
Martin et al., 1996; Ohguchi et al., 1996), it has generally been accepted that the main
members of the Rho family RhoA, Racl and cdc42 can all activate PLD in a similar manner
(Hammond et al., 1995; Hammond et al., 1997) and synergistically with ARF (Kuribara et
al., 1995; Siddiqi et al., 1995; Hammond et al., 1997). The fatty acid modification of RhoA
can greatly increase potency, with geranylgeranylated RhoA being able to stimulate PLD
much more effectively than unmodified RhoA (Hammond et al., 1997). It is now known
that in the presence of PIP2 as a cofactor, ARF, Rho and PKC can interact with and activate
PLD to a different extent in different cell types (Provost et al., 1996; Hammond et al.,
1997). In 1999, a yeast two-hybrid assay revealed that RhoA could interact with the
carboxy-terminal domain of human PLD1 (residues 712-1074) (Yamazaki et al., 1999).
Point mutagenesis studies of this region indicated that the mutation of residue 870 from
isoleucine (I) to an arginine (R) conferred insensitivity to regulation by Rho family




Rho family proteins are implicated in the regulation of the actin cytoskeleton and
they have been shown to control stress fibre formation and focal adhesions in different cell
types, facilitating cell migration (Ridley and Hall, 1992; Ridley et al., 1992; Xu et al., 2003;
Burridge and Wennerberg, 2004). In addition, phosphatidic acid has been implicated in the
formation of stress fibres (Ha and Exton, 1993a; Cross et al., 1996; Wakelam et al., 1997;
Kam and Exton, 2001) and even PLD itself has been shown to interact with the actin
cytoskeleton (Lee et al., 2001; Kusner et al., 2002). RhoA has also been shown to be
activated indirectly by the heterotrimeric G proteins of the G12/13 family, via the activation
of the GTPase activating protein (GAP), pi 15RhoGEF (guanine nucleotide exchange factor)
(Kurose, 2003). Interestingly, activated RhoB has been demonstrated to inhibit the transport
of internalised epidermal growth factor receptor to lysosomes (Gampel et al., 1999)
implicating a potential role for Rho family members in the recycling of membrane-
associated receptors.
ARF and Rho mediated, G protein-coupled receptor stimulation ofPLD
The GPCR stimulated activation of PLD through heterotrimeric G proteins has been well
characterised (Cockcroft, 1984; Gelas et al., 1989; Martinson et al., 1989). In 1995,
Rumenapp and colleagues demonstrated that PLD activation by the M3 muscarinic receptor
in HL-60 cells was ARF-dependent, as brefeldin A (an inhibitor of the ARF-guanine
nucleotide exchange factors known as BIG1/2) could inhibit the response (Donaldson et al.,
1992b; Rumenapp et al., 1995; Morinaga et al., 1999). Additionally a role for Rho in the
GPCR-mediated stimulation of PLD was implicated when PLD activity could be attenuated
by the addition of the specific Rho inhibitors C3 exoenzyme from Clostridium botulinum or
toxin-B from Clostridium difficile (Kuribara et al., 1995; Schmidt et al., 1996). In 1998, the
Mitchell group showed that ARFs and Rho could associate with GPCRs to activate PLD via
a mechanism independent of heterotrimeric Gq protein activation (Mitchell et al., 1998).
Furthermore, the signalling of the receptor to PLD via ARF and Rho was dependent on the
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conserved region at the end of the seventh transmembrane spanning helix that contained the
conserved motif NPxxY; receptors found to couple to PLD via an ARF/Rho independent
mechanism contained the motif DPxxY. The mutation of the aspartate (D) to an asparagine
(N), conferred BFA (for ARF) or C3 exoenzyme (for Rho) sensitivity onto BFA/C3-
insensitive receptor types (such as the gonadotrophin releasing hormone receptor), and the
reciprocal mutation conferred insensitivity onto BFA/C3-sensitive receptors (such as the 5-
HT2A receptor), implicating the region as a molecular switch for ARF dependent PLD
activation (Mitchell et al., 1998).
The domain structure ofPLD
The cloning of the mammalian phosphatidylcholine specific PLDs, PLD1 and PLD2 led to
investigations into the domain structure of the isoforms and to comparisons with
phospholipase C to determine any regions of homology. It transpired that human PLD1 did
not contain specific domain regions in common with PLC family members, such as
recognisable SH2 or SH3 domains and that the PIP2 interacting domain was distinct from
that of PLC5 (Hammond et al., 1995). The sequences of other PLD family members, such
as the phosphatidylinositol-glycan specific PLD isolated from bovine sera (Scallon et al.,
1991), indicated that there were conserved domains within the PLD family group. One of
these homologous domains is an invariant charged region with residues HxKxxxxD, known
as the HKD motif, present at residues 455-490 and 892-926 in the human PLD 1 isoform,
which is thought to be important for catalytic activity (Hammond et al., 1995). Subsequent
studies using mutagenesis of the lysine (K) to an arginine (R) at position 898 have borne out
this hypothesis and the mutant human PLD1 K898R has been shown to be catalytically
inactive (Sung et al., 1997). The same mutation at the equivalent residue in the PLD2
isoform, K758R, elicits the same loss of catalytic activity (Sung et al., 1997). It is thought
that a loop region within the enzyme allows PLD to fold, the amino- and carboxy-terminals
are brought into closer proximity and the two HKD motifs can associate together to form a
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catalytic centre (Figure 1.5) (Xie et al., 2000; Leiros et al., 2004). The two HKD motifs,
along with two other areas of high homology within the PLD family, the IYIENQFF motifs,
make up the conserved regions I, II, III and IV (Figure 1.3) (Morris et al., 1996; Frohman et
al., 1999).
Mammalian PLD1 and PLD2 both have Phox homology domains, which are
conserved regions found in many proteins, that facilitate protein-protein interactions
(Frohman et al., 1999). PLD1 has a Phox homology (PX) domain between residues 81-212
and PLD2 has a PX domain between residues 65-195 (Hammond et al., 1995; Lopez et al.,
1998). The presence of the PX domains is critical for PLD activity (Frohman et al., 1999;
Sung et al., 1999) and it is regions of the PX domain that may interact with the different
PKC isoforms (Zhang et al., 1999b). In addition, the PX domains may be necessary for the
modulation of the phospholipid-interacting pleckstrin homology domain (Sugars et al.,
2002; Ktistakis et al., 2003).
The ability of PLD to localise to cellular membranes is influenced by fatty acid
modification of a PIP2-interacting pleckstrin homology (PH) domain, present in both
mammalian PLD isozymes (Sugars et al., 1999; Sung et al., 1999; Xie et al., 2001).
Pleckstrin homology domains are conserved peptide regions within many different types of
proteins, which allow recruitment of the protein to phosphoinositides of cellular membranes
(Kavran et al., 1998). The PH domain of PLD1 is between residues 219-328 and within
PLD2 it is between residues 203-311; palmitoylation occurs on two adjacent cysteine
residues in the PH domain of both mammalian PLD isozymes (PLD1 240-241 and PLD2
223-224) to facilitate membrane association (Hammond et al., 1995; Lopez et al., 1998;
Sugars et al., 1999; Sung et al., 1999; Xie et al., 2001). Furthermore, PIP2 has additionally
been shown to be necessary as a cofactor for PLD activity (Whatmore et al., 1996) and,
although the PH homology domain is required for PLD localisation to membranes, the
actual site for PIP2 that is involved in functional activation has been contentious. It was




The crystal structure of a bacterial phospholipase D.
The solved crystal structure for a bacterial phospholipase D from Streptomyces at 1.4 A
resolution (Berman et al., 2000; Leiros etal., 2004). The peptide chain is rainbow colour
coded, from the blue N-terminus to the red C-terminus. The catalytic centre is formed by the
enzyme folding at the loop domain to coordinate the HKD motifs together.
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(Hodgkin et al., 2000). However, experiments performed more recently would suggest that
although the PH domain facilitates PLD localisation with PIP2-containing lipid membranes,
the site of PIP2 activation of PLD is present in an arginine and lysine rich sequence in the
region 691-712 on PLD1 and 554-575 on PLD2 (Du et al., 2003). This region, in addition to
the PH and PX regions, is also necessary for efficient PLD1 translocation to the plasma
membrane upon cellular stimulation (Du et al., 2003).
PLD localisation
Phospholipase D activity has been reported in many mammalian cell types (Colley et al.,
1997a; Morgan et al., 1997; Brown et al., 1998; Exton, 1999; Hodgkin et al., 1999; Czarny
etal., 2000; Vitale et al., 2001). However the subcellular localisation of PLD isozyme
activity within cells has remained unclear. Currently it is generally agreed that PLD2 mainly
localises to the plasma membrane in most cell types (Colley et al., 1997b; Czarny et al.,
2000). However the distribution of PLD1 is more variable depending on the cell type. Most
PLD1 activity in resting cells appears to be associated with intracellular perinuclear
compartments, including the Golgi apparatus, the endoplasmic reticulum (ER), endosomes
and lysosomes (Ktistakis et al., 1995; Chen et al., 1997; Colley et al., 1997a; Morgan et al.,
1997; Hodgkin et al., 2000; Freyberg et al., 2001). However some groups have also reported
PLD 1 activity associated with the plasma membrane and the extent to which this is
observed may be dependent on the cell type (Hodgkin et al., 1999; Kim et al., 1999a;
Lucocq et al., 2001; Vitale et al., 2001).
It is apparent that PLD1 is more mobile than PLD2, and studies demonstrate that
upon cellular stimulation, PLD1 translocates from the intracellular compartment membranes
to the plasma membrane (Morgan et al., 1997; Brown et al., 1998; Du et al., 2003). When
present at the plasma membrane, the PLD activity of either isozyme has been reported to be
primarily localised within caveolin-enriched or cytoskeletal domains (Czarny et al., 1999;
Hodgkin et al., 1999; Kim et al., 1999a; Czarny et al., 2000; Xu et al., 2000; Han et al.,
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2002). PLD is dependent on the phospholipid PIP2 as a cofactor for activation and so must
associate with suitable PIP2-enriched membranes for activity (Hodgkin et al., 2000). The
differences in the distribution of the PLD isozymes within different cell types indicates that





14-3-3 proteins are acidic small molecular weight proteins of approximately 30 kDa that are
expressed in all eukaryotic organisms. Initially named due to the unique migration pattern
on DEAE cellulose gel electrophoresis (Moore et al., 1968), 14-3-3 proteins have become
extensively studied due to their important roles in a great diversity of cellular function.
Seven conserved 14-3-3 isoforms are expressed in mammalian cells, |3, y, z, t/0, r], £ and a,
and are named due to their elution pattern in high performance liquid chromatography
(Ichimura et al., 1988; Toker et al., 1990; Toker et al., 1992). Isoforms of 14-3-3 were
characterised by a number of different groups working on a number of different mammalian
species, however their highly conserved nature and homology allowed them to be correlated
successfully (Ichimura et al., 1988; Watanabe et al., 1991; Aitken et al., 1992b; Ichimura-
Ohshima et al., 1992; Toker et al., 1992; Leffers et al., 1993; Watanabe et al., 1993; Patel et
al., 1994; Roseboom et al., 1994).
Apart from the 14-3-3t/0 (tau or theta) isoform, which is expressed predominantly
in T-lymphocytes (Jones et al., 1995b) and the 14-3-3a (sigma) isoform (also known as
stratifin), which is expressed almost exclusively in epithelial cells (Leffers et al., 1993), the
remaining mammalian isoforms are expressed ubiquitously in the brain and peripheral
tissues. Up to 1% of the total brain protein level is 14-3-3, suggesting that 14-3-3 proteins
are highly expressed and therefore provide a number of important functions in neural cells
(Aitken et al., 1992a). 14-3-3 proteins exist in vivo as homo- and heterodimers, which are
extremely stable and do not readily exchange unless they are denatured and renatured (Jones
et al., 1995a). This aspect of 14-3-3 dimerisation has important implications for expressing
dominant negative forms of the proteins, as the specificity of dimer formation may influence
the functional activity of 14-3-3. The crystal structures of 14-3-3x (Xiao et al., 1995) and
14-3-3^ (Liu et al., 1995) were determined in 1995 and indicated that 14-3-3 monomers
were made up of nine antiparallel a-helixes and were coordinated together as a dimer to
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form a large amphipathic, negatively charged groove. The proximal a-helix of one
monomer (residues 5-21) contacts the proximal a-helix of the partner monomer (residues
58-89) to form the base of the groove, the rest of the dimer forming the two opposing faces
(Figure 1.6) (Liu et al., 1995; Xiao et al., 1995). Phosphorylation of the serine residue at
position 58 by protein kinase B (also known as Akt) has been proposed to negatively
regulate the assembly of the 14-3-3 dimer and maintain a monomeric structure (Woodcock
et al., 2003). However this site is masked in the stable dimer form (Xiao et al., 1995), so
any regulatory phosphorylation in vivo would probably need to take place before dimeric
14-3-3 could associate.
The amino acid composition of the groove is highly conserved amongst all isoforms
of 14-3-3 (Aitken, 1996). Mutagenesis studies indicated that the residues lysine-49,
arginine-56, arginine-127 and a tyrosine-128 (as numbered in 14-3-3'Q are thought to be
important for the interaction with binding partners (and specifically with the coordination of
the phosphoserine motif - see below) (Yaffe et al., 1997; Zhang et al., 1997). However, the
amino-terminal domains (residues 9-16) and residues on the outer surface of the dimer are
variable (Aitken et al., 1992b; Martin et al., 1993; Aitken et al., 1995c). This variability
may confer distinct functional roles to different dimer combinations and some target protein
interactions. Indeed, studies of the specificity of dimer combinations has revealed that
whilst 14-3-3y generally only forms homodimers (with a small percentage of heterodimers
formed with 14-3-3e), the 14-3-3e isoform usually only forms heterodimers (with 14-3-3(3,
14-3-3rj, 14-3-3£ and 14-3-3y) (Jones et al., 1995a; Chaudhri et al., 2003). It has been
proposed that the dimeric nature of the 14-3-3 proteins may facilitate different cellular
mechanisms, with homodimers acting as chaperone proteins and heterodimers acting as
functional adapter proteins, coordinating two targets (each binding to a different isoform of
the heterodimer) to interact together (Jones et al., 1995a; Aitken et al., 2002). The potential
dimeric isoform specificity arising from many 14-3-3 interactions remains to be addressed.
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Figure 1.6
The crystal structure of a 14-3-3 dimer.
The solved crystal structure at 2.0 A resolution of a 14-3-3t homodimer complexed with
two RSxpSxP phosphopeptides (Rittinger et ai, 1999; Berman et al., 2000). The peptide
chains are rainbow colour coded on each monomer (the N-terminus is blue, progressing to
the red C-terminus). The large amphipathic groove, forming the main channel of the dimer,
is bounded on either side by the C-terminal domains of each monomer and is shown from
the side (A) and from above (B).
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14-3-3 interactions with c-Raf
The serine-threonine kinase c-Raf is a downstream effector of the membrane bound small G
protein Ras. Following activation of tyrosine kinase receptors by growth factors, c-Raf is
recruited to the plasma membrane where it is activated by Ras in the presence of v-Src and
where it subsequently activates the mitogen activated protein kinase (MAPK) (also known
as the extracellular signal-regulated kinase (ERK)) pathway by phosphorylating MAPK-
kinase (Dent et al., 1992; Kyriakis et al., 1992; Avruch et al., 1994). In 1994 it was
discovered that 14-3-3 was a potential binding partner for c-Raf and could be involved in
the activation of c-Raf in vivo. It appeared to bind readily to c-Raf, and could associate with
both inactive c-Raf in cytosol and with activated c-Raf at the plasma membrane (Fantl et al.,
1994; Freed et al., 1994; Fu et al., 1994; Irie et al., 1994). The conserved regions CR1 and
CR2 of c-Raf are found in the amino-terminal domain, which is thought to fold back onto
the carboxy-terminal region of the enzyme to negatively regulate the catalytically active
CR3 region found in the carboxy-terminal domain (Stanton et al., 1989; Heidecker et al.,
1990). The inactive conformation of c-Raf has a high affinity for 14-3-3 dimers rather than
monomers in vivo (Tzivion et al., 1998). The 14-3-3 interaction sites on c-Raf were
determined by tryptic digests of the phosphorylated c-Raf protein and affinity binding
studies to peptide lengths of the protein. 14-3-3 was found to interact with c-Raf within the
conserved regions CR2 and CR3, where 14-3-3 specifically recognises the consensus
sequence RSxpSxP (where pS is phosphoserine) centred on phosphorylated serine residues
259 (RSTpSTP) and 621 (RSApSEP) (Morrison et al., 1993; Muslin et al., 1996). The
kinase that phosphorylates c-Raf is quite likely to be protein kinase A (Dhillon et al., 2002;
Dumaz and Marais, 2003). The exact nature of the function of 14-3-3 and c-Raf association
is still uncertain - some groups have proposed that 14-3-3 mediates the translocation of
inactive c-Raf to the plasma membrane and dissociates upon c-Raf activation by Ras
(helping recycle c-Raf back to the cytosolic compartment) (Roy et al., 1998), whilst others
claim that the continual presence of 14-3-3 is necessary as a cofactor for the maintenance of
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c-Raf activity (Thorson et al., 1998; Tzivion et al., 1998). In addition, 14-3-3 may remain
bound to active c-Raf at the distal serine site (residue 621) but dissociate from c-Raf at the
proximal serine site (residue 259), to coordinate c-Raf into a catalytically active
conformation by allowing the protein to unfold (and expose the catalytic CR3 region)
(Rommel et al., 1996; Yip-Schneider et al., 2000). Competitive inhibition of the c-Raf
binding site by short peptides has been shown to interfere with lipid-dependent activation of
the MAPK pathway in Xenopus oocytes (Radziwill et al., 1996). However, mutation of the
serine-259 to alanine in c-Raf resulted in undiminished MAPK activation, with only a loss
of cellular proliferation (Dhillon et al., 2003). Furthermore, a number of reports have
indicated that the recruitment of c-Raf to the plasma membrane may be dependent upon the
action of phosphatidic acid as a cofactor (Rizzo et al., 1999; Rizzo et al., 2000). PA has
been shown to directly bind to c-Raf (between residues 389-423) with high affinity, and
inhibition of (PLD-mediated) PA production by pre-treatment with 1% primary alcohol,
interrupted 14-3-3 facilitated translocation of c-Raf to the plasma membrane in vivo (Ghosh
et al., 1996). In addition, mutations of the putative PA binding domain of c-Raf have been
shown to cause morphological defects in embryo development, supporting the importance
of PA association with c-Raf for full activation of the MAPK pathway (Ghosh et al., 2003).
Protein kinase C can activate c-Raf and the MAPK pathway (see below) in a
manner independent of Ras activation (Siegel et al., 1990; Sozeri et al., 1992; Kolch et al.,
1993; Ueda et al., 1996; van Dijk et al., 1997). This association is proposed to involve 14-3-
3 in a similar way to the coordination of Ras activation of c-Raf, with 14-3-3 behaving as a
functional linker to coordinate the two proteins together (Van Der Hoeven et al., 2000b).
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14-3-3 interaction with PKC
A family of 29 kDa proteins that potently inhibited protein kinase C (PKC) activity in sheep
brain, known as the protein kinase C inhibitor proteins (KCIP), were characterised in 1990
and were shown to be identical in sequence to members of the 14-3-3 family of proteins
(Toker et al., 1990; Toker et al., 1992). The characterisation of 14-3-3 as an endogenous
PKC inhibitor became complicated by reports that 14-3-3 could activate, rather than inhibit
PKC, in vitro (Isobe et al., 1992; Tanji et al., 1994). It remains unclear exactly how 14-3-3
can regulate PKC, with many reports finding that 14-3-3 acts as either an inhibitor or
activator of PKC (Robinson et al., 1994; Meller et al., 1996; Hausser et al., 1999; Van Der
Hoeven et al., 2000a; Gannon-Murakami and Murakami, 2002), although the multiplicity of
isoforms for both 14-3-3 and PKC raises the possibility of a broad range of functional
interactions. Although the precise mechanism of PKC regulation is unclear, it is apparent
that 14-3-3 may associate directly with conventional, atypical and novel PKC isoforms in
vivo (Meller et al., 1996; Hausser et al., 1999; Van Der Hoeven et al., 2000b; Gannon-
Murakami and Murakami, 2002). In T-cells, 14-3-3x was shown to interact with the novel
PKC0 isozyme, and overexpression of 14-3-3x negatively regulated the PKC mediated
activation of the interleukin-2, but not the interleukin-4 promoter (Meller et al., 1996). In
PC 12 cells, 14-3-31; could associate with PKC6 and PKC^ in undifferentiated cells and
additionally with PKCe and PKCa in differentiating cells, suggesting the existence of
distinct isoform specificity in the association within the cell cycle and differentiation
mechanisms (Gannon-Murakami and Murakami, 2002).
Significant matches to the 14-3-3 binding sequence RSxpSxP are present in PKCa,
PKC|3 and PKCy, as the motif RRLSVE (residues 238-243) and an additional matching
motif RSPSSP is found in PKCy (686-691) (Muslin et al., 1996). In PKC6, the interaction
motif is thought to be RSDSAS (301-306) and in PKCe, RSKSAP (343-348) (Acs et al.,
1995; Aitken et al., 1995a). In PKCi, the recognition sequence may be RSLSVK (474-479)
49
Chapter I: introduction
(Selbie et al., 1993) and in PKC£ the site was demonstrated to be RHDMSYMP (182-189)
(Van Der Hoeven et al., 2000a), although this is more similar to a mode-2 phosphoserine
interaction (see below). There are also potential interaction sites in PKCr), and PKC0
(Meller et al., 1996; Gannon-Murakami and Murakami, 2002). In addition, the conventional
PKC homologue in the organism Dictyostelium discoideum, the myosin II heavy chain-
specific protein kinase C (MHC-PKC), binds the endogenous Dd 14-3-3 and mammalian
14-3-31; within the CI regulatory domain of MHC-PKC to inhibit kinase activity, and this
interaction was independent of phosphorylation on a phosphoserine motif (Matto-Yelin et
al., 1997).
The 14-3-3 binding motifs
Recent evidence suggests the phosphoserine-containing 14-3-3 binding motif, typified in c-
Raf, may not be the only site for interaction. Most of the 14-3-3 interacting proteins contain
one of two phosphoserine based consensus motifs; the mode-1 RSxpSxP or mode-2
RxY/FxpSxP (where pS is phosphoserine) (Muslin et al., 1996; Yaffe et al., 1997). The
proline residue, although in the cis- conformation in one mode and trans- in the other, is
thought to provide a sharp change in chain direction, which allows the consensus target
region to exit the binding groove of the 14-3-3 dimer (Obsil et al., 2001; Aitken et al.,
2002). Mutagenesis has shown that the residues important in coordinating the binding of 14-
3-3 to the phosphoserine consensus sequence are lysine-49 and arginine-56, with
contributions from other residues such as arginine-127, tyrosine-128, valine-176 and
conserved leucine residues 216, 220 and 227 (numbered as in 14-3-3Q (Zhang et al., 1997;
Wang et al., 1998). Usually the consensus sequence contains serine residues, however there
is no structural reason why threonine residues would not provide a similar interaction
domain and indeed many 14-3-3 interacting proteins have phosphorylated threonine
residues, such as the serotonin N-acetyltransferase (RRHpTLP) (Aitken et al., 2002). The
residue immediately preceding the phosphorylated serine or threonine is often a basic
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residue (Aitken et al., 2002). In addition some binding partners contain an alternative,
unphosphorylated motif based on the Exoenzyme S recognition sequence WLDLE (Petosa
et al., 1998; Masters et al., 1999) or DALDL (Hallberg, 2002). The binding of these motifs
is thought to be coordinated by similar interactions within the amphipathic groove of the 14-
3-3 dimer, as a peptide based upon the WLDLE sequence (R18 peptide) was able to inhibit
c-Raf association and has also been crystallised with 14-3-3 (Liu et al., 1995; Petosa et al.,
1998).
Regulation of14-3-3 interactions andfunction by phosphorylation
In addition to 14-3-3 recognising a specific phosphorylated motif in many of the 14-3-3
binding partners, the 14-3-3 proteins themselves are regulated by phosphorylation. The 14-
3-3a and 14-3-38 isoforms were shown to be identical to the 14-3-3(3 and 14-3-31; isoforms
except they were phosphorylated on a serine residue at position 185 (Martin et al., 1993;
Aitken et al., 1995b). This phosphorylation event was able to alter the regulatory properties
of 14-3-3 in the interaction with PKC (increasing the inhibition of PKC by nearly two-fold)
(Aitken et al., 1995b). Another important regulatory modification of 14-3-3 is the
phosphorylation of 14-3-31; and 14-3-3x isoforms by casein kinase la (Dubois et al., 1997).
This phosphorylation occurs on a threonine residue at position 233 (serine in 14-3-3x) and
has been shown to act to reduce 14-3-3 affinity for binding c-Raf, as only the non-
phosphorylated form of 14-3-31; interacts with the amino-terminal domain of c-Raf
(Rommel et al., 1996; Dubois et al., 1997). The phosphorylation of 14-3-31; could therefore
potentially yield an isoform specific level of regulation, which may be particularly effective
roles of 14-3-3 isoforms in coordinating intracellular signalling pathways.
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14-3-3 and apoptosis
The involvement of 14-3-3 in the apoptotic pathway was demonstrated when 14-3-3 was
found to bind to the pro-apoptotic protein Bad (Zha et al., 1996). The binding of 14-3-3 to a
phosphorylated serine residue at position 136 sequestered Bad into the cytosol and
prevented it binding mitochondrial membrane associated Bcl-2 or Bcl-XL, thereby triggering
the apoptotic pathway (Zha et al., 1996; Masters and Fu, 2001; Masters et al., 2001). This
binding could be competed off with a 16-mer peptide corresponding to the phosphorylated
RSxpSxP motif - [phosphoserine259]-Raf 252-265 (pS-Raf259 phosphopeptide) (Yang et al.,
2001). Subsequently it has been shown that 14-3-3e is an endogenous target for caspase-3,
which cleaves 14-3-3e at Asp-238 to impair the regulatory 14-3-3/Bad interaction, driving
the cell into apoptosis by facilitating Bad interaction with Bcl-XL (Won et al., 2003).
Furthermore, 14-3-3 has been shown to bind to (and negatively regulate by sequestering into
the cytosol) other pro-apoptotic proteins such as the forkhead transcription factor FKHRL1
(Brunet et al., 1999), Askl (Zhang et al., 1999a) and Nur77 (Masuyama et al., 2001), which
are transcription factors involved in the activation of various genes involved in apoptosis
(Brunet et al., 1999). This implicates 14-3-3 as an important regulatory partner in apoptotic
mechanisms.
14-3-3 and receptors
In 1999, Prezeau and co-workers reported that the 14-3-31; isoform could interact with the
third intracellular loop of the a2 adrenergic G protein-coupled receptor (Prezeau et al.,
1999). Additionally it has been reported that 14-3-31; and 14-3-3r) isoforms can interact with
the carboxy-terminal tail of the metabotropic GABAb GPCR (Couve et al., 2001). 14-3-3
proteins have also been shown to interact with phospholipid membranes in an isoform-
dependent manner (Roth et al., 1994; Jones et al., 1995b). Among other 14-3-3 binding
partners are a number of transmembrane spanning proteins, including the tyrosine kinase-
linked insulin-like growth factor receptor, ion channels, CLIC4 and the plant plasma
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membrane H+-ATPase (Marra et al., 1994; Craparo et al., 1997; Furlanetto et al., 1997;
Suginta et al., 2001; Yuan et al., 2003). Furthermore, 14-3-3 has been shown to facilitate
trafficking of the insulin receptor substrate (IRS-1), an important downstream effector
involved in the signalling mechanism of the insulin receptor, from the membrane to
cytosolic compartments (Craparo et al., 1997; Kosaki et al., 1998; Xiang et al., 2002). This
translocation was shown to be dependent on phosphatidylinositol 3-kinase activity and was
proposed to be a mechanism of desensitisation of the insulin-dependent activation of IRS-1
(Xiang et al., 2002). Phosphatidylinositol 3-kinase (PI3K) is an enzyme that phosphorylates
phosphatidylinositols on the D3 hydroxyl position to produce phosphatidylinositol-3-
phosphates. For example, PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate
(PIP2), to convert it to phosphatidylinositol 3,4,5-trisphosphate (PIP3). PI3K has been shown
to bind to 14-3-3 directly at the pi 10 catalytic subunit and the activity of the enzyme is
attenuated in the presence of high levels of 14-3-3 (Bonnefoy-Berard et al., 1995). The
potential effects of 14-3-3 in PI3K-mediated signalling mechanisms (which has implications
for cell cycle regulation and proliferation) indicates that 14-3-3 may have a functional role
in other phospholipid-dependent signalling processes.
In addition, 14-3-3 has been shown to interact with the GTPase activating proteins
(GAPS) for the heterotrimeric G proteins, the regulator of G protein signalling (RGS)
proteins RGS3 and RGS7 (Benzing et al., 2000; Niu et al., 2002). 14-3-3 proteins have been
shown to bind to a phosphorylated serine in the Ga-interacting domain of the RGS protein
to inhibit the GTPase activating properties of the protein (Benzing et al., 2000). In doing so,
14-3-3 proteins may act on the transmission of the heterotrimeric G protein signal and help
to modulate the signalling of the system following activation, or they may act as scavengers,
keeping a pool of the RGS proteins in a negatively regulated state (Niu et al., 2002).
53
Chapter I: Introduction
The hypothesis of this study
The nature of 14-3-3 interaction with the third loop of the a2-adrenergic G protein-coupled
receptor and the tail of the metabotropic GABAb receptor indicates that 14-3-3 may have
some physiological role that it can accomplish whilst in association with certain GPCRs.
This association may be of functional significance in regulating the signalling of these
receptors. In this study, the possibility that 14-3-3 can associate in a similar way with the M3
muscarinic receptor and the potential location of interaction is investigated.
Phospholipase D contains the sequence YRSLSYPFLL at amino acid residues 711-
720 and this motif is identical to the consensus 14-3-3 interaction site, based on the c-Raf
sequence RSxpSxP. The implication of a possible direct interaction of 14-3-3 with PLD as
well as the possibility that 14-3-3 may interact with the M3 receptor (as it does with other
GPCRs) suggests that 14-3-3 may have an important role in regulating PLD (and perhaps
other) signalling mechanisms by this receptor.
The project is therefore designed to investigate the possibility of physical and
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Materials and Methods
Plasmids used in this study
Plasmids encoding N-terminally haemagluttinin tagged human phospholipase Dlb (HA-
PLD1) and mouse phospholipase D2 (HA-PLD2) in pCGN vector were kindly gifted by Dr
M. Frohman. The plasmid encoding GST fusion protein of the third intracellular loop of the
human M3 muscarinic receptor (residues Gly308-Leu497) in pGEX 3X was kindly gifted by
Dr S. Lanier. Plasmids encoding GST fusion protein of the C-terminal tail domain of the
human M3 muscarinic receptor (residues Asn450-Leu590) in pGEX 2T and the N-terminally
signal FLAG tagged human M3 muscarinic receptor (sFM3) in pcDNA 3.1 were created and
gifted by Dr E. Lutz in collaboration. Plasmids encoding GST fusion proteins of the 14-3-3^
and 14-3-3r) isoforms in pGEX 2T-1 and those encoding the C-terminally myc-tagged wild
type 14-3-3^, T233D 14-3-3^ mutant and wild type 14-3-3e in pcDNA 3.1 were created by
Dr T. Dubois. The original wild type 14-3-3r) clone was a gift from Dr H. Leffers and was
subcloned into pZeo 3.1 by Dr T. Dubois to make the N-terminally myc-tagged 14-3-3r].
The deletion mutant A" 26 14-3-3e in pcDNA 3.1 was created by Dr D. Jones.
Cell lines
COS 7 green monkey kidney fibroblast cells were used throughout this study. The culture
media used was Dulbecco's Modified Eagle's Media (DMEM) (with 4500 mg/1 glucose and
1-glutamine but without pyruvate) supplemented with 10% normal calf serum (NCS) and the
antibiotics penicillin and streptomycin at 50 units/ml. All tissue culture media and normal
calf serum in this study was obtained from Gibco (Invitrogen Life Technologies, Paisley,
UK).
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Cell culture
Cell lines were grown and maintained in a humidified atmosphere of 5% C02 (v/v) at 37 °C
at all times unless otherwise indicated. Culture medium was refreshed every 3-4 days, all
flasks, 6/12 well plates for culturing and plastics were obtained from Greiner Bio-One
(Gloucestershire, UK).
The cells were harvested by a brief incubation with 10 ml/175 cm2 Hank's Buffered
Saline Solution (HBSS) containing 10% (v/v) lOx trypsin-EDTA (Gibco), which was
applied to the cell layer, agitated and aspirated after 20 seconds. After a further 10 minutes,
the cells were washed off the flask surface with the appropriate medium and resuspended.
The cells were then reseeded into flasks at a ratio of 1:3 or onto 6 or 12 well plates for
microscopic or assay purposes.
For storage purposes, 0.5 ml volumes of cells at 106 cells/ml in medium or foetal
calf serum containing 7-10% (v/v) dimethylsulfoxide (DMSO) were aliquoted into cryosafe
tubes and stored in an insulted polystyrene box at -70°C overnight. The tubes were then
transferred to the liquid nitrogen storage facility. To recover the cells from the cryostore, the
tubes were allowed to thaw at room temperature and then warmed in a 37°C water bath for
two minutes. The cells were resuspended in 8 ml medium, transferred to a 25 cm2 flask and
incubated overnight. The medium was then refreshed to remove any trace of DMSO and the
cells cultured as normal.
Preparation ofmammalian cDNA
I. Transformation of competent cells
A 200 pi aliquot of either JM109 or TOP10 competent strains of Escherichia coli was added
to 1 pg of plasmid cDNA, carefully mixed and incubated on ice for 30 minutes. The cells
were subjected to heat shock at 42 °C for 45 seconds in a water bath and placed back on ice
immediately. Following a further incubation of 5 minutes, 400 pi of sterile Furia Bertani
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(LB) medium (10 g/1 bacto-tryptone, 5 g/1 yeast extract, 10 g/1 NaCl; pH 7.5) was added to
the cell mixture and incubated with rotation at 37 °C for 1 hour. 100 pi of this suspension
was then spread onto LB-agar (LB medium containing 1% (w/v) bactoagar) plates,
supplemented with 50 pg/ml ampicillin for plasmid selection and incubated overnight at 37
°C. A single discrete colony was picked and inoculated into 3 ml of sterile LB medium
containing 100 pg/ml ampicillin (LB-amp) and incubated with agitation for four hours at 37
°C. This culture was then seeded into 100 ml LB-amp in a sterile 250 ml conical flask (to
allow sufficient aeration) and incubated overnight at 200 rpm in an orbital shaking incubator
at 37 °C.
II. Plasmid purification
Plasmid cDNA was purified using QIAfilter Plasmid Maxi Kit (Qiagen, West Sussex, UK)
according to the manufacturer's instructions. The bacterial cells were harvested by
centrifugation at 6000 x g for 15 minutes at 4 °C and all traces of medium were removed.
The pellet was resuspended in 10 ml ice cold Resuspension Buffer PI (50 mM Tris-HCl pH
8.0, lOmM EDTA) containing 100 pg/ml RNase A solution until homogeneous. Following
resuspension, 10 ml of Lysis Buffer P2 (200 mM NaOH, 1% (w/v) SDS) was added and
mixed gently by inversion. This was incubated at room temperature for 5 minutes precisely.
Subsequently 10 ml of chilled Neutralisation Buffer P3 (3.0 M potassium acetate; pH 5.5)
was added and mixed thoroughly to prevent further lysis. The mixture of supernatant and
fluffy white precipitate (containing genomic DNA, cell debris and SDS) was then poured
immediately into a previously prepared QIAfilter Maxi cartridge and allowed to incubate at
room temperature for 10 minutes. During the cartridge incubation, a QIAGEN-tip 500
column was equilibrated with 10 ml Equilibration Buffer QBT (750 mM NaCl, 50 mM
MOPS pH 7.0, 15% (v/v) isopropanol, 0.15% (v/v) Triton X-100). Following incubation,
the bacterial lysate was filtered into the QIAGEN-tip 500 and the cleared supernatant
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allowed to flow through. The tip was then washed with 2 x 30 ml Wash Buffer QC (1.0 M
NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol) and the DNA eluted into an ethanol
washed polypropylene tube using 15 ml Elution Buffer QF (1.25 M NaCl, 50 mM Tris-HCl
pH 8.5, 15% (v/v) isopropanol). The DNA was precipitated by adding 10.5 ml isopropanol
at room temperature, mixed and centrifuged at 15 000 x g for 30 minutes at 4°C (Sorvall
SS-34 rotor). The pellet was carefully washed with 5 ml of sterile 70% (v/v) ethanol at room
temperature and centrifuged at 15 000 x g for 10 minutes. The pellet was washed a further
time and the pellet subsequently air dried for 10 minutes before being resuspended and
dissolved in approximately 200 pi sterile TE buffer (10 mM Tris-HCl pH 8.0, ImM EDTA;
pH 7.6).
Transient transfection of cDNA into mammalian cells
COS 7 cells were trypsinised as described earlier and seeded into 75 cm2 or 175 cm2 flasks
or onto 6 or 12 well plates at approximately 50% confluency for transfection the following
day. Fugene-6 transfection reagent (Roche Diagnostics, East Sussex, UK) or Genejuice
(Novagen, Merck Biosciences, Nottingham, UK) was added to DMEM (with 4500 mg/1
glucose, with 1-glutamine, without pyruvate) according to the manufacturers instructions
and incubated for 5 minutes. cDNAs encoding proteins of choice or empty vector pcDNA3
(as a control) were added to the Fugene-6/DMEM or Genejuice/DMEM according to the
manufacturers instructions and swirled gently to mix, then incubated for a further 15
minutes. The transfection mixture was added to the cell layer, swirled gently and the cells
incubated at 37 °C for 48 hours. Cells were made quiescent by replacing culture media with
serum free media.
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Preparation ofcell extracts overexpressing specifiedproteins
COS 7 cells used for preparing cellular extracts were seeded into 175 cm2 flasks and
transfected with relevant cDNAs as previously described. Cells were made quiescent
approximately four hours before lysis. The cells were washed once in HBSS and solubilised
in 2 ml/175 cm2 flask Extraction buffer (PBS pH 7.5 containing 20% (w/v) glycerol, 1.0%
(w/v) CHAPS, 1.0% (w/v) sodium deoxycholate, 2 pg/ml aprotinin, 4 ug/ml leupeptin, 2
ug/ml pepstatin, 1 mM AEBSF) on ice for 1 hour with occasional agitation. The cellular
lysate and debris was scraped into two 1.5 ml tubes on ice and centrifuged at 12 000 x g for
20 minutes at 4 °C. Each supernatant was then transferred to a clean tube and was reserved
on ice for immediate use in GST fusion studies and the remaining pellet was lysed to check
for any detergent insoluble fractions with x2 Laemmli buffer (50 mM Tris, 2% (w/v)
sodium dodecyl sulphate, 5% (v/v) mercaptoethanol) containing 8 M urea for efficient
running of membrane associated proteins (Sung et al., 1999).
Glutathione S-transferase (GST) fusion studies
I. Transformation of competent cells
The procedure for transforming competent bacterial JM109 or BL-21 RIL E. coli strains
with plasmids encoding GST-fusion constructs was carried out as described previously for
the preparation of mammalian cDNA; however transformed bacterial colonies were selected
for by plating cells onto 2x YT (16 g/1 bacto-tryptone, 10 g/1 yeast extract, 5 g/1 NaCl; pH
7.0) supplemented with 1.5% (w/v) bacto-agar and 100 qg/ml ampicillin.
II. Bacterial growth and expression of fusion proteins
A single selected bacterial colony from the 2x YT selection plate was used to inoculate 20
ml of 2x YT medium containing 2% (w/v) glucose (2x YTG) and 100 pg/ml ampicillin in a
sterile 250 ml conical flask and was incubated overnight at 200 rpm in an orbital shaking
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incubator at 37 °C. This overnight culture was then seeded at a ratio of 1:100 (4 ml) into
400 ml 2x YTG with 100 pg/ml ampicillin in a sterile 2 1 flask and incubated at 37 °C until
the optical density at a wavelength of 600 nm (AWI0) of the culture reached between 0.4 and
0.6 - indicative of the culture reaching exponential growth. The tac promoter (Ptac) of the
pGEX GST plasmid requires isopropyl-p-D-thiogalactopyranoside (IPTG) in order to
induce protein production from the open reading frame (ORF) that encodes the GST gene
and inserted DNA sequences. Bacterial expression of the specific GST fusion protein was
therefore induced by adding IPTG to yield a final concentration of 0.5 mM per culture and
incubated for a further 3 hours. The culture was transferred to 2 x 300 ml centrifuge bottles
(Nalgene, Hereford, UK) and the cells pelleted by centrifugation at 7700 x g for 10 minutes
at 4 °C (Sorvall GSA rotor). The pellet was washed with 20 ml PBS, centrifuged again,
drained and stored overnight at -40 °C.
III. GST fusion protein purification
The bacterial pellet was allowed to thaw at room temperature and then gently resuspended
until homogeneous in 10 ml BugBuster reagent (Novagen, Merck Biosciences, Nottingham,
UK). The resulting lysate was centrifuged at 16 000 x g for 20 minutes at 4 °C. The clear
supernatant was reserved and the pellet discarded. Each bacterial supernatant was diluted
appropriately to allow for efficient comparison of GST-construct binding. To this was added
400 ql of a glutathione sepharose 4B suspension (1:1 glutathione sepharose 4B:PBS)
(Amersham Biosciences) and the mixture was incubated for 20 minutes at room temperature
with rolling. The beads were pelleted by centrifugation at 3000 x g for 2 minutes at 4 °C and
the supernatant removed. The beads were washed with 2 ml PBS and again pelleted, this
wash process was repeated twice more. Samples of enriched COS 7 cell extracts were
incubated with the GST fusion protein-linked glutathione beads in the absence or presence
of 100 qM [Pser^J-Raf 252-265 (Raf259 phosphopeptide) where indicated overnight at 4
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°C with rolling. The beads were then pelleted by centrifugation at 3000 x g for 2 minutes
and the supernatants removed. The beads were washed with 1 ml cold extraction buffer and
again pelleted, this wash process was repeated a further three times. Finally the supematants
were removed and the associated proteins were solubilised from the matrix by adding 80 pi
x2 Laemmli buffer containing 8 M urea and stored at -20 °C for electrophoresis and
immunoblot analysis.
[3H]N-Methyl-QNB binding to immunoprecipitates
Cells used in co-immunoprecipitation studies were seeded into 175 cm2 flasks and
transfected with relevant cDNAs as previously described. Cells were made quiescent 16
hours before lysis and if required, agonist stimulation was carried out for 20 minutes unless
otherwise described. The cells were washed once in HBSS and solubilised in 2 ml/175 cm2
flask immunoprecipitation (IP) buffer (PBS pH 7.5 containing 20% (v/v) glycerol, 1.0%
(w/v) CHAPS, 1.0% (w/v) sodium deoxycholate, 2 pg/ml aprotinin, 4 pg/ml leupeptin, 2
pg/ml pepstatin, 1 mM AEBSF) on ice for 1 hour with occasional agitation. The cellular
lysates and debris was scraped into two 1.5 ml tubes on ice and centrifuged at 12 000 x g for
20 minutes at 4 °C. Each supernatant was then transferred to clean 1.5 ml tubes and 20 pi of
a Protein G-sepharose (PrG) suspension (1:1 PrG beads:IP buffer) was added to 'preclear'
the lysate and remove any non-specific antibody interaction, this incubation was carried out
for 1 hour with rolling at 4 °C. The pellets were reserved and resuspended in 1 ml QNB
binding buffer (50 mM NaP04, 2 mM MgCl2; pH 7.4, 2 pg/ml aprotinin, 1% (w/v) BSA)
before being centrifuged at 12 000 x g for 30 minutes at 4 °C. The pellets were resuspended
in 1 ml QNB binding buffer and stored at -40 °C. The precleared cellular supernatants were
incubated overnight with primary antibody or species specific non-immune IgG as a
negative control with 40 pi PrG suspension, in the absence or presence of 100 pM [Pser259]-
Raf 252-265 (Raf259 phosphopeptide) where indicated, rolling at 4 °C. Following
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incubation, the supernatants were reserved, to 500 pi was added 100 pi of 0.1% (w/v)
bovine gamma globulin in PBS and 600 pi 30% (w/v) polyethylene glycol (PEG; 8000 wt)
in PBS, the samples were mixed and centrifuged for 15 minutes at 12 000 x g at 4 °C. The
supernatant was discarded and the PEG pellet was resuspended in 1.2 ml QNB binding
buffer. The immunoprecipitate beads were washed twice with 1 ml IP buffer and
resuspended in 1.2 ml QNB binding buffer. Samples of 200 pi of each condition were
aliquoted into clean tubes to yield appropriate triplicates of total binding compared to
duplicates of non-specific binding (a total of 5 x 200 pi per condition). A final concentration
of 2.38 nM [3H]N-methyl-quinuclindinyl benzilate ([3H]NMe-QNB; 3.1 TBq/mmol) (Kd =
0.58 ± 0.04 nM in COS 7 cells) (Mitchell et al., 2003) was added to all the tubes in a
volume of 25 pi. An additional 25 pi of buffer was added in the tubes where total binding
was being assessed, whereas in the tubes determining non-specific binding, 25 pi of 1 pM
final concentration N-methyl atropine was added. Ligand binding was carried out by
incubation at room temperature for 4 hours. Binding was quenched by addition of 250 pi of
cold QNB binding buffer to each sample, followed by 100 pi of 0.1% (w/v) bovine gamma
globulin in PBS and 600 pi 30% (w/v) polyethylene glycol (PEG; 8000 wt) in PBS. The
samples were centrifuged at 12 000 x g for 10 minutes at 4 °C and aspirated carefully. The
tips of the tubes containing the PEG pellets were cut from each sample into 6 ml Pony
'hang-in' vials (Perkin Elmer, Bucks, UK) and 4 ml of scintillation fluid (Perkin Elmer) was
added to each. Vials were capped and shaken briefly, incubated overnight at room
temperature and then counted on a Beckman LS 5801 series scintillation counter (Beckman,
Bucks, UK) using a 4 minute/sample, [3H] decays per minute (DPM) program.
Co-immunoprecipitation
Cells used in co-immunoprecipitation studies were seeded into 175 cm2 flasks and
transfected with relevant cDNAs as previously described. Cells were made quiescent 16
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hours before lysis and if required, agonist stimulation was carried out for 10 minutes unless
otherwise described. The cells were washed once in HBSS and solubilised in 2 ml/175 cm2
flask immunoprecipitation (IP) buffer (PBS pH 7.5 containing 20% (v/v) glycerol, 1.0%
(w/v) CHAPS, 1.0% (w/v) sodium deoxycholate, 2 pg/ml aprotinin, 4 pg/ml leupeptin, 2
pg/ml pepstatin, 1 mM AEBSF) on ice for 1 hour with occasional agitation. The cellular
lysates and debris was scraped into two 1.5 ml tubes on ice and centrifuged at 12 000 x g for
20 minutes at 4 °C. Each supernatant was then transferred to clean 1.5 ml tubes and 20 pi of
a Protein G-sepharose (PrG) suspension (1:1 PrG beads:IP buffer) was added to 'preclear'
the lysate and remove any non-specific antibody interaction, this incubation was carried out
for 1 hour with rolling at 4 °C. The pellet was reserved and lysed with x2 Laemmli buffer
(50 mM Tris, 2% (w/v) sodium dodecyl sulphate, 5% (v/v) mercaptoethanol) containing 8
M urea to check for any detergent insoluble fractions. During the 'preclear' incubation, the
antibody-Protein G conjugate was prepared by adding primary antibody (or an equivalent
concentration of species specific non-immune IgG as a negative control) to 40 pi of the
PrG:IP suspension in another clean 1.5 ml tube and this was incubated for 1 hour at 4 °C
with rolling. Following the 'preclear' step, the mixture was centrifuged at 12 000 x g for 30
seconds at 4 °C to pellet the Protein G beads and 1 ml of the supernatant transferred to the
antibody-PrG conjugated beads for incubation overnight at 4 °C with rolling. The remainder
of the precleared supernatant was reserved and an equal volume of x2 Laemmli buffer
containing 8 M urea was added to quantify the transfection efficiency and check the levels
of protein present in the cells. Following overnight incubation, the solution was centrifuged
at 12 000 x g for 30 seconds to pellet the Protein G beads and the supernatant was removed.
The Protein G was resuspended in 1 ml IP buffer and then pelleted by centrifugation. This
wash process was repeated twice more. The Protein G pellet was finally resuspended in 40
pi x2 Laemmli buffer containing 8 M urea and stored at -40 °C for electrophoresis and
immunoblot analysis.
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SDS-PAGE and immunoblotting (Western blot)
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) and
electroblotting was performed using two systems, depending on the sample type and
volume. The procedure used for immunoblotting was common to both methods.
I. PhastSystem (Amersham Biosciences)
The manufacturers instructions were followed using 12.5% pre-cast homogeneous
polyacrylamide gels (PhastGel Homogeneous 12.5, Amersham Biosciences, Bucks, UK).
The gel was placed, excluding air bubbles, film side down onto 80 pi of UHP H20 on the
pre-cooled (16 °C) gel bed of a PhastSystem separation and control unit (Amersham
Biosciences). The buffer strip assembly was placed upon the gel and PhastGel SDS buffer
strips (Amersham Biosciences) were placed into the holder, ensuring an even contact was
made with the gel underneath. The electrode assembly was then put into place, ensuring an
even contact with the buffer strips. The samples for SDS-PAGE (4 pl/lane) were loaded
onto the sample strip holder and this was placed in the apparatus. The separation program
was pre-set (at 250 V, 16 °C) and the samples were run for 90 AVh (approximately 35
minutes). During this time, Immobilon-PSQ polyvinyldifluoride (PVDF) transfer membrane
(0.2 pM pore size, 20 cm x 20 cm, Millipore, Gloucestershire, UK) was prepared by cutting
to 5 cm x 5 cm and marked for orientation. The membrane was immersed in 100% methanol
and then washed briefly five times with UHP H20 on a rotary shaker. The membrane was
then incubated in transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol; pH
8.3) with three changes until PAGE separation was completed.
Following PAGE, the gel was removed from the bed and the gel separated from the film
backing using the clamp and wire apparatus (Amersham Biosciences) at the interface of the
stacking and separating gel. The Immobilon-Ps° membrane was placed onto the separating
gel, ensuring that the orientation was correct and the plastic film back removed. Filter
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papers (3 pieces of 5 cm x 5 cm) were soaked in transfer buffer and placed onto the anode
plate of the PhastSystem development unit and the Immobilon-PSQ placed directly onto them
(gel uppermost). Another three filter papers were soaked in transfer buffer and placed on top
of the gel/Immobilon-PSQ. The cathode block was connected to the assembly and placed
carefully on top of the filters. The system was then switched on and transferred for 80
minutes using another automatic program (20 V, 16 °C).
II. Invitrogen NuPAGE Novex gel and XCell SureLock Mini-Cell system
Prior to PAGE, samples for separation were prepared by adding 2 pi of lOx Loading buffer
(0.04% (w/v) bromophenol blue in glycerol) to 20 pi of sample (in x2 Laemmli buffer).
This loading sample was then vortexed to mix, centrifuged for 2 minutes at 14 000 rpm and
heated to 70 °C for 5 minutes. A 4-12% Novex Bis-Tris pre-cast NuPAGE gradient gel
(Invitrogen, Paisley, UK) was placed into an XCell SureLock Mini-Cell (Invitrogen)
according to the manufacturers instructions. The inner buffer chamber was filled with 200
ml of lx MES (50 mM MES, 50 mM Tris base, 1 mM EDTA, 0.1% (w/v) SDS; pH 7.3) or
lx MOPS (50 mM MOPS, 50mM Tris base, ImM EDTA, 0.1% (w/v) SDS; pH 7.7) SDS
running buffer containing 500 pi NuPAGE antioxidant, the outer buffer chamber was filled
with 600 ml of lx MES or lx MOPS SDS running buffer. A sample volume of 20 pi was
loaded into each well. The mini-cell was connected to a power supply that provided a
constant potential of 200 V and was run for 45 minutes (MES buffer) or 55 minutes (MOPS
buffer). Meanwhile, Immobilon-PSQ polyvinyldifluoride (PVDF) transfer membrane (0.2
pM pore size, 20 cm x 20 cm, Millipore) was prepared by cutting to 9 cm x 7.5 cm and
marked for orientation. The membrane was immersed in 100% methanol and then washed
briefly three times with UHP H20 on a rotary shaker. The membrane was then incubated in
lx NuPAGE transfer buffer (25 mM bicine, 25 mM bis-tris, ImM EDTA, 10% (v/v)
methanol; pH 7.2) with three changes until PAGE separation was completed. Following
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separation, the gel was removed from the plastic cassette and the 'foot' was removed. The
membrane was placed on top of the gel (excluding any air bubbles) and two pieces of filter
paper pre-soaked in lx NuPAGE transfer buffer were used to sandwich the gel/membrane
on each side. Three pre-soaked blotting pads were then placed in the cathode core of the blot
module, the paper/gel/membrane sandwich was placed onto the pads (membrane uppermost)
and three pre-soaked blotting pads were placed on top of the arrangement. The anode plate
was put into place and the module was put into the mini-cell carefully, ensuring the
assembly remained airtight. The inner chamber of the blot module was filled with remaining
lx NuPAGE transfer buffer and the outer chamber of the mini-cell was filled with UHP
H20. The mini-cell was connected to the power supply and run at a constant 30 V for 80
minutes.
III. Immunoblotting
The Immobilon-PSQ membrane was removed form the appropriate transfer system, briefly
rinsed and given five washes in UHP H20 to remove any residual transfer buffer. The
membrane was then stained for 2 minutes in 0.1% (w/v) coomassie blue-R250 (Amersham
Biosciences), 50% (v/v) methanol and subsequently destained in 50% (v/v) methanol, 10%
(v/v) acetic acid until dark protein bands were contrasted with a pale background. The
membrane was washed in UHP H20 and placed into a clear polythene sheet for
documentary visualisation of protein loading. The membrane was scanned using Adobe
Photoshop 7.0 (Adobe Systems, CA, USA) software on an Apple Macintosh. The
membrane was cut as appropriate and all stain was removed using several washes of 100%
methanol. The membrane was washed again in UHP H20 (5x5 minutes) to remove any
residual methanol and blocked overnight in 5% (w/v) non-fat dried milk (Marvel) in PBS at
4 °C. Following blocking, the membrane was washed 5x5 minutes in 0.1% (v/v) tween-20
in PBS and incubated with an appropriate primary antibody concentration in primary buffer
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(2.0% (w/v) non-fat dried milk, 0.05% (v/v) tween-20 in PBS) for 90 minutes at room
temperature. The membrane was washed at least 5x5 minutes in 0.1% (v/v) tween-20 in
PBS. The membrane was incubated with an appropriate horseradish peroxidase conjugated
secondary antibody concentration (raised against the species used for the primary) in
secondary buffer (2.0% (w/v) BSA; 0.1% (v/v) tween-20 in PBS) for 50 minutes at room
temperature. Following secondary antibody incubation, the membrane was washed at least 5
x 5 minutes in 0.1% (v/v) tween-20 in PBS. The membrane was visualised using enhanced
chemiluminescence (ECL) detection methods. LumiGLO reagent and peroxide (Cell
Signalling Technology, NEB, Herts UK) were mixed in a 1 in 20 dilution and incubated on
the membrane for 1 minute. Excess ECL solution was removed and the membrane sealed in
a clear polythene bag. The membrane was exposed to ECL film (Amersham Biosciences) in
an X-ray cassette for between 30 seconds and 20 minutes and the film developed using an
automatic X-ray developer (Konica-Minolta, Bucks, UK). The film was scanned using
Adobe Photoshop 7.0 (Adobe Systems, CA, USA) software on an Apple Macintosh. Any




COS 7 cells used in immunocytochemistry were first plated onto sterile 2.5 mm2 glass
coverslips in 6 well dishes and transfected with relevant cDNAs as described previously.
Cells were made quiescent 16 hours before stimulation. Agonist stimulation was carried out
for 10 minutes unless otherwise indicated. Following stimulation, the medium was aspirated
and the cells permeabilised and fixed using 1 ml/well of ice cold 1:1 HBSS (w/o Ca2+ or
Mg2+): 4% (w/v) paraformaldehyde (PFA), 0.3% (v/v) Triton X-100 in PBS. The cells were
incubated for 16 hours at 4 °C. Following incubation, the cells were aspirated and the fix
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medium was replaced with 1 ml/well 4% PFA, 0.3% Triton X-100 in PBS and incubated for
10 minutes at room temperature. This was aspirated and the cells washed twice with 1
ml/well 0.2% (v/v) fish skin gelatin (FSG) in PBS. Following washes, the cells were
incubated with 1 ml/well 2% (w/v) BSA, 0.05% (v/v) tween-20 in PBS for 40-60 minutes at
room temperature to block non-specific antibody binding. The cells were then washed twice
with 1 ml/well 0.2% FSG in PBS. Primary antibody incubation was carried out by inverting
each coverslip onto 200 pi primary antibody buffer (primary antibody in 2% BSA, 0.05%
tween-20 in PBS) spotted onto a polythene sheet and then incubated for an hour at room
temperature. The cells were returned to the 6 well plates and washed five times with 1
ml/well 0.2% FSG in PBS with agitation. Secondary antibody incubation was then carried
out using 1 ml/well secondary antibody buffer - Alexa Fluor conjugated secondary
antibodies: green (488 nm) anti-mouse and red (568 nm) anti-rabbit, 1:1000 in 0.2% FSG in
PBS (Molecular Probes, Leiden, The Netherlands) - for 30 minutes in the dark with
agitation. The cells were washed five times with 1 ml/well 0.2% FSG in PBS in the dark.
The coverslips were briefly washed in UHP HzO and then mounted onto glass microscope
slides (BDH, Dorset, UK) using approximately 50 pi movial mounting fluid per coverslip,
ensuring no air bubbles formed. The slides were left overnight at room temperature and
subsequently stored at 4 °C in the dark before use.
II. Image acquisition
All data were acquired using a Zeiss LSM 510 laser scanning confocal microscope (Carl
Zeiss, Oberkochen, Germany) with a PlanApochromat 63x/1.4 Oil DIC objective. Cells
were imaged using scanning with a double dichroic excitation beam splitter; emission
wavelengths corresponding to 488 nm excitation were collected through a Band Pass
525/550 nm filter, and emission wavelengths corresponding to 568 nm excitation were
collected through a Long Pass 590 nm filter. The pinhole was set to 1 Airy Unit and scan
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speed to maximum. Images were acquired at Nyquist sampling rates at 8 bit per pixel depth
and all scanned frames were sequentially tracked for each channel with a minimum average
of four passes to reduce noise.
II. Image analysis
Image data were deconvolved using the Huygens 2 software package (Scientific Volume
Imaging, Hilversum, The Netherlands) on SGI Octane II workstations. Each channel was
subjected to a maximum of 20 iterative algorithms to reach quality threshold levels for
reducing blur and noise. Optical aberration and the point-spread-function were determined
in software using a maximum likelihood estimation (MLE) algorithm. The data was
subsequently analysed using the Bitplane Imaris suite of image analysis software (Bitplane
AG, Zurich, Switzerland). The total number of colocalised voxels above thresholds per
channel was measured along with proportional amounts for each channel. The channel
correlation coefficient was determined from the whole dataset according to the Pearson
method (Bitplane AG).
Assay for Phospholipase C activity: fHJinositol phosphate production
COS 7 cells used in phospholipase C (PLC) activity assays were first plated into 12 well
dishes and transfected with relevant cDNAs as described previously. Cells were maintained
at 37 °C in a humidified atmosphere of 5% C02 (v/v) throughout the assay. Prior to the
assay, cells were made quiescent in EBSS (Earle's balanced salt solution) with lOmM
HEPES and 1.8% (w/v) glucose. The cells were labelled with 37 KBq/well myo-[2-
[3H](N)]inositol (37 MBq/ml, 888 GBq/mmol, Perkin-Elmer, Bucks, UK) for 16 hours.
Following incubation, the labelling medium was aspirated and the cells washed twice with 1
ml/well EBSS containing lOmM HEPES, 1.8% (w/v) glucose and 0.2% (w/v) BSA
(fractionV) and then incubated with 0.5 ml/well of the same medium for approximately 20
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minutes. 10 minutes prior to stimulation, 10 pi of 500 mM LiCl was added to yield a final
concentration of 10 mM Li+ per well. The cells were stimulated with agonist and incubated
for 30 minutes unless otherwise indicated. The assay was stopped by aspirating the assay
medium and adding 1 ml of ice cold 10 mM formic acid per well (Almaula et al., 1996) and
incubating overnight at 4°C. Each sample was then carefully applied to a 1 ml bed volume
Dowex anion exchange column (1x8 resin; formate form; 200-400 mesh) and a stepwise
gradient of ammonium formate was used to elute the [3H] inositol phosphate products as
described by Berridge (Berridge et al., 1983).
Each column was washed with:
15 ml of UHP water
5 ml of 50 mM ammonium formate
The [3H] inositol phosphates were eluted and collected into 20 ml Zinsser scintillation vials
(Zinsser analytic, Berks, UK) using:
10 ml of 1.0 M ammonium formate/0.1 M formic acid
The columns were then washed with:
5 ml of 2.0 M ammonium formate/0.1 M formic acid
15 ml UHP water
Following collection of the eluted products, 500 pi of each eluate was aliquoted in duplicate
into 6 ml Pony 'hang-in' polyethylene vials (Perkin-Elmer) and 4 ml of Emulsifier-safe
liquid scintillation cocktail (Perkin-Elmer) was added. Vials were capped and shaken
briefly, incubated overnight at room temperature and counted on a Beckman LS 5801 series
scintillation counter (Beckman, Bucks, UK) using a 4 minute/sample, [3H] decays per
minute (DPM) program.
71
Chapter 2: Materials and Methods
Assay for Phopholipase D activity: fH]phosphatidyl butanol production
COS 7 cells used in phospholipase D (PLD) activity assays were first plated into 12 well
dishes and transfected with relevant cDNAs as described previously. Cells were maintained
at 37 °C in a humidified atmosphere of 5% C02 (v/v) throughout the assay. Prior to the
assay, cells were made quiescent in DMEM (w/o sodium pyruvate, with 4500 mg/1 glucose,
with pyroxidine HC1) and the fatty acid moiety of phosphatidylcholine was labelled with
185 KBq/well [9,10-3H]palmitate (185 MBq/ml, 1 TBq/mmol, Perkin Elmer) for 16 hours.
Following incubation, the labelling medium was aspirated and the cells were washed once
with 0.75 ml/well MEM (Eagles; with 25 mM HEPES, with Earles salts, w/o 1-glutamine)
containing 1.0% (w/v) essentially fatty acid free BSA and then incubated with 0.5 ml/well
of the same medium. Immediately prior to the assay, Butan-l-ol in MEM was added to each
well to give a final concentration of 30 mM butan-l-ol per well. The assay was initiated
with agonist and incubated for 30 minutes unless otherwise stated. The assay was
terminated by the aspiration of assay medium and addition of 500 pi ice cold methanol per
well. Cells were scraped and the extraction of [3H]PtdBut product followed a method of
lipid extraction described by Bligh and Dyer (Bligh and Dyer, 1959). Samples were
transferred to 2 ml glass vials (Chromacol, Merck/BDH) and 500 pi chloroform and 400 pi
H20 were added to yield a ratio of methanol:chloroform:water of 5:5:4. They were
vortexed, capped with rubber seals, and left overnight at 4 °C. The samples were
centrifuged for 20 minutes at 1000 rpm to separate the aqueous and organic layers. The
upper aqueous layer was discarded and 250 pi of the lower organic layer was transferred to
new clean vials. The solvent was evaporated overnight or under vacuum at 30 °C in a
centrifugal evaporator (Gyrovap, V A Howe, Oxfordshire, UK) for 30-50 minutes. Each
sample was resuspended in 50 pi of a solvent mixture of 19:1 chlorofornrmethanol and
spotted onto a lane of a LK5D 150 A silica gel thin layer chromatography (TLC) plate (250
pm thick) (Whatman, Kent, UK). The plates were developed using the organic phase of the
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running solvent mixture (ethyl acetate, 2,2,4-trimethylpentane, acetic acid, water, in the
ratio 110:50:20:100). The region of TLC plate corresponding to the migration of [3H]PtdBut
had been identified previously using a [14C]PtdBut standard (McCulloch, 1998). Six
segments of 0.5 cm length per lane, from between 4.0-7.0 cm from the plate origin, were
scraped into six 6 ml Pony 'hang-in' polyethylene vials (Perkin-Elmer) and 4 ml of
Emulsifier-safe liquid scintillation cocktail (Perkin-Elmer) was added. Vials were capped
and shaken briefly and counted on a Beckman LS 5801 series scintillation counter
(Beckman, Bucks, UK) using a 4 minute/sample, [3H] decays per minute (DPM) program.
Data analysis
All quantitative values from assays were expressed as mean ± standard error of the mean
(SEM) acquired from a number (n) of individual experiments. Statistical analysis was
carried out using the Wilcoxon matched pairs nonparametric test unless otherwise indicated.
The Graphpad Prism program (Graphpad Software, CA, USA) was used to analyse and plot
the data.
All Research Collaboratory for Structural Bioinformatics (RCSB) protein databank
(pdb) molecular visualisations were performed using the PyMOL Molecular Graphics
System software (DeLano Scientific, CA, USA). Quantitative densitometry values were
derived using the ScanAnalysis program (Biosoft, Cambridge, UK).
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Introduction
Experiments carried out by Prezeau and colleagues in 1999 revealed the unexpected finding
that 14-3-31; could bind to the third intracellular loop of subtypes A-C of the a2-adrenergic
receptor (Prezeau et al., 1999). Whilst much work had been done on other 14-3-3 binding
partners, this was the first indication that 14-3-3 could interact with G protein-coupled
receptors and suggested that 14-3-3 may be providing a scaffolding or even functional role
by this association. It was subsequently reported that 14-3-31; and 14-3-3r] isoforms could
interact with another GPCR, the metabotropic GABAb receptor, within the carboxy-terminal
tail domain, potentially to regulate the heterodimerisation or functionality of the receptor
(Couve et al., 2001). In addition, 14-3-3 has been shown to interact with the regulator of G-
protein signalling (RGS) proteins RGS3 and RGS7 (Benzing et al., 2000; Niu et al., 2002).
The 14-3-3 protein appears to sequester RGS proteins by binding to a phosphorylated serine
and inhibiting the GTPase activating properties of these proteins. These results together
suggest that 14-3-3 may provide a direct structural role in GPCR scaffolding by binding to
receptors directly, or 14-3-3 may provide a functional role by binding to partners involved
in signalling cascades or their associated proteins and such interaction may act to regulate
receptor-mediated signalling pathways. To determine whether 14-3-3 proteins could
potentially interact with the M3 muscarinic receptor in a similar way to the findings of other
groups with the a2 adrenergic and GABAb receptors, the experimental approaches of in
vitro glutathione S-transferase fusion protein pull-down assays and co-immunoprecipitation
studies were used. In addition, the isoform specificity of 14-3-3 involved in any potential
interaction was investigated to find out whether 14-3-3 isoforms differed in their properties
of association with the M3 receptor. Any such finding of isoform selectivity would suggest
the potential for fine control of 14-3-3:M3 receptor interactions (and of any further cellular
events dependent on these interactions).
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The native 14-3-3 isoforms in COS 7 cells
Many of the isoforms of 14-3-3 proteins are expressed abundantly in the peripheral tissues
and brain-up to 1% of brain protein is 14-3-3 (Aitken et al., 1992). In order to understand
the effects of expressing additional 14-3-3 constructs, it was necessary to determine which
14-3-3 isoforms were endogenously present in the COS 7 cell line. Untransfected serum-
deprived COS 7 cells were lysed on ice in cold CHAPS/deoxycholate-containing extraction
buffer, proteins were separated by SDS-PAGE and Western blotted. Different endogenous
14-3-3 isoforms were visualised using rabbit polyclonal primary antisera specific to each of
the isoforms (Martin et al., 1993) followed by anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (Chemicon, Hants, UK) and the results are shown in Figure
3.1. COS 7 cells were found to contain reasonably high levels of endogenous 14-3-3(3, 14-3-
3e, 14-3-3y and 14-3-3r|, and much lower levels of 14-3-31; and 14-3-3o isoforms. As it was
the 14-3-31; isoform that was determined to interact with the a2 adrenergic receptor (Prezeau
etal., 1999) and 14-3-31; was additionally implicated in the interaction with the
metabotropic GABAb receptor (Couve et al., 2001), we considered that additional
expression of myc-tagged 14-3-31; or other 14-3-3 isoforms may be required to optimally
observe the influence of these proteins on M3 receptor function. Therefore myc-tagged 14-3-
3 isoforms (N-terminally myc-tagged 14-3-3r| and C-terminally myc-tagged 14-3-3e and
14-3-3^) were transiently transfected into COS 7 cells. The fact that these were myc-tagged
yielded an extra level of control within the model system, so that isoform specificity could
be determined (especially as the normally poorly expressed 14-3-31; was a likely candidate)
and allowed for greater sensitivity with regard to detection of 14-3-3 using high affinity
antibodies for the myc-tag of the specific 14-3-3 isoform transfected.
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Figure 3.1
Endogenous 14-3-3 isoforms in COS 7 cells.
Samples of native COS 7 cell extract were separated by SDS-PAGE and immunoblotted
with specific rabbit polyclonal primary antibodies (Martin et. al., 1993) to determine native
expression of six of the isoforms of 14-3-3 proteins. The (3, e, y, and rj isoforms of 14-3-3
were found to be normally expressed at readily detectable levels in COS 7 cells. COS 7 cells
appeared to express very little of the isoforms 14-3-3a and 14-3-31;.
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14-3-3 isoforms interact with the M3 receptor in vitro
To determine whether 14-3-3 proteins could interact with the intracellular domains of the
M3 muscarinic receptor, an in vitro binding assay was used. Glutathione S-transferase (GST)
fusion proteins of the third intracellular loop of the M3 receptor (M3i3), corresponding to
residues G308-L497, and the C-terminal domain of the M3 receptor (M3ct), corresponding to
residues N540-L590, were kindly gifted by Dr S. Lanier and Dr E. Lutz respectively. These
GST fusion proteins and GST alone (as a negative control) were immobilised onto
glutathione Sepharose 4B and incubated overnight with CHAPS/deoxycholate-solubilised
cellular extracts from COS 7 cells that had been transiently overexpressing myc-tagged 14-
3-3 isoforms (14-3-3^-myc, 14-3-3£-myc and myc-14-3-3r]). Bound proteins were lysed
from the beads, separated by SDS-PAGE, and Western blotted. Myc-tagged 14-3-3 isoforms
were visualised using rabbit anti-myc polyclonal primary antibody (Upstate Biotech, Milton
Keynes, UK) followed by HRP-conjugated anti-rabbit secondary antibody (Chemicon).
Input levels of 14-3-3-myc immunoreactivity in extracts were also monitored and both
fusion protein and binding protein inputs were carefully balanced as far as possible to
ensure comparability between samples. The GST-fusion constructs, visualised using rabbit
polyclonal anti-GST (Santa Cruz, Autogen Bioclear Ltd., Wilts, UK), expressed with
different efficiencies, however only bands that corresponded to the intact constructs were
taken into account when balancing the GST-fusion input levels (Figure 3.2). The three 14-3-
3 isoforms specifically associated with both the third intracellular loop and carboxy-terminal
tail domains of the M3 muscarinic receptor and the binding of 14-3-31; but not 14-3-3r) or
14-3-3e exhibited interaction site specificity. Although the 14-3-3e association with the M3
receptor constructs showed an apparently stronger binding than the other 14-3-3 isoforms,
the difference in expression levels of the 14-3-3e isoform may have been sufficient to
account for the higher apparent binding levels. Densitometric analysis of the Western blot
bands suggested that in contrast to the other 14-3-3 isoforms, 14-3-31; displayed a lower
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Figure 3.2
B
<# <# .0? & & rt^? O£J











14-3-31; 14-3-3r| 14-3-3e COS 7 input
(Blot - myc) (Blot - myc)
GST input
(Blot - GST)
14-3-3 isoforms bind to the M, receptor in vitro.
Extracts of COS 7 cells, transiently overexpressing different myc tagged 14-3-3 isoforms
were applied to GST-fusion constructs of the M3 receptor third intracellular loop (M3i3) and
tail (M3ct) domains. The immunoblot shows the binding of the three isoforms of 14-3-3 to
the constructs (A) compared to input levels of protein (B) (both probed for the myc tag) and
input levels of GST (blotted for GST) (C). A non-specific band, which was immunoreactive
in all preparations, is indicated (NS). The GST reactive bands above 60 kDa are probably
due to breakdown products in the bacterial expression system.
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affinity for the M3 carboxy-terminal tail domain compared to the third intracellular loop
domain (a reduction in band grey scale density of approximately 30% given balanced inputs
of constructs and potential binding protein in each case) and similar findings were made in
three independent experiments. This parallels the findings made with subtypes of the a2-
adrenergic receptor (where 14-3-3'C, specifically interacted with the third intracellular loop)
(Prezeau et al., 1999). The 14-3-3e and 14-3-3r| isoforms, however, bound to both GST-
M3i3 and GST-M3ct constructs with a similar affinity, suggesting that any molecular
interactions of these isoforms with the receptor in vivo may be provided by a contribution of
both the loop and tail domains.
14-3-3 isoforms co-immunoprecipitate with the M3 receptor
COS 7 cells were transiently transfected with signal FLAG tagged M3 (sFM3) receptor and
myc-tagged 14-3-31; (14-3-3^-myc) cDNA in a 1:1 ratio and were serum-deprived for 16
hours prior to the experiment. Immunoprecipitates directed against the FLAG tag were
prepared by incubating precleared supernatants from CHAPS/deoxycholate-containing
cellular extracts with 3 pg/ml mouse monoclonal anti-FLAG antibody clone M2 (Sigma
Aldrich, Dorset, UK) or 3 pg/rnl non-immune mouse IgG as a control, followed by 40 p,l/ml
of a 1:1 suspension of Protein-G Sepharose in immunoprecipitation buffer. The beads were
washed and co-immunoprecipitates lysed from the matrix using Laemmli buffer, separated
by SDS-PAGE, Western blotted and visualised using rabbit anti-myc primary antibody
(Upstate Biotech) followed by HRP-conjugated anti-rabbit secondary antibody (Chemicon).
The input levels of immunoprecipitated M3 receptor were visualised with rabbit polyclonal
anti-M3 receptor primary antibody (kindly gifted by Dr A. Tobin), followed by anti-rabbit
HRP-conjugated secondary antibody (Chemicon). Figure 3.3 shows the co-
immunoprecipitation of the 14-3-31; isoform with the M3 receptor and the levels of
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14-3-35 co-immunoprecipitates with the M3 receptor.
COS 7 cells were transiently transfected with sFM3 receptor and 14-3-3^-myc constructs.
Immunoprecipitation was made with anibody directed against the FLAG tag of the receptor
and co-immunoprecipitated 14-3-3 levels were visualised by probing Western blots for the
myc tag (A). The levels of FLAG immunoprecipitate of the sFM3 receptor, probed with anti-
M3 antibody (A. Tobin), are shown in (B). A sample of the cellular supernatant was applied
as a positive control (COS 7 input) and the non-specific antibody bands resulting from the
reagent input are indicated (IgG). The M3 receptor specifically pulls down the 14-3-35
isoform compared to the control.
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experiments). This interaction corroborates the finding of the in vitro binding assay, where
the 14-3-31; bound to the third intracellular loop of the M3 receptor (apparently with a higher
affinity than to the tail) and corroborates the findings of Prezeau and colleagues who
observed 14-3-3^ associating with the third loop of the a2A_c-adrenergic receptors. However,
in the study from Prezeau and co-workers, the co-immunoprecipitation of 14-3-3^ with the
a2-adrenergic receptor subtypes could not be demonstrated (Prezeau et al., 1999), indicating
that any interaction of 14-3-3 with the M3 receptor is either more stable, or of a higher
affinity, than that with the a2-adrenergic receptor.
These immunoprecipitation experiments were repeated with 14-3-3rj, to determine
whether there was any isoform specificity in the association. COS 7 cells were transiently
co-transfected with the sFM3 receptor and myc-14-3-3r| cDNAs at a 1:1 ratio and were
serum deprived for 16 hours. The M3 receptor was immunoprecipitated from the precleared
CHAPS/deoxycholate cellular lysates with antibody against the FLAG tag of the M3
receptor (anti-FLAG, clone M2, Sigma) or non-immune mouse IgG (as a control) and the
levels of co-immunoprecipitated 14-3-3r) were visualised by SDS-PAGE, Western blotting
and probing for the myc-tag (Figure 3.4). As with the 14-3-31; isoform, the M, receptor
pulled down 14-3-3r) and the interaction appeared to be quite robust. In the studies
demonstrating 14-3-3 association with the metabotropic GABAb receptor, it was the 14-3-
3C, and 14-3-3r] isoforms that were shown to associate with the carboxy-terminal tail
domain of the receptor (Couve et al., 2001). In that study, other 14-3-3 isoforms were not
tested, so it was important to determine whether 14-3-3 and M3 receptor association was
selective with respect to 14-3-3 isoforms, by using a third 14-3-3 isoform.
The 14-3-3e-myc isoform was transfected together with the sFM3 receptor into COS
7 cells and the M3 receptor was immunoprecipitated using the FLAG tag exactly as before.
A representative result of the co-immunoprecipitation of 14-3-3e with the M3 receptor is















14-3-31) co-immunoprecipitates with the M3 receptor.
COS 7 cells were transiently transfected with sFM3 receptor and myc-14-3-311 constructs.
Immunoprecipitation was made with anibody directed against the FLAG tag of the receptor
and co-immunoprecipitated 14-3-3 levels were visualised by probing Western blots for the
myc tag (A). The levels of FLAG immunoprecipitate of the sFM3 receptor, probed with anti-
M3 antibody (A. Tobin), are shown in (B). A sample of the cellular supernatant was applied
as a positive control (COS 7 input) and the non-specific antibody bands resulting from the
reagent input are indicated (IgG). The M3 receptor specifically pulls down the 14-3-3r]
isoform compared to the control.
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14-3-3s co-immunoprecipitates with the M3 receptor.
COS 7 cells were transiently transfected with sFM3 receptor and 14-3-3e-myc constructs.
Immunoprecipitation was made with anibody directed against the FLAG tag of the receptor
and co-immunoprecipitated 14-3-3 levels were visualised by probing Western blots for the
myc tag (A). The levels of FLAG immunoprecipitate of the sFM3 receptor, probed with anti-
M3 antibody (A. Tobin), are shown in (B). A sample of the cellular supernatant was applied
as a positive control (COS 7 input) and the non-specific antibody bands resulting from the
reagent input are indicated (IgG). The M3 receptor specifically pulls down the 14-3-3e
isoform compared to the control.
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specifically co-immunoprecipitate with the M3 receptor, in accordance with the in vitro GST
association described earlier. This suggests, at least for the isoforms tested here, that 14-3-3
interaction with the receptor may not show any marked isoform specificity.
The binding of14-3-3 to the M} receptor may involve the amphipathic groove
The binding of 14-3-3 to many binding partners depends on the recognition of the c-Raf-like
motif RSxpSxP or RxY/FxpSxP (Muslin et al., 1996; Yaffe et al., 1997) whilst other
interactions may depend on an unphosphorylated WLDLE (Petosa et al., 1998) or DALDL
(Hallberg, 2002) motif. Experiments were carried out to assess whether the binding of 14-3-
3 to the M3 muscarinic receptor could be disrupted by a peptide consisting of the c-Raf
phosphoserine motif as a competitive binding partner for the 14-3-3 amphipathic groove.
The M3:14-3-3 interaction was assayed by immunoprecipitating 14-3-3 (for the myc tag)
and using specific binding of radiolabeled M3 receptor antagonist [3H]N-Me-QNB to
determine the presence of M3 receptor co-immunoprecipitating with 14-3-3. COS 7 cells
were transiently transfected with signal FLAG-tagged M3 (sFM3) receptor and myc-tagged
14-3-3^ (14-3-3^-myc) cDNA in a 1:1 ratio and were serum deprived for 16 hours prior to
the experiment. Immunoprecipitates directed against the myc tag were prepared by
incubating precleared cellular supernatants with 2 pg/ml mouse monoclonal anti-myc
antibody clone 9E10 (Sigma Aldrich, Dorset, UK) or 2 pg/ml non-immune mouse IgG as a
control, followed by 40 pl/ml of a 1:1 of Protein-G Sepharose suspension, in the absence or
presence of 100 pM [phosphoserine259]-Raf 252-265 (pS-Raf259 phosphopeptide),
LSQRQRSTpSTPNVHMV (KD~ 120 nM for 14-3-31;) (Muslin et al., 1996). The 14-3-3
myc immunoprecipitates, along with the precleared supernatants were assayed for the
presence of the M3 muscarinic receptor binding sites by incubating the immunoprecipitates
with 2.4 nM [3H]N-Me-QNB to determine total binding (KD = 0.58 ± 0.04 nM in COS 7
cells) (Mitchell et al., 2003) or radioligand plus 1 pM N-methyl atropine to determine non-
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specific binding (KD ~ 0.5-2.0 nM) (Maggio et al., 1999; Mitchell et al., 2003), for four
hours at room temperature. The immunoprecipitates were centrifuged at 12 000 x g for 10
minutes at 4 °C, washed and assayed for levels of [3H] ligand binding by liquid scintillation
counting. The non-specific binding was subtracted from the total binding to yield specific
binding (Figure 3.6). Although 14-3-3 has many cellular binding partners (Aitken, 1996),
the increased sensitivity of the radiolabelled-antagonist binding assay is able to detect very
low levels of associated M3 receptor. This association was attenuated by the presence of the
high affinity 16-mer phosphoserine motif 14-3-3 binding peptide, pS-Raf 259, suggesting
that 14-3-31; interacts with the M3 receptor, either directly or indirectly, at a similar site to
the phosphoserine peptide, in the amphipathic groove of the 14-3-3 dimer. Further
experiments with control peptides (for example scrambled and de-phosphorylated
sequences) would enable the specificity of this effect to be fully substantiated and further
characterise the mode of interaction.
Membrane localised 14-3-3 is primarily in the plasma membrane fraction
It has been well documented that 14-3-3 is a mainly cytosolic protein (Moore et al., 1968;
Boston et al., 1982), yet there is also evidence of 14-3-3 localising with synaptic membranes
in neuronal cells (Martin et al., 1994; Jones et al., 1995b) and with the Golgi apparatus
(Celis et al., 1988). In addition to this, and because the M3 receptor is a membrane inserted
protein, it was important to determine whether 14-3-3 could associate with cellular
membranes and elucidate the localisation of any membrane-associated 14-3-3 in COS 7
cells. To do this, serum-deprived untransfected cellular membranes from COS 7 cells were
prepared by Dr Rory Mitchell and fractionated through Percoll gradients (Amersham
Biosciences, Bucks, UK) as described in a previous study (Mitchell et al., 2003) to separate
endosomal, Golgi and plasma membrane fractions. The membrane fractions 1-10,
corresponding to the membranes of different subcellular compartments, were solubilised in
Laemmli buffer, separated by SDS-PAGE and Western blotted (Figure 3.7).
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Control +pS-Raf259 Blank Supernatant
The binding of 14-3-3 with the M, receptor involves the amphipathic groove of 14-3-3.
The immunoprecipitates of 14-3-3^-myc under control conditions and in the presence of
100 pM of the 14-3-3 recognition sequence 16-mer peptide pS-Raf 259
(LSQRQRSTpSTPNVHMV) (+pS-Raf 259) were assayed for the presence of M3 receptor
by specific [3H]N-MeQNB binding. The non-specific binding (black bars) was subtracted
from the total binding (grey bars) for each condition to yield specific binding. The binding
levels of Protein-G Sepharose beads only (Blank) and the binding from the precleared
cellular supernatants (Supernatants) are also shown. The presence of the pS-Raf 259 peptide
prevents specific binding of the M3 receptor to 14-3-31; immunoprecipitates, indicating that
occlusion of the amphipathic groove of 14-3-3 prevents 14-3-3 association with the M3
receptor (*p<0.05, Unpaired student t-test; n=5).
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The marker for the Golgi-associated membranes, GM-130 (130 kDa) was visualised using
anti-GM-130 mouse monoclonal primary antibody (Transduction Laboratories, BD
Biosciences, Cowley, UK) with anti-mouse HRP-conjugated secondary antibody
(Chemicon) and was detected most highly in the fractions 7 and 8, with a smaller amount
present in fractions 6 and 9. The Na+/K+ ATPase al subunit (112 kDa), used as the marker
for the plasma membrane, was visualised using anti-Na7K+ ATPase al mouse monoclonal
primary antibody (Upstate Biotech) with anti-mouse HRP-conjugated secondary antibody
(Chemicon) and was present most highly in fractions 9 and 10, with smaller amounts in
fraction 8. The 14-3-3 levels were visualised using anti-14-3-3 (clone H8, isoform non¬
specific) mouse monoclonal primary antibody (Santa Cruz) with anti-mouse HRP-
conjugated secondary antibody (Chemicon). The 14-3-3 was found in increasing amounts in
the later fractions and was present at the highest levels in fractions 9 and 10 - corresponding
to the plasma membrane, with a smaller presence in fraction 8 corresponding to the Golgi.
These results, which were typical of two independent experiments, indicate that whilst 14-3-
3 may predominantly be a cytosolic protein, it has the ability to associate with cellular
membranes and specifically the plasma membrane. These findings support previous
experimental information from other groups by demonstrating that 14-3-3 has a similar
potential localisation to that of the M3 muscarinic receptor and indicates that under basal
conditions, some isoforms of 14-3-3 at least may enter into a complex with the M3
muscarinic receptor. Indeed, as 14-3-3 has also been shown to localise to the plasma
membrane of neuronal cells (Martin et al., 1994; Jones et al., 1995b), the implication that
14-3-3 may play an important functional role in facilitating neurotransmitter activity (by
interacting with GPCRs) is quite compelling.
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Figure 3.7
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Membrane associated 14-3-3 is located primarily at the plasma membrane.
Membrane fractions 1-10 were prepared from resting COS 7 cells using Percoll gradient
fractionation as described in Mitchell, et. al., 2003. The Golgi membrane marker GM-130
was visualised with high levels in fractions 7-9, the Na+/K+ ATPase was used for
identification of the plasma membrane and was present in high levels in fractions 9 and 10.
The 14-3-3 was visualised using a pan-isoform specific antibody, and was at highest levels
in fractions 9 and 10 - corresponding to the plasma membrane.
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Effects of wild-type and mutant 14-3-3£ expression on the agonist-stimulated signalling
properties of the M} receptor
The 14-3-31; isoform has a phosphorylation site on threonine-233, which allows negative
regulatory phosphorylation by casein kinase la (Dubois et al., 1997). Phosphorylation of
this residue has been demonstrated to negatively regulate 14-3-31; association with c-Raf
(Rommel et al., 1996). A mutation of this site from threonine (T) to aspartate (D) is
expected to confer surrogate phosphothreonine (233)-like behaviour onto 14-3-31; and
therefore should reduce 14-3-31; affinity for target proteins containing the RSxpSxP motif
(Dubois et al., 1997). The effects of the expression of wild type 14-3-31; and mutant T233D
14-3-3^ isoforms on agonist-stimulated M3 muscarinic receptor phospholipase C and
phospholipase D signalling characteristics were investigated. COS 7 cells were transiently
transfected with sFM3 and wild type 14-3-3^-myc, mutant T233D 14-3-3^-myc or empty
vector (as a negative control) cDNAs in a 1:1 ratio and seeded into 12 well plates. The
muscarinic agonist carbachol was used in all assays, with a constant stimulation time of 20
minutes. For PLC responses, the cells were labelled with [3FI]inositol and serum-deprived
for 16 hours. For PLD responses, the cells were labelled with [3H]palmitate and serum-
deprived for 16 hours. The [3H]inositol phosphate and [3H]phosphatidylbutanol products
were assayed in response to carbachol stimulation and the results are shown in Figure 3.8.
The PLC response to carbachol was attenuated by the overexpression of wild type
14-3-3^ compared to the control COS 7 cells, which was significant when compared with
the overexpression of T233D 14-3-3t, at concentrations of 100 uM carbachol (p<0.05,
Wilcoxon test; n=4). The overexpression of either 14-3-31; types, did not significantly affect
the signalling of PLD compared to control levels (p>0.05, Wilcoxon test; n=4).
Any evidence for a specific modulation of one M3-coupled signalling pathway
(PLC) compared to another (PLD), would suggest that 14-3-3 could be involved
functionally. One basis for such an influence may be that overexpression of 14-3-3
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interferes somehow with the normal expression of the M3 receptor at the cell surface.
However, because the PLD responses are not affected by 14-3-3 expression while PLC
responses are attenuated, this may be unlikely to be the mechanism of modulation. Another
possibility is that 14-3-3^ expression could potentially exert a differential influence, as 14-
3-3 proteins have been shown to interact with the regulators of G protein signalling (RGS)
proteins and have been proposed to negatively regulate their GTPase-activating properties
(Benzing et al., 2000; Benzing et al., 2002; Niu et al., 2002). Modulation of the RGS
function has been shown to act as a 'molecular switch' for the facilitation of one M3 coupled
pathway over another (Rumenapp et al., 2001). Therefore, if the wild type 14-3-3^ isoform
could negatively regulate an RGS protein involved in controlling the coupling of the M3
receptor to the Gq heterotrimeric G protein and PLC pathway, overexpression of the wild
type 14-3-3^ might yield a selective attenuation of that pathway. The T233D 14-3-3^
mutant, which may have a reduced affinity for RGS interaction, might therefore not regulate
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14-3-35 type and mutant effects on PLC and PLD responses of COS 7 cells.
COS 7 cells, transiently transfected with empty control vector (•), wild type 14-3-3^-myc
(A) orT233D 14-3-3^-myc (▼) were stimulated for 20 minutes with various concentrations
of the M3 agonist carbachol (CCh). The PLC-mediated accumulation of radiolabelled
inositol phosphates (A) or the PLD-mediated accumulation of radiolabelled
phosphatidylbutanol (B) were measured. The overexpression of wild type 14-3-3^ caused an
attenuation of PLC responses to M3 agonist, which was significant at concentrations of 100
pM CCh (*p<0.05, Wilcoxon test) compared to the T233D 14-3-3^ mutant (n=4).
Overexpression of either of the 14-3-3^ forms did not significantly affect PLD responses to
M3 agonist (p>0.05, Wilcoxon test; n=4).
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A putative dimerisation-deficient 14-3-3e mutant affects the agonist-stimulated properties
of the M3 muscarinic receptor
14-3-3 dimers are formed by interactions of the amino-terminal domains of each monomer
(residues 5-21 and 58-89) (Liu et al., 1995; Xiao et al., 1995). Deletion of residues in this
domain has been shown to disrupt efficient dimer formation (Jones et al., 1995b). A
truncation mutant of the first twenty six amino acid residues of the 14-3-3e isoform, A" 26
14-3-3e, was used to investigate the potential signalling implications of dimer disruption in
the context of the PLC and PLD signalling pathways of COS 7 cells. The cDNAs of the
sFM3 receptor and wild type 14-3-3 e-myc, mutant A" 26 14-3-3 e-myc, or empty vector as a
control, were transiently transfected into COS 7 cells in a 1:1 ratio. The cells were labelled
with [3H]inositol and serum-deprived for 16 hours for PLC assays or labelled with
[3H]palmitate and serum-deprived for 16 hours for PLD assays. The [3H]inositol phosphate
and [3H]phosphatidylbutanol products were assayed in response to 20 minutes of carbachol
stimulation and the results are shown in Figure 3.9. The PLC responses to carbachol were
significantly attenuated (between the concentrations of 1-100 pM) with wild type 14-3-3e
overexpression (p<0.05, Wilcoxon test), but not the A" 26 14-3-3e mutant, which exhibited
no difference from control levels (n=4). For PLD responses, the overexpression of both wild
type and A" 26 14-3-3e isoforms did not significantly affect PLD response to the M3 agonist
(p>0.05, Wilcoxon test, n=4).
Similarly to the results with the 14-3-3^ isoform, a likely candidate target for 14-3-
3e in attenuating carbachol-induced PLC activation may be an RGS protein. The
dimerisation deficient mutant of 14-3-3e, A" 26 14-3-3e, may not be able to assemble as a
stable heterodimer, and the lack of any equivalent inhibitory effect suggests that dimer
assembly is necessary for 14-3-3 function here, as proposed by others in different situations
(Jones et al., 1995a; Tzivion et al., 1998; Aitken, 2002).
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Figure 3.9
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14-3-3e wild type and mutant effects on PLC and PLD responses of COS 7 cells.
COS 7 cells, transiently transfected with empty control vector (•), wild type 14-3-3e-myc
(A) or A" 26 14-3-3£-myc (▼) were stimulated for 20 minutes with various concentrations
of the M3 agonist carbachol. The PLC mediated accumulation of radiolabelled inositol
phosphates (A) or the PLD mediated accumulation of radiolabelled phosphatidylbutanol (B)
were measured. The overexpression of wild type 14-3-3e caused a significant attenuation of
the PLC response to M3 agonist stimulation (*p<0.05, Wilcoxon test), which was mitigated
by the overexpression of the A" 26 14-3-3e mutant (n=4). The overexpression of both wild
type 14-3-3e and A26 14-3-3e caused a slight but not significant attenuation of the PLD
response to agonist (p>0.05, Wilcoxon test; n=4).
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The lack of significant attenuation of the carbachol-induced PLD response by
overexpression of both wild type 14-3-3e and A" 26 14-3-3e indicates that the mechanism
used by 14-3-3e to attenuate M3 receptor-mediated PLC response is likely to be distinct
from that used by the receptor for activation of PLD. This concurs with previous evidence
that the mechanism of M3 receptor mediated PLC and PLD activation are largely distinct in
COS 7 cells (Mitchell et al., 2003). An important point that should be considered when
interpreting these observations is that one isoform of 14-3-3 may potentially interrupt the
usual modulation of certain signalling events by another isoform by functioning as a
competitive binding partner or even by forming less effective heterodimers.
Summary
In summary, these experimental findings have shown that 14-3-3 isoforms can associate
with the M3 muscarinic receptor both in GST-fusion studies and in co-immunoprecipitation
studies. With the exception of 14-3-31;, the isoforms were found to bind to both the M3
receptor third intracellular loop and carboxy-terminal tail domains with apparently
equivalent affinity, suggesting that the site of interaction may be composed of contributions
from each of these domains. The specific association of all 14-3-3 isoforms tested with the
M3 receptor, demonstrated by co-immunoprecipitation, indicates that 14-3-3 proteins may
associate with the M3 receptor similarly to the a2-adrenergic and GABAb receptors (Prezeau
et al., 1999; Couve et al., 2001). However, the precise functional significance of this is not
yet clear. The 14-3-3 proteins have been shown to recognise the c-Raf-like phosphoserine
motif RSxpSxP or RxY/FxpSxP (Muslin et al., 1996; Yaffe et al., 1997). The closest M3
receptor sequences as candidates for the 14-3-3 recognition site, are the residues
RSCSSYEL (288-295) or TATLP (451-455) within the third intracellular loop domain
(Obenauer et al., 2003). However, the likely interaction site would need to be more
thoroughly investigated by using mutagenesis studies involving the third intracellular loop
and carboxy-terminal tail domains of the M3 receptor. Furthermore, as membrane-associated
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14-3-3 is primarily found at the plasma membrane, this indicates that a functional assembly
of the M3 receptor and 14-3-3 isoforms could potentially occur in vivo and may implicate
14-3-3 in the signalling of GPCRs.
The nature of wild type (but not mutant) 14-3-3 e potentially influencing the whole-
cell signalling characteristics of the M3 muscarinic receptor activation of PLC, but not PLD,
implies that there may be a modulation of a protein involved in the pathway. A likely
candidate for this is the RGS protein, involved in coupling the heterotrimeric G protein to
the PLC pathway, as 14-3-3 has been shown to interact with these signalling regulators
(Benzing et al., 2000; Benzing et al., 2002). This may also be the case with the modulation
of signalling by the wild type 14-3-3^ isoform, which displayed a similar inhibitory trend
when compared to the T233D 14-3-31; mutant. If the RGS proteins can influence the
signalling characteristics within the cell by facilitating or impeding G protein activation
(Berman and Gilman, 1998; Rumenapp et al., 2001), the modulation of specific RGS
protein activity by 14-3-3 proteins (in an isoform dependent manner) may present a
mechanism of regulation that is consistent with the results found in this chapter. Further
investigations into whether the RGS proteins are involved (for example whether a specific
type of RGS protein is associated with 14-3-3 upon carbachol stimulation or whether the
RGS/14-3-3 may exist as a complex with the M3 receptor) would need to be made, for
example in the use of siRNA or specific blockade of the interface for 14-3-3 binding by
decoy peptides.
Furthermore, it has been previously shown that the product of PLD activity,
phosphatidic acid, is an important cofactor for the activation of the MAP kinase pathway
(Rizzo et al., 1999; Andresen et al., 2002; Ghosh et al., 2003) and the M3 receptor has been
shown to couple to the MAP kinase signalling pathway upon agonist stimulation and
desensitisation (Budd et al., 1999). As 14-3-3 proteins have already been demonstrated to be
important in the Ras and PKC mediated activation of c-Raf (and subsequent MAP kinase
activation) (Fantl et al., 1994; Freed et al., 1994), it may be possible that 14-3-3 proteins are
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involved in the M3 receptor-mediated (and possibly PLD-dependent) activation of the MAP
kinase pathway. Following activation of the M3 receptor, the subsequent involvement of
PKC-phosphorylated c-Raf may compete for M3:14-3-3 interaction and allow the receptor to
undergo another series of critical signalling or internalising interactions. Further
investigations into the role of both 14-3-3 and PLD in the potential facilitation of MAP
kinase activation may be very valuable in understanding the coordination of parallel
signalling pathways (signal crosstalk).
The physiological implications of the role of 14-3-3 in the signal transduction
characteristics of the M3 receptor remain unclear. The interaction of 14-3-3 isoforms with
the receptor, as demonstrated in this chapter, may imply that 14-3-3 provides a scaffolding
role for the receptor. However, the potential modulation by 14-3-3 of the effector responses
to agonist stimulation of the M3 receptor also implies that 14-3-3 may have distinct
functional roles in modulating the signalling mechanism of the M3 receptor.
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Introduction
The potential for a phospholipase D to interact directly with a G protein-coupled receptor
(GPCR) was identified when the amino terminal domain of PLD2 was found to interact with
the carboxy-terminal tail domain of the p-opioid receptor in a yeast two-hybrid screen
(Koch et al., 2003). The PLD2 (but not PLD1) isozyme could further be co-
immunoprecipitated with the p-opioid receptor in a constitutive manner and was
demonstrated to be necessary for the agonist-dependent internalisation of the receptor.
Phosphatidic acid produced by PLD2 activity was proposed to recruit the AP-2 adapter
complex and the clathrin coat protein to the membrane for the formation of endocytotic
vesicles, which were necessary for receptor internalisation. Inhibition of PLD activity
resulted in an inhibition of receptor endocytosis (Koch et al., 2003; Koch et al., 2004). The
GPCR interacting domain within PLD2 was determined to be in the amino-terminal region
of the isozyme, which contains a Phox homology (PX) domain. As PLD1 also contains a
conserved PX domain, it is interesting to question why isozyme specificity for PLD2 was
observed in that study. Furthermore, PLD2 rather than PLD1 has been implicated in the
endocytic internalisation of the angiotensin II type 1A (AT1a) receptor. However the
possibility of a direct interaction between the receptor and PLD2 was not addressed (Du et
al., 2004). It was therefore important to question whether PLD could interact with the M3
muscarinic receptor as found with other GPCRs and whether any interaction was isozyme
specific. In this chapter the strategies of GST-fusion pull-downs and co-
immunoprecipitation were used to determine whether PLD could interact with the M3
muscarinic receptor.
Basal endogenous PLD levels are low within most cells and PLD activity is only
transiently elevated upon stimulation (Exton, 1994; Cockcroft, 1996; Cockcroft, 2001). This
has led to a difficulty in elucidating the signalling role of PLD and has necessitated using
epitope tagged PLD constructs in the determination of PLD localisation and function. The
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subcellular localisation of PLD isozymes has been investigated by a number of different
groups (Chen et al., 1997; Colley et al., 1997; Brown et al., 1998; Czarny etal., 1999;
Czarny et al., 2000; Freyberg et al., 2001; Sarri et al., 2003; Du et al., 2004). In the majority
of these studies, the PLD2 isozyme has been characterised as being associated almost
exclusively with the plasma membrane of most cell types under resting conditions (Colley et
al., 1997; Czarny et al., 2000; Cockcroft, 2001; Du et al., 2004). A recent report using high
affinity antibodies considered to selectively recognise endogenous PLD2 has suggested that
it is present at high levels in the Golgi apparatus, with only a small proportion present at the
plasma membrane (Freyberg et al., 2002). This localisation, however, remains disputed, as
endogenous PLD2 activity has also been demonstrated primarily at the plasma membrane
by others (Du et al., 2004).
The distribution of PLD1 appears to be quite divergent in different cell types. The
majority of reports indicate that PLD 1 localises mainly to intracellular membranes such as
the Golgi apparatus, endosomes and lysosomes in most resting cells (Ktistakis et al., 1995;
Chen et al., 1997; Cockcroft, 2001). Investigations made by Freyberg and colleagues, using
highly selective antibodies for PLD1 have shown that endogenous PLD1 is present in the
Golgi apparatus and even in the nuclear compartment (Freyberg et al., 2001). In PC12 cells
however, PLD1 associates mainly with the plasma membrane (Vitale et al., 2001; Du et al.,
2003) and there are also reports of PLD1 activity at the plasma membrane (as well as
intracellular membranes) in other cell types (Kim et al., 1999; Lucocq et al., 2001). The
ability of PLD to localise to particular membranes is thought to be conferred by the lipid-
interacting domains. The pleckstrin homology (PH) domain has been shown to be important
for PLD localisation to membranes, as it interacts with PIP2 (although this particular
interaction is not necessarily involved in PLD activation) (Hodgkin et al., 2000; Du et al.,
2003). Upon cellular stimulation, it has been shown that PLD1 translocates from
intracellular membrane compartments to the plasma membrane (Morgan et al., 1997; Brown
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et al., 1998; Du et al., 2003; Mitchell et al., 2003). It has been proposed that this
translocation and subsequent recycling from the plasma membrane to the intracellular
compartment may involve a series of sequential interactions of the different conserved lipid-
interacting domains with lipid membranes (Du et al., 2003).
In order to substantiate and develop previous results from subcellular fractionation
(Mitchell et al., 2003) it was important to visualise the expression characteristics of PLD
isoforms in the COS 7 cell system. The technique of confocal microscopy was used to
determine the subcellular localisation of the M3 receptor and PLD isozymes in COS 7 cells
and to observe the effect of muscarinic receptor agonist stimulation on these localisations.
The phospholipase D signalling ability of the M3 muscarinic receptor through both
the classical heterotrimeric G-protein activated pathway and ADP-ribosylation factor (ARF)
activated (or other small G protein-dependent) pathways has been investigated previously
(Rumenapp et al., 1995; Schmidt et al., 1995; Schmidt et al., 1997; Mitchell et al., 1998).
The receptor-activated ARF-dependent component of PLD signalling is sensitive to the
ARF-guanine nucleotide exchange factor (ARF-GEF) inhibitor brefeldin A (BFA)
(Donaldson et al., 1992; Guillemain and Exton, 1997; Mitchell et al., 1998). Therefore the
contribution of the receptor-mediated ARF-dependent component of PLD activity, can be
calculated from the relative reduction in the agonist activated response in the presence of
BFA (Mitchell et al., 1998). Furthermore, the demonstration that a dominant negative
mutant of PLD1 (K898R), but not PLD2 (K758R), can partially inhibit the PLD response to
the M3 agonist carbachol indicates that in COS 7 cells, the PLD1 isozyme is the primary
mediator of the receptor stimulated PLD response (Mitchell et al., 2003).
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Confocal immunofluorescence imaging ofPLD
Visualising the basal localisation of PLD was carried out by confocal immunofluorescence
imaging after transfecting COS 7 cells with HA tagged PLD1 or PLD2. The cells were
serum-deprived for 6 hours, permeabilised and fixed overnight. The fixed cells were stained
with primary mouse monoclonal anti-HA antibody clone 12CA5 (Roche Diagnostics, East
Sussex, UK) followed by Alexa Fluor goat anti-mouse (488 nm) secondary antibody
(Molecular Probes, Leiden, The Netherlands). The cells were then imaged by confocal
microscopy, acquiring data at Nyquist sampling rates. Healthy (non-rounded) transfected
cells were selected at random and were scanned equivalently using identical experimental
conditions throughout image acquisition (maintaining both laser power and photon-
multiplier tube amplification in software). The Nyquist sample rate is defined as the
minimum theoretical sampling rate to fully describe a band limited signal; for a maximum
frequency component of f0 the Nyquist rate would need to at be least 2f0 (for a wavelength
of 488 nm the values were typically an xy-field of 47 x 47 nm and z-step of 130 nm at 1024
x 1024 pixel resolution).
Confocal images of unstimulated COS 7 cells expressing HA-PLD1 and HA-PLD2
are shown in Figure 4.1 and Figure 4.2 respectively. The localisation of PLD2 in COS 7
cells is mainly associated with the plasma membrane, consistent with most other findings
(Colley et al., 1997; Czarny et al., 2000; Sarri et al., 2003; Du et al., 2004). There was
minimal PLD2 antibody staining of intracellular compartments, such as the Golgi apparatus,
which was observed by Freyberg and colleagues (Freyberg et al., 2002). In contrast to that
report, our findings with HA-tagged PLD2 expressed in COS 7 cells yielded results entirely
consistent with most other studies showing a predominant plasma membrane localisation.
In COS 7 cells, PLD1 was localised mainly to the perinuclear regions, presumed to
be the Golgi apparatus, in accordance with other findings (Brown et al., 1998; Cockcroft,
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Chapter 4: The interaction of PI.D with the M, receptor
The localisation of PLD1 in unstimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an unstimulated COS 7 cell, transiently
transfected with HA-PLD1 and stained for the HA tag with AlexaFluor 488 nm antibody
(green). The PLD1 isoform consistently localises predominantly to punctate intracellular
and perinuclear structures with a small proportion localising with the plasma membrane.
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The localisation of PLD2 in unstimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an unstimulated COS 7 cell, transiently
transfected with HA-PLD2 and stained for the HA tag with AlexaFluor 488 nm antibody
(green). The PLD2 isoform consistently localises to the plasma membrane in agreement
with other findings.
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been observed by some others (Lucocq et al., 2001). It is possible that the large vesicular-
type structures visualised may be indicative of the expression of the transfected PLD
compared to endogenous PLD levels (Freyberg et al., 2001). In a previous study by our
group, endogenous PLD1 was found mainly on the intracellular compartment membranes,
with little presence at the plasma membrane in unstimulated COS 7 cells (Mitchell et al.,
2003). In the Freyberg study, endogenous PLD1 was localised to the perinuclear and nuclear
regions, but there was also some endogenous PLD1 present at the plasma membrane
(Freyberg et al., 2001). This suggests that the partial localisation of transfected HA-PLD1 to
the plasma membrane is a good reflection of the distribution seen normally with native
PLD1.
Signalling of the M, receptor to PLD
It has been proposed that full activity of PLD 1 requires the synergistic co-activation by
ARF, Rho and PKC together (Kuribara et al., 1995; Hodgkin et al., 1999). The PLD1
mutant PIM87/I870R (PIM/IR HA-PLD1) construct has mutations in the residues that are
thought to be important for the activation of PLD1 by RhoA (a mutation of isoleucine 870
to arginine) and PKC (an insertion of GVPLE at position 87) (Yamazaki et al., 1999; Zhang
et al., 1999). The mutant can be thought of as being only ARF responsive (Du et al., 2000).
Signal FLAG-tagged M3 receptor and either empty vector, wild type HA-PLD1 or the
PIM/IR HA-PLD1 mutant were transiently expressed in COS 7 cells and the PLD response
to the muscarinic M3 receptor agonist, carbachol, was measured in a concentration-
dependent manner. The log concentration-response curves to carbachol for the wild type
PLD1 and the PIM/IR PLD1 mutant are shown in Figure 4.3.
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The contribution of direct ARF dependent PLD activation in COS 7 PLD responses.
COS 7 cells were transiently transfected with sFM3 receptor and empty vector (•), sFM3
and wild type HA-PLD1 (A) (A) or sFM3 receptor and the ARF only responsive PLD1
mutant HA-PIM87/I870R (▼) (B). The cells were stimulated for 20 minutes with different
concentrations of the M3 receptor agonist carbachol (CCh) and the log-concentration
response curves are shown. In (A), non-linear regression analysis indicated that the mean
EC50 values for CCh in wild type PLD1 and control vector transfected cells were 0.35 and
0.23 pM respectively (n=4). The mean maximal response to CCh in wild type PLD1
transfected cells was increased to 162 ± 18.2% of that in control (p>0.05, Wilcoxon test). In
(B), non-linear regression analysis indicated that the mean EC50 values for CCh in
PIM87/I870R PLD1 and control vector transfected cells were 6.86 pM and 0.27 pM
respectively (n=4). The mean maximal response to CCh in PIM87/I870R PLD1 cells was 89
± 5.6% of that in control (p>0.05, Wilcoxon test). These findings are consistent with the
hypothesis that full M3 agonist-mediated PLD1 activation arises from a synergistic action of
ARF, PKC and also potentially RhoA in COS 7 cells.
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Non linear regression analysis indicated that the mean EC50 in wild type PLD1-
transfected cells was 0.35 |iM and for PIM/IR PLD1 was 6.86 p.M carbachol - this yielded a
dose ratio of approximately 25 fold (n=4) and is consistent with a lower potency of M3
receptor-evoked PLD1 activation. The mean EC50 of M3 and vector only-transfected cells
was 0.23 pM and 0.27 pM carbachol respectively. However, the mean maximal response of
the PIM/IR PLD1 mutant was 89 ± 5.6% of control (compared to 162 ± 18.2% in wild type
PLD1), indicating that it did not attenuate the response in the way seen with the catalytically
inactive PLD1 mutant (K898R-PLD1) (Mitchell et al., 2003). These observations agree with
previous evidence that PKC, RhoA and ARF act synergistically to fully activate PLD1 and
that each may potentially play a role in M3 receptor-evoked PLD responses.
M3 receptor domains interact with PLD in vitro
Glutathione S-transferase (GST) fusion proteins of the third intracellular loop of the M3
receptor (M3i3) and the carboxy-terminal tail domain of the M3 receptor (M3ct) were
prepared as in the previous chapter. These GST fusion proteins and GST as a negative
control were immobilised onto glutathione Sepharose 4B to create an affinity matrix.
Cellular extract from COS 7 cells overexpressing HA-tagged PLD1 was applied to the
prepared affinity matrix and incubated at 4 °C overnight with rolling. Bound proteins were
lysed from the beads, separated by SDS-PAGE, and Western blotted. HA-PLD1 levels were
visualised with a primary rat monoclonal anti-HA antibody conjugated to horseradish
peroxidase (HRP) (Roche Diagnostics) and a representative result from three independent
experiments is shown in Figure 4.4A. Input levels of HA-PLD immunoreactivity in extracts
were also monitored and both fusion protein and interacting protein inputs were balanced to
ensure comparability between samples. The level of GST fusion protein in the input matrix
was visualised using primary rabbit polyclonal anti-GST antibody (Santa Cruz), followed by
anti-rabbit HRP-conjugated secondary antibody (Chemicon) and is shown in Figure 4.4B.
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PLD1 associates with the M3 receptor in vitro.
COS 7 cell extracts transiently overexpressing HA-PLD1 were incubated with GST fusion
proteins of the M3 receptor third intracellular loop (M3i3) and carboxy-terminal tail (M3ct)
domains, and with GST only as a negative control. The associated PLD1 was visualised
using anti-HA antibody (A). The GST fusion proteins of the M3 receptor pull down PLD1
with an equal affinity for both constructs. The GST fusion constructs of the input proteins
are also shown, visualised using anti-GST antibody (B). The bands above 60 kDa are
probably due to breakdown products in the bacterial expression system.
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The expression of the GST-fusion construct of the M3ct was consistently accompanied by a
high level of expression of GST alone. Nevertheless, inputs were balanced for the band of
the correct molecular mass for the complete GST-M3ct construct and because the levels of
PLD association with GST control were so low, it was most unlikely that the contribution of
GST itself was a significant factor in the results. The matching of the band density for both
the M3i3 and M3ct GST-fusion constructs allowed effective comparison of the results. PLD1
appeared to bind to both GST-fusion constructs of the M3 receptor specifically above GST
control levels and with apparently similar affinity, suggesting that any interaction of PLD 1
with the receptor in vivo may be dependent upon a molecular mechanism involving both the
third intracellular loop and carboxy-terminal tail domains.
The in vitro GST-fusion binding assay was repeated, using cell extracts from HA-
PLD2 transfected COS 7 cells and incubating with GST-M3i3, GST-M3ct and GST only, as
a negative control. The associated proteins were lysed, separated by SDS-PAGE, Western
blotted and visualised as before. The PLD2 associating with the affinity matrices is shown
in Figure 4.5A, with the input levels of GST-fusion constructs in Figure 4.5B (and is a
representative result from three independent experiments). PLD2, as PLD1, bound to both
M3 constructs specifically, and also with an apparently similar affinity for both. These
results contrast with the findings made by Koch and colleagues in the p-opioid receptor,
where the PLD2 isozyme was found to interact with the carboxy-terminal tail domain of the
receptor and PLD1 was not found to interact at all (Koch et al., 2003). Evidence that the
interaction of PLDs with GST-fusion proteins is dependent on domain amino acid sequence
and not non-specific receptor interaction has been provided by other studies in the
laboratory (where PLD1 has been shown to bind very selectively to the carboxy-terminal
domain but not the third intracellular loop of the 5-HT2A GPCR). The results of the GST-
fusion protein studies here imply that the molecular interactions underpinning the
association of both PLD1 and PLD2 to the M3 receptor in vitro are largely equivalent and
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Figure 4.5
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PLD2 associates with the M3 receptor in vitro.
COS 7 cell extracts transiently overexpressing HA-PLD2 were incubated with GST fusion
proteins of The M3 receptor third intracellular loop (M3i3) and carboxy-terminal tail (M3ct)
domains, and with GST only as a negative control (visualised with anti-HA antibody) (A).
The GST fusion proteins of the M3 receptor pull down PLD2 with an equal affinity for both
constructs. The GST fusion constructs of the input proteins are also shown, visualised with
anti-GST antibody (B).
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are not isozyme dependent in this system. We therefore carried out further co-
immunoprecipitation experiments to determine whether equivalent results were obtained
under more physiological conditions.
PLD1 co-immunoprecipitates with the M, receptor
COS 7 cells were transiently transfected with signal FLAG tagged M3 receptor and HA
tagged PLD1 cDNAs in a 1:1 ratio. Cells were stimulated where necessary with 100 pM of
the M3 receptor agonist, carbachol, for 3, 10 and 20 minutes prior to lysis.
Immunoprecipitates directed against the FLAG tag were prepared by incubating precleared
cellular supernatants with 3 pg/ml mouse anti-FLAG antibody clone M2 (Sigma Aldrich,
Dorset, UK) or 3 pg/ml non-immune mouse IgG as a control, followed by 40 pl/ml of a 1:1
suspension of Protein-G Sepharose in immunoprecipitation buffer. The beads were washed
and co-immunoprecipitates were lysed from the matrix before the proteins were separated
by SDS-PAGE, Western blotted and visualised using rat anti-HA HRP-conjugated primary
antibody (Roche Diagnostics). The levels of PLD 1 that were co-immunoprecipitated with
the M3 receptor are shown in Figure 4.6A. The levels of directly immunoprecipitated M3
receptor were visualised with anti-M3 receptor rabbit polyclonal primary antibody (kindly
gifted by Dr A. Tobin), followed by anti-rabbit HRP-conjugated secondary antibody and are
shown in Figure 4.6B.
The PLD1 isozyme was found to specifically co-immunoprecipitate with the M3
receptor under basal conditions. This association was transiently and consistently reduced
upon agonist stimulation of the M3 receptor where it was at a minimum of approximately
75% ± 10% (n=5) of basal association at the 10 minute time point. This reduction was
statistically significant (p<0.05, Unpaired student t-test) (Figure 4.6C). After 20 minutes of
carbachol stimulation, the level of PLD 1 co-immunoprecipitating with the M3 receptor was
no different to basal levels. One explanation for this decrease may be that the agonist-
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PLD1 co-immunoprecipitates with the M3 receptor.
COS 7 cells were transiently transfected with sFM3 receptor and HA-PLD1. The cells were
stimulated with 100 pM carbachol (CCh) for the times indicated. Immunoprecipitates were
directed against the FLAG tag of the receptor and co-immunoprecipitated PLD 1 levels
visualised by immunoblotting against the HA tag (A). The levels of FLAG
immunoprecipitate, probed with anti-M3 antibody (A. Tobin), are shown in (B). PLD1 co-
immunopecipitates with the M3 receptor and the association is significantly reduced upon
M3 agonist stimulation at 10 min (C) (n=5).
114
Chapter 4: The interaction of PLP with the M? receptor
induced stimulation of the M3 receptor causes dissociation of PLD1 from the receptor due to
the activation state of PLD (i.e. that it exists as a complex in a basal state) and active PLD1
dissociates from the receptor, re-associating with the receptor as PLD1 is later inactivated.
An alternative reason for the dissociation could be that PLD1 may facilitate agonist
stimulated endocytosis of the M3 receptor as is the case with the p,-opioid receptor (Koch et
al., 2003). In this model, it may be the case that PLD1 facilitates the internalisation of the
receptor, resulting in the dissociation of PLD 1 from the receptor after the receptor has been
successfully sequestered away from the plasma membrane. Indeed, Koch and colleagues
noted that the facilitation of the p-opioid receptor internalisation by PLD2 resulted in a
dissociation of the PLD2 isozyme from the receptor after 30 minutes of agonist stimulation
(Koch et al., 2003). The internalisation of the M3 muscarinic receptor is quite swift in COS
7 cells, with the majority of final sequestered receptor binding sites being internalised
within 10 minutes of agonist stimulation (Johnson et al., 2004). In addition to this, this
translocation of PLD1 to the plasma membrane upon carbachol stimulation has been shown
to have taken place at this time point (Mitchell et al., 2003). If the agonist-induced
translocation and subsequent dissociation of PLD1 from the receptor is indicative of the
active phospholipase D facilitating endocytosis (possibly by the production of phosphatidic
acid and the recruitment of clathrin assembly proteins), this would agree with the findings
made by Koch and colleagues (Koch et al., 2003). Furthermore, a subsequent report made
by Koch and co-workers has demonstrated that PLD may have an additional role in the
recycling of the G protein-coupled receptors (Koch et al., 2004). The apparent re-
association of PLD1 with the M3 receptor after 20 minutes of agonist stimulation may be
indicative of a similar mechanism of PLD-dependent recycling of the M3 receptor to cause
resensitisation.
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PLD2 co-immunoprecipitates with the M} receptor
The co-immunoprecipitation experiment was repeated as before, following co-transfection
of the M3 receptor with HA-PLD2 into COS 7 cells. Stimulation was carried out with 100
pM carbachol for 3, 10 or 20 minutes where indicated. Immunoprecipitates directed against
the FLAG tag of the receptor were prepared and co-immunoprecipitated proteins were lysed
from the beads, separated by SDS-PAGE, Western blotted and visualised as before. PLD2
was also co-immunoprecipitated with the M3 receptor under basal conditions, however this
interaction was not detectably altered following carbachol stimulation (after 10 min
stimulation the band density was 95% ± 8% of basal, n=4) (Figure 4.7). This contrasts with
the finding made previously with the PLD1 isozyme and implies that any functional role
that the dissociation of phospholipase D from the M3 receptor may reflect some isozyme
specific function within the COS 7 system. This difference may be attributed to a number of
things. It may be that although PLD2 co-immunoprecipitates with the M3 receptor it does
not have any functional purpose (if dissociation is an indicator of the facilitation of receptor
endocytosis). This seems unlikely, as the p-opioid receptor associated with PLD2 but not
PLD1 at all when undergoing endocytosis (Koch et al., 2003). The indication that PLD1 and
PLD2 both interact with the receptor, also implies that both may be able to mediate any
functional role. It may possibly be that there is a reduction in the association of PLD2 with
the M3 receptor that is not as readily detectable using standard immunodetection methods as
for the PLD1 isozyme. The reduction in the levels of PLD1 may be significant, however
there may be very small changes in the levels of PLD2 that are too sensitive for
immunodetection. The fact that PLD2 is substantially localised to the plasma membrane and
is therefore available in greater supply for receptor interaction compared to PLD1 (which
has to translocate to the plasma membrane) may mean that any PLD2 dissociating from the
receptor is rapidly replaced so that no overall reduction in interaction can be detected. It
may also be the case that it is PLD2 that facilitates the endocytosis of the M3 receptor,
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Figure 4.7
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PLD2 co-immunoprecipitates with the M3 receptor.
COS 7 cells were transiently transfected with sFM3 receptor and HA-PLD2. The cells were
stimulated with 100 pM carbachol (CCh) for the times indicated. Immunoprecipitates were
directed against the FLAG tag of the receptor and co-immunoprecipitated PLD2 levels
visualised by immunoblotting against the HA tag (A). The levels of FLAG
immunoprecipitate, probed with anti-M3 antibody (A. Tobin), are shown in (B). PLD2 co-
immunopecipitates with the M3 receptor and the association is not significantly affected by
M3 agonist stimulation (C) (n=5).
117
preferentially to the PLD1 isozyme. The continued association of PLD2 may be a more
accurate reflection of the facilitation of M3 receptor endocytosis, compared to the on-off
characteristics of the PLD1 association with the receptor.
The M3 receptor co-immunoprecipitates with PLD1 and PLD2
The interaction of PLD with the M3 receptor has been demonstrated by immunoblot
detection of both PLD1 and PLD2 co-immunoprecipitating with the M3 receptor. To provide
independent corroboration of this interaction, the co-immunoprecipitation of the M3 receptor
with PLDs was investigated using specific [3H]N-Me QNB ligand binding to the M3
receptor in HA-PLD-directed immunoprecipitates (this experiment was performed by Dr R.
Mitchell and Ms M. S. Johnson).
COS 7 cells were transiently transfected with signal FLAG tagged M3 (sFM3)
receptor and HA-tagged PLD 1 or PLD2 (HA-PLD) cDNAs in a 1:1 ratio. The COS 7 cells
were stimulated with 200 pM of the M3 agonist carbachol, where necessary, for 10 minutes
before lysis. Immunoprecipitates directed against the HA tag were prepared by incubating
precleared cellular supernatants with 2 pg/ml mouse monoclonal anti-HA antibody clone
12CA5 (Roche Diagnostics) or 2 pg/ml non-immune mouse IgG as a control, followed by
40 pl/ml of a 1:1 of Protein-G Sepharose suspension. The washed HA-PLD
immunoprecipitates were assayed for the presence of M3 muscarinic receptor binding sites
by incubating the immunoprecipitates with 2.38 nM [3H]N-Me-QNB (to determine total
binding) or ligand plus 1 pM N-methyl atropine (to determine non-specific binding) for four
hours at room temperature. The immunoprecipitates were centrifuged at 12 000 x g for 10
minutes at 4 °C, washed and assayed for levels of [3H] ligand binding by liquid scintillation
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M3 receptor co-immunoprecipitation with PLD is affected by agonist stimulation.
The immunoprecipitates of HA-PLD1 or HA-PLD2 under control (basal) conditions and
with 10 min stimulation by 100 pM of the M3 receptor agonist carbachol (CCh) were
assayed for the presence of M3 receptor by [3H]N-MeQNB binding. The non-specific
binding (black bars) was subtracted from the total binding (grey bars) for each condition to
yield specific binding. The non-immune IgG controls are shown for each condition. The M3
receptor was specifically co-immunoprecipitated by both PLD1 and PLD2 under basal
conditions. Upon stimulation by CCh, the association of M3 with PLD1 was significantly
attenuated (*p<0.05; Wilcoxon test, n=5). The co-immunoprecipitation of M3 with PLD2
was not significantly reduced.
119
Chapter 4: The inu-raction of Fl.D with the M-? receptor
The results show that the immunoprecipitation of both HA-PLD1 and HA-PLD2
specifically pulled down the M3 muscarinic receptor. Furthermore, the stimulation of the M3
receptor by carbachol resulted in a significant reduction of the association of the M3 receptor
with PLD1 (p<0.05, Unpaired student t-test; n=5). The stimulation of the receptor also
resulted in a modest decrease of the association with PLD2, however this was not
statistically significant (p>0.05, Unpaired student t-test; n=5). These results support the
findings of the M3 receptor-directed immunoprecipitation of the PLD1 and PLD2 isozymes
under basal conditions. Furthermore, the sensitivity of the radiolabeled assay compared to
Western blot analysis indicates that there may have been a slight undetected decrease in
association of the PLD2 isozyme with the M3 receptor upon carbachol stimulation for 10
minutes (as was found for PLD1). These results therefore suggest that PLD1 and perhaps
also PLD2 could potentially mediate any PLD-dependent facilitation of internalisation of
the M3 muscarinic receptor.
Visualising colocalisation of the M} receptor and PLD1 within COS 7 cells
COS 7 cells, grown on glass coverslips, were transiently transfected with sFM3 receptor and
HA-PLD1 in a 1:1 ratio. The cells were serum-deprived for six hours before fixing,
permeabilised and fixed overnight, and stained with primary mouse monoclonal anti-FIA
antibody clone 12CA5 (Roche Diagnostics) and rabbit polyclonal anti-M3 antibody (kindly
gifted by Dr A. Tobin), followed by Alexa Fluor goat anti-mouse (488 nm) and anti-rabbit
(567 nm) secondary antibodies (Molecular Probes, Leiden, The Netherlands). Healthy cells
that had been co-transfected were chosen at random then imaged by confocal microscopy,
acquiring data at Nyquist sampling rates.
The cells imaged under basal conditions displayed a distribution of PLD1 (green)
localised to the perinuclear regions, punctate intracellular structures and the plasma
membrane, that was similar to that found previously. The M3 receptor (red) was localised
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primarily to the plasma membrane as expected (Figure 4.9). From empirical observations
the area of potential colocalisation of the M3 receptor with PLD appeared to be mainly at the
plasma membrane.
Equivalent samples of co-transfected COS 7 cells, containing sFM3 and HA-PLD1
as before, were stimulated with 100 pM of the muscarinic agonist carbachol for 10 minutes
prior to fixing. These cells were imaged as for unstimulated cells (Figure 4.10). Agonist
stimulation of the muscarinic receptor lead to an increase in recruitment of PLD 1 to the
plasma membrane in COS 7 cells, consistent with other reports of PLD1 translocating to the
plasma membrane upon cellular stimulation (Morgan et al., 1997; Brown et al., 1998; Du et
al., 2003; Mitchell et al., 2003). As well as the translocation of PLD 1, the stimulated cells
showed a marked internalisation of the M3 receptor after 10 minutes of agonist stimulation
(demonstrated with the large levels of red staining on intracellular structures). This yields
additional information regarding the time course of the M3 receptor intemalisation. It has
been shown that many GPCRs are desensitised within minutes and are endocytosed
following this step, with some GPCRs held in a subcellular pool so that they can be re¬
inserted into the plasma membrane following agonist treatment (receptor recycling) and
others being directed into a more degradative pathway (Zhang et al., 1996; von Zastrow,
2003; Du et al., 2004; Koch et al., 2004). We have demonstrated that the M3 receptor can be
internalised within 10 minutes of agonist stimulation (Johnson et al., 2004) and the confocal
images support this finding. In addition, the distribution of the M3 receptor in a
compartment just below the plasma membrane may be consistent with the notion that
receptors are present on early endosomes before being sorted for recycling or degradation
by lysosomes (von Zastrow, 2003). PLD2 has been proposed to play a functional role in the
resensitisation of the p-opioid receptor back to the plasma membrane (Koch et al., 2004),
and so by analogy, the presence of the PLD 1 at the plasma membrane here may potentially
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Chapter 4: The interaction of Pl.D with the Mj receptor
The localisation of the M, receptor and PLD1 in unstimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an unstimulated COS 7 cell transiently
transfected with sFM, receptor (red) and HA-PLD1 (green). The perinuclear distribution of
PLD1 is indicative of PLD1 localising with the Golgi apparatus and can be seen clearly in






















































The localisation of the M, receptor and PLD1 in M, agonist stimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an agonist stimulated COS 7 cell, transiently
transfected with sFM3 receptor (red) and HA-PLD1 (green). The M, agonist carbachol (100
uM for 10 minutes) was used to stimulate the cells. The translocation of PLD1 to the plasma
membrane is apparent and there is also substantial intemalisation of the M3 receptor.
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To examine the nature of the potential M3 receptor:PLD interaction further, voxel
colocalisation analysis studies were carried out on imaged resting and stimulated COS 7
cells containing M3 and PLD 1. Colocalisation describes the presence of two fluorochromes
at the same (resolvable) physical location and is determined by voxels (three dimensional
pixels) that contain two or more image channel intensities. This colocalisation can be
expressed as a coefficient of correlation when all the voxels of one channel are plotted
against all the voxels of another channel (2D voxel plot). A value of 1 indicates that all
voxels within the dataset contain equal channel intensities (a perfect linear correlation) and
is visualised on the voxel plot as a straight line with an equal rise and run passing through
the origin. A value of 0 is indicative of no correlation between channel intensities and a
value of-1 indicates inverse correlation. The 2D voxel plots for sFM3 and HA-PLD1 in two
unstimulated COS 7 cells (Figure 4.11 A) and two carbachol stimulated COS 7 cells (Figure
4.1 IB) are shown. These plots indicate qualitatively that the colocalisation of M3 and PLD1
is reduced with receptor stimulation. Colocalisation thresholds were maintained where
possible, providing that channel bleed through was eliminated. Voxels above threshold
intensity levels containing both red (sFM3 receptor) and green (HA-PLD1) channel
information were analysed for the correlation coefficient of colocalisation. Analysis
revealed that the average colocalisation correlation coefficient for M3 and PLD1 in resting
cells was 0.48 ± 0.07 (n=6) and following M3 receptor agonist stimulation (with 100 qM
carbachol for 10 minutes) was 0.30 ±0.10 (n=4) - a reduction of 38%. However this was not
quite significant (p=0.07, Unpaired student t-test) (Figure 4.12A). Moreover, approximately
10.46 ± 2.16% of the total number of voxels above threshold levels were colocalised for
sFM3 and HA-PLD1 under basal conditions and this figure was reduced to 6.50 ± 1.47%
upon agonist stimulation, indicating a reduction of colocalised voxels of 3.94% in the total
dataset and a relative reduction of 38% (Figure 4.12B). Although colocalisation itself does
not imply interaction, these data support the biochemical analysis and suggest that the
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Figure 4.11
A
The colocalisation of the M , receptor and PLD1 is qualitatively affected by carbachol.
The 2-dimensional plots of all voxels from datasets containing channel intensities for the M3
muscarinic receptor (red) and PLD1 (green) in basal COS 7 cells (A) and carbachol
stimulated COS 7 cells (100 uM for 10 min) (B). A perfect correlation (where all voxels of
one channel are colocalised with all voxels of another channel) would be a straight line of
equal rise and run passing through the origin (with a gradient of 1). The colocalisation plots
from the basal COS 7 cells (A) show a better correlation (and thus colocalisation) than those
from agonist stimulated COS 7 cells (B).
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Figure 4.12
Basal Stimulated Basal Stimulated
The effect of agonist stimulation on the colocalisation of the M, receptor and PLD1.
The coefficient of correlation (indicating colocalisation) of voxels containing information
for both channel intensities (M3 and PLD 1) for both resting COS 7 cells (n=6) and COS 7
cells that had been stimulated for 10 min with 100 pM of the M3 agonist carbachol (n=4) is
shown (A). A perfect correlation of colocalisation would have a value of 1, whereas no
correlation would have a value of 0. The reduction is not quite significant (p=0.07, Unpaired
student t-test). The percentage of voxels above thresholds that contained two channel
intensities was measured as a proportion of the total voxels in the dataset and was plotted
for both resting and stimulated COS 7 cells (B). The stimulation of the muscarinic receptor
induces an apparent decrease in the number of voxels that contain both M3 and PLD1
channel information and this implies a reduction in co-localisation.
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interaction of the M3 muscarinic receptor with PLD1 may be primarily localised at the
plasma membrane in COS 7 cells and that agonist stimulation of the receptor can induce
transient dissociation of the putative M3 receptor/PLD 1 complex.
Visualising colocalisation of the M3 receptor and PLD2 within COS 7 cells
Imaging studies were repeated in COS 7 cells transiently transfected with sFM3 receptor and
HA-PLD2 cDNAs in a 1:1 ratio. The cells were grown on coverslips, serum deprived for six
hours and stimulated where necessary with 100 pM carbachol for 10 minutes. The cells
were permeabilised and fixed overnight, and stained with primary mouse monoclonal anti-
HA antibody clone 12CA5 (Roche Diagnostics) and rabbit polyclonal anti-M3 antibody
(kindly gifted by Dr A. Tobin), followed by Alexa Fluor goat anti-mouse (488 nm) and anti-
rabbit (567 nm) secondary antibodies (Molecular Probes). The cells were then imaged by
confocal microscopy as before.
In unstimulated cells, the M3 receptor (red) localised mainly to the plasma
membrane. The majority of the PLD2 isozyme (green) also associated closely with the
plasma membrane as found previously (Figure 4.13). There was no detectable level of PLD2
in the Golgi or nucleus of the cells - contrasting with the report from Freyberg and
colleagues (Freyberg et al., 2002) but actively consistent with most other relevant studies.
In agonist-stimulated cells, the M3 receptor appeared to internalise and was present
in discrete intracellular structures. The PLD2 remained mainly associated with the plasma
membrane, with a small proportion diffusely localised under the plasma membrane (Figure
4.14). The PLD2 appeared to form areas of high concentrations around the plasma







































Chapter 4: The interaction of P1.D with the M. receptor
The localisation of the M, receptor and PLD2 in unstimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an unstimulated COS 7 cell transiently
transfected with sFM3 receptor (red) and HA-PLD2 (green). The M3 receptor and PLD2 are
localised at the plasma membrane of the cell.
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The localisation of the M, receptor and PLD2 in M, agonist stimulated COS 7 cells.
The gallery (A) and mid-section (B) views of an agonist stimulated COS 7 cell, transiently
transfected with sFM3 receptor (red) and HA-PLD2 (green). The M3 agonist carbachol (100
uM for 10 minutes) was used to stimulate the cells.
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The correlation coefficent of colocalisation was determined for both unstimulated
and stimulated cells as before (Figure 4.15). In unstimulated cells, the mean colocalisation
correlation coefficient was determined to be 0.31 ± 0.04 (n=6) and in stimulated cells, this
was significantly reduced to 0.12 ± 0.03 (n=6) (p<0.05, Unpaired student t-test), a relative
reduction of 61 %. The value under basal conditions was surprising, as PLD2 is more
associated with the plasma membrane than PLD1, yet the colocalisation coefficient under
basal conditions is lower for the colocalisation of PLD2 and M3 than it is for PLD1 and M3.
It may be the case that although the PLD2 and M3 are localised to the same cellular
compartment, the precise incidence of colocalisation may be lower due to PLD2 being in a
different membrane microdomain than the receptor under physiological conditions. The
value for potential colocalisation does not make any implications about whether the proteins
interact, but only whether they occupy the same space. This may mean that proteins can
colocalise without physically interacting, or alternatively that the localisation of the M3
receptor and PLD at any time does not necessarily reflect the population of these molecules
that are physically interacting, as assessed by co-immunoprecipitation. The average number
of colocalised voxels was also determined for the M3 receptor and PLD2; in unstimulated
cells the average was 1.70 ± 0.29% (n=6) and this reduced to 1.18 ± 0.26% (n=6) in






Basal Stimulated Basal Stimulated
The effect of agonist stimulation on the colocalisation of the M3 receptor and PLD2.
The coefficient of correlation of voxels containing information for both channel intensities
(M3 and PLD2) for both resting COS 7 cells (n=6) and COS 7 cells that had been stimulated
for 10 min with 100 pM of the M3 agonist carbachol (n=6) is shown (A). The stimulation by
carbachol results in a significant decrease in the colocalisation of PLD2 with the M3
receptor (*p<0.05; Unpaired student t-test). The percentage of voxels above thresholds that
contained two channel intensities was measured as a proportion of the total voxels in the
dataset and was plotted for both resting and stimulated COS 7 cells (B). The stimulation of
the muscarinic receptor induces an apparent decrease in the number of voxels that contain
both M3 and PLD2 channel information similarly but smaller than that for the colocalisation
of M3 and PLD1.
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The effect ofPKC stimulation on the association of the M3 receptor and PLD
To determine whether the change in association of M3 and PLD was due to the activation
state of PLD, the co-immunoprecipitation of PLD 1 and PLD2 with the M3 receptor was
repeated with the stimulation of PLD by an alternative receptor-independent route, by using
phorbol 12,13-dibutyrate (PDBu) to stimulate the PLD activator, protein kinase C (PKC).
COS 7 cells were transiently transfected with the sFM3 receptor and HA-PLD1 or HA-
PLD2. The cells were stimulated where necessary with 500 nM PDBu for 10 minutes to
activate PKC and subsequently PLD. The FLAG tag of the M3 receptor was
immunoprecipitated by 3 pg/ml mouse anti-FLAG antibody clone M2 (Sigma Aldrich) or 3
pg/ml non-immune mouse IgG as a control, followed by 40 pl/ml of a 1:1 suspension of
Protein-G Sepharose in immunoprecipitation buffer. The beads were washed and co-
immunoprecipitates lysed from the matrix, separated by SDS-PAGE, Western blotted and
visualised using rat anti-HA HRP-conjugated primary antibody (Roche Diagnostics) (Figure
4.16). The co-immunoprecipitation of PLD 1 and PLD2 was not discernibly affected by
PDBu stimulation in COS 7 cells. This suggests that it may not be the activation state of
PLD itself that causes the dissociation from the M3 receptor. However, the activation of
PKC by phorbol ester may have additional complicating effects on either the receptor or




















PLD association with the M3 receptor is not affected by PKC stimulation.
Wild type HA-PLD1 or HA-PLD2 were transiently transfected with the sFM3 receptor into
COS 7 cells. The cells were stimulated with 500 nM PDBu for 10 min where indicated and
immunoprecipitates directed against the FLAG tag of the receptor were pulled down. The
co-immunoprecipitating levels of the PLDs, visualised with anti-HA, are shown (A). The
stimulation by PBDu does not cause a reduction in associating PLD levels compared to
basal controls. The levels of immunoprecipitates are also shown (B).
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The effect of catalytically inactivating mutations in PLD1I2 on their association with the
M3 receptor
The HA-tagged catalytically inactive PLD mutants, HA-K898R PLD1 and HA-K758R
PLD2 (kindly gifted by Dr M. Frohman), were transiently co-transfected into COS 7 cells
with the sFM3 receptor cDNAs in a 1:1 ratio. The cells were serum-deprived for 16 hours
and were stimulated where necessary with 100 pM of the M3 receptor agonist carbachol for
10 minutes. The levels of catalytically inactive PLDs co-immunoprecipitating with the M3
receptor, visualised with anti-HA (Roche Diagnostics), are shown in Figure 4.17. Specific
association of the dominant negative PLD1 and PLD2 with the M3 receptor was observed
under basal conditions, as previously shown with the wild type PLD isozymes. Upon M3
stimulation by carbachol, the levels of co-immunoprecipitating K898R PLD1 and K758R
PLD2 were not affected compared to basal levels. This contrasts with the findings made
with the wild type PLD1, which was transiently reduced with stimulation of the M3 receptor
by carbachol. This implies that the catalytic activity of PLD1 may be necessary for the
dissociation from the M3 receptor, whereas PLD 1 activation by PKC rather than the M3
receptor is not sufficient to cause dissociation. This may imply that changes in the receptor
as well as PLD activation are necessary to allow dissociation. Furthermore, we have
demonstrated that the catalytic activity of both PLD1 and PLD2 is necessary for facilitation
of M3 receptor internalisation as the presence of K898R PLD1 and K758R PLD2, as well as
the PLD inhibitor calphostin C, are inhibitory to the agonist-induced endocytosis of the M3
muscarinic receptor from the cell surface (Johnson et ai, 2004).
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Mutant PLD association with the M3 receptor is not agonist dependent.
The catalytically inactive PLD mutants, HA-PLD1 K989R and HA-PLD2 K758R, were
transiently transfected with the sFM3 receptor into COS 7 cells. The cells were stimulated
with 100 p,M carbachol (CCh) for 10 min where indicated and immunoprecipitates directed
against the FLAG tag of the receptor were pulled down. The co-immunoprecipitating levels
of the dominant negative PLDs, visualised with anti-HA, are shown (A). The stimulation by
carbachol, does not cause a reduction in associating PLD levels compared to basal controls.
The levels of immunoprecipitates are also shown (B).
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Summary
The findings in this chapter demonstrate that PLD1 and PLD2 have an intracellular
distribution in COS 7 cells that is in broad agreement with other reports. The PLD isozymes
can both interact with the M3 muscarinic receptor under basal conditions (shown by co-
immunoprecipitation studies) and this interaction is probably at a site provided by regions of
both the third intracellular loop and the carboxy-terminal tail domain of the receptor (shown
by GST-fusion studies). Stimulation of the M3 receptor by the agonist carbachol leads to a
significant but transient decrease in the co-immunoprecipitation of the M3 receptor with
wild type PLD1 but not wild type PLD2 at ten minutes. Dissociation of the M3 receptor and
PLD1 is transient and is rapidly restored to basal levels by twenty minutes. The dissociation
of PLD and the M3 receptor was not apparent with the catalytically inactive mutants of
either PLD isozyme, nor could it be caused by PKC-mediated stimulation of the wild type
PLDs. Furthermore, confocal microscopy revealed that the colocalisation of either PLD1 or
PLD2 with the M3 receptor was reduced by agonist stimulation and this may support the
biochemical observations. However, more experimental data would be necessary to further
elucidate the mechanisms involved. The use of real-time cell imaging of cells expressing
fluorescently tagged receptor and PLD isozyme constructs would be an elegant method of
delineating the changing mechanisms involved in the receptor-PLD interaction upon cellular
stimulation. The use of fluorescence resonant energy transfer (FRET), whereby the close
association of proteins can be determined from the transfer of energy from one fluorophore
on one protein to another on a separate protein (and thus indicating interaction) would also
be extremely useful in this kind of cellular system. Additionally it would be desirable to use
high affinity antibodies for the native M3 receptor and PLD isozymes, as this would
eliminate any inconsistencies that may arise when looking at a transiently transfected
population of cells.
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These findings are consistent with the hypothesis that the association of PLD
isozymes (PLD 1 or PLD2) with the M3 receptor may make a functional contribution to
agonist-induced desensitisation, endocytosis (sequestration) and perhaps resensitisation of
the M3 receptor as proposed by other groups working with other GPCRs (Koch et al., 2003;
Du et al., 2004; Koch et al., 2004). One mechanism for which PLD activity has been
demonstrated to be important is in the initial stages of the assembly of clathrin coated pits
(Arneson et al., 1999; Lee et al., 2000). Phosphatidic acid, the product of PLD activity, is
necessary as a cofactor for the efficient assembly of the AP-2 adapter complex on
lysosomes (Arneson et al., 1999) and AP-2 has been shown to be important for the
endocytosis of the (3-adrenergic receptor (Laporte et al., 1999). Phosphatidic acid is thought
to affect the physical properties of the lipid bilayer to allow efficient budding of the vesicle
away from the plasma membrane (Andresen et al., 2002). The results found in this study are
consistent with the notion that activation of PLD may facilitate endocytic sequestration of




The interaction of 14-3-3 with PLD
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Introduction
14-3-3 proteins have many intracellular binding partners (Aitken, 2002), among them are
proteins involved in cell cycle regulation (Pallas et al., 1994), proteins involved in apoptosis
(Zha et al., 1996; Masters and Fu, 2001) and proteins involved with signalling mechanisms
(Toker et al., 1992; Fantl et al., 1994; Freed et al., 1994; Fu et al., 1994; Bonnefoy-Berard
et al., 1995; Benzing et al., 2000). The ability to interact with many (but not all) of these
binding partners depends upon the presence of the c-Raf-like RSxpSxP phosphoserine
binding motif (Muslin et al., 1996; Yaffe et al., 1997). The interaction of 14-3-3 with
enzymes such as phosphatidylinositol 3-kinase (PI3K) (Bonnefoy-Berard et al., 1995) and
the regulators of G-protein signalling (Benzing et al., 2000) has implicated the importance
of 14-3-3 in certain cellular signalling pathways. 14-3-3 may act to coordinate binding
partners to facilitate interaction, sequester proteins to prevent interaction or target proteins
to specific compartments for activation. Isoforms of 14-3-3 have been shown to be present
at intracellular and plasma membranes in other studies (Celis et al., 1988; Jones et al.,
1995b) and in this study it has already been shown that 14-3-3 is present in both the cytosol
and at the plasma membrane.
Analysis of the human PLD1 isozyme sequence reveals that it contains a putative
14-3-3 binding site with the residues RSLSYP (712-717) (Figure 5.1A). Scansite analysis of
this domain reveals that it is a high stringency 14-3-3 mode 1 phosphoserine recognition site
(Obenauer et al., 2003). Human PLD2 contains two similar threonine-based sequences,
RLLTMS (172-177) or KTPTYP (573-579) that may also potentially be 14-3-3 recognition
motifs (Figure 5. IB), however these domains are only recognised with a medium stringency
threshold (Obenauer et al., 2003). In this chapter, the interaction of 14-3-3 isoforms with the
PLD isozymes is investigated, along with the subcellular localisation and colocalisation of
the proteins. In addition, the functional implications of 14-3-3 expression in vivo are
investigated using whole cell PLC and PLD signalling assays.
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Figure 5.1
A
I M3I.KMEPRVH TSALQKIAAD HSNIIEMLDT RELHFEGEEV DSDVSPSDPK IQEVYIPFSA IYMTQOPKEP
71 NXQTYLSGCP IKAQVLBVER FTSTTRVPSI SLYTIELTHG EFKWQVKRKF KHPQEFHREL LKYKAFIRIF
141 IPTRRHTFRR QNVREEPREM PSLPRSSENM IREEQFLGRR KQLEDYLTKI &KMPMYRNYB ATTEFLDISQ
211 LSFIHDLGPK GIEGMIMKRS GGHRIPGLNC CGQGRACYRW SKRV3LIVKDS FLLYMKPDSG AXAFVLLVOK
231 EFKIKVGKKE TETKYGIRID NLSRTLItKC SSYRHARWHG GAIEEFIQKH GTNFIiKDBRF GSYAAIQEHA
351 LAKWYVNAKG YFEDVANAME EANEEXFITD HWLSREIFLK RPWEGNRWR LDCXLKRRAQ QGVRIF1MLY
-121 KEVELALGIN SEYTKRTLMR LHI'NXKVHRH PDHVSSTVYL WAHHEKLVII DQSVAFVGGX DLAYGRWDDN
491 EHRLTDVGSV KRVTSGPSLG SLPPMHBSH ESX.RLKDKNE FVyNLPIQKS IDDVDSKLKG IGKPRKFSKF
561 SI.YKQt.HRHH LHDADSXSSI DSTSSYPmX KSBttHtlSOL KPHFK1.PHPS SfJSEQGL'PRP JtACTGSXRSt.
631 QTGVG.ELBGE TRFWHGKDYC NFVFKDWVQL DKPFADFIDR Y5TPRMPWBD IASAVHGKA& RPVARHFIQR
791 IvNFTKXMKSK RSLSYP 1 .. PKS0TTAHEL RYQVPGSVHA NVQLLRSAAE WSRGIKYHEE SMSAYVKVI
771 ENSR.HYIY1E NQFFXSCADD XWFNKIGDA IAQRILKAHR ENOKYRVYvV IPLLPGFEGD ISTGGGHALO
841 AIHHFNYRTM CRGENSILGQ LKAELGBQWI NYISFCGLRT HAELEGHLVT ELIYVHSKLL XADDKTVIXG
911 SAKIN0RSML GKRDSBMAVI VQDEKTVPSV MDGKEYQAGR FARGLRLQCF RWI.GYLDDP SEDIQDPVSD
991 KFFKEWHVST AARSATIYOK VFRCX.PNDEV HNLIQLRDFI NKPVLAKEDP IRAEEELKKI RGFLVQFPFY
1051 FLSEESLLPS VGTKEAXVPM EVWT
B
1 MTATPESLFP TGDSLDSSQL QMESDEVDTL KBGEDPAPRM HPFLAIYELQ SLKVHPLVFA PGVPVTAQW
71 GTERYTSGSK VGTCTX.YSVR LTHGDFSWTT KKKYRBFQEL HRDLLRHKvl, MSLLPLARFA VAYSPARDAG
141 NREMPSLPRA GPEGSTRHAA SKQXYLENYL l-RLLTMS VI: NYHAMTEFLE VSQLSFIPDL GRKGLEGMIR
213. KRSGGBRVPG LTCCGRDQVC YRSSKRWDW KDSFLLYMCL ETGAISFVQI, FDPGFEVQVG KR5TEARHGV
281 RIDTSHRSLI LKCSSYRQAR WWAQEITELA QGPGRDFLQL HREDSYAPPR PGTLARWFVN GA6YFAAVAD
351 AILRAOBE IF ITDWWLSPEV YLKRPAHSDD WRLDIMLKRK AEEGVRVSIL LFKEVELALG INSGYSKRAL
421 HLEHPNXXVM RHPDQVTLWA HHEXLLWDQ WAFLGGLDL AYGRWDDLHY RLTDLGDSSE SAASQFPTPR
491 PDSPATPDLS HNQFFMLGKD YSNI.ITKDWV QtDRPFEDFI QRETTPRMPW RDVGVWHGL PARDLARHFX
561 QRWNFTKTTK AKVKTPTYPY XLPKSTSTAH QLPFTLPGGQ CTTVQVLRSV DRWSAGTUBH SILNAYLHT1
631 RESQHFLYXE KQFFISCSDG RTVLHKVGDE IVDRXLKAHK QGWCYRVYVL LPI.LPGFEGD ISTGGGNSIQ
701 AILHFTYRTL CRGEYSILBR LKAAMGTAWR DYISXCGLRT HGELGGHPVS ELIYIHSKVI. IADDRTVXIG
771 SAKIHDRSLL GKRDSELAVL IEDTETEPSL MNGAEYQAGK FALSLRKKCF GVILGANTRF DLDLRDPICD
841 DFFQLWQDMA ESNANIYEQI FRCLPSNATR SLRTLREYVA VEPLATV5PP I.ARSELTQVQ GHLVHFPLKF
911 LEDESt.LPPL GSKEGMIPLE VMT
Sequences of human PLD1 and PLD2, showing the putative 14-3-3 recognition motifs.
The amino acid sequences of human phospholipase Dla (A) and human phospholipase D2
(B) are shown. The amino acid residues 712-717 in PLD1 are very similar to the c-Raf
based 14-3-3 recognition motif RSxpSxP. The consensus sequences 172-177 or 573-579 in
PLD2 may also be 14-3-3 recognition domains. These consensus sequences are underlined
and in bold. The italicised region in PLDla (585-623) is substituted for an asparagine (N)
residue in the splice variant PLDlb (Hammond et al., 1997).
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14-3-3 isoforms interact with PLD1 and PLD2 in vitro
To determine whether PLD isozymes could interact with isoforms of 14-3-3, as predicted by
the recognition sequence, glutathione S-transferase (GST) constructs of full length 14-3-3
isoforms (GST-14-3-3^ and GST-14-3-3r]) were immobilised onto glutathione Sepharose
4B beads. Cellular extracts from serum-deprived COS 7 cells, transiently transfected with
HA-PLD1 and HA-PLD2 were incubated overnight with the prepared GST fusion protein
beads. GST alone was used as a negative control. The bead-associated proteins were lysed,
separated by SDS-PAGE, Western blotted and visualised using rat anti-HA HRP-conjugated
primary antibody (Roche Diagnostics, East Sussex, UK). The Western blots of the bait
associated proteins are shown in Figure 5.2 together with blots for the input levels of 14-3-
3-GST fusion proteins. Both PLD1 and PLD2 specifically associated with both 14-3-31; and
14-3-3-q above control levels in the in vitro GST-fusion protein binding assay. The binding
of PLD 1 to both the 14-3-3 constructs was consistently similar (1.89 ±0.16 fold over GST
control for 14-3-3^ and 2.10 ± 0.20 fold over GST control for 14-3-3r|, n=4). The binding of
PLD2 appeared to have a higher affinity for the 14-3-3r| isoform (3.20 ± 0.55 fold over
GST, n=3) compared to the 14-3-31; isoform (2.28 ± 0.51 fold over GST, n=3) but this was
not significant. Whilst PLD1 has the motif that more closely matches the optimal consensus
target for 14-3-3 association, the binding in vitro does not seem to indicate a higher affinity
for PLD1 over PLD2 compared to GST control levels. The potential 14-3-3 isoform
specificity arising from the PLD2 binding may arise from the less than optimal PLD2
binding motif. It has been suggested that the 14-3-3 isoforms bind specifically to optimum
target consensus sequences with little difference in affinity (as the amphipathic groove is
highly conserved amongst all 14-3-3 isoforms), although isoform specificity may become
apparent as the potential 14-3-3 recognition motif deviates from that of the optimum
RSxpSxP consensus (Yaffe et al., 1997; Aitken et al., 2002). PLD1 contains an optimal
high stringency mode-1 14-3-3
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PLD1 and PLD2 associate with 14-3-3 isoforms in vitro.
COS 7 cell extracts, transiently overexpressing HA-tagged PLD1 and PLD2 isoforms were
incubated with GST-fusion protein constructs of full length isoforms of 14-3-3^ and 14-3-
3r| on a glutathione sepharose matrix. The immunoblots show the specific binding of both
PLD1 and PLD2 to the GST-14-3-3 constructs above control levels (GST alone).
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interacting domain (if indeed this is where 14-3-3 binds) whereas that in PLD2 shows some
differences, so 14-3-3/PLD2 interaction may be more dependent upon isoform variation
than 14-3-3/PLD1 interaction. This may explain why 14-3-3^ interacts less well with PLD2
than 14-3-3r| does in vitro.
The interaction ofPLD with 14-3-3 isoforms may be via the 14-3-3 amphipathic groove
The GST-fusion binding assay was repeated using COS 7 cell lysate enriched with HA-
PLD1 and this was incubated with the GST-fusion construct of 14-3-3^ in the presence or
absence of 100 pM of the pS-Raf 259 phosphoserine motif blocking peptide. PLD1 was
chosen as it has the more distinct 14-3-3 recognition motif. The bound proteins were lysed,
separated by SDS-PAGE, Western blotted and visualised using anti-HA HRP-conjugated
primary antibody (Roche Diagnostics) (Figure 5.3). The presence of the pS-Raf 259 peptide
in the incubation attenuated the binding of PLD1 to the 14-3-3^ construct. Analysis revealed
that the band grey scale density of the pS-Raf 259 peptide incubated condition was 67 ± 8%
of the density of basal association of PLD1 (n=2). In comparison, the density of HA-PLD1
associated with the GST control condition was 53 ± 20% of that for the GST-14-3-3^
construct (from previous data, n=4). Whilst the concentration of 100 pM pS-Raf 259 should,
in principle, be sufficient to saturate the GST-14-3-3 in an in vitro binding assay (which
may be up to 10 mg/ml total GST-fusion protein bound), the incubation conditions using the
pS-Raf 259 peptide may not be optimal to efficiently bind to all of the immobilised GST-14-
3-3. Thus, a certain amount of GST-14-3-3 could still be available for interaction and may
bind cellular partners, including PLD. Nevertheless, the reduction in the pS-Raf 259 treated
incubation suggests that competitive inhibition of the 14-3-3 binding site attenuates 14-3-3^
and PLD1 association, implying that binding is specific and occurs in the amphipathic
groove of the 14-3-3 dimer.
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Figure 5.3















The pS-Raf 259 peptide partially attenuates PLD and 14-3-3 association.
COS 7 cell extracts, transiently overexpressing HA tagged PLD1 were applied to GST-
fusion constructs of 14-3-31; in the presence or absence of the phosphoserine motif blocking
peptide pS-Raf 259. The presence of the pS-259 peptide partially attenuates PLD
association with 14-3-3, indicating that it is a competitive blocker of the interaction site.
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14-3-3 isoforms co-immunoprecipitate with PLD1 and PLD2
Co-immunoprecipitation studies were carried out to determine whether there might be
isoform specificity in the association of PLD isozymes with 14-3-3 isoforms and to
determine whether PKC stimulation of PLD had any effect on the potential association. HA-
PLD1 or HA-PLD2 and the myc-tagged 14-3-31; isoform (14-3-3^-myc) cDNAs were
transiently transfected into COS 7 cells in a 1:1 ratio. The cells were serum-deprived for 16
hours and stimulated where necessary with 500 nM phorbol 12,13-dibutyrate for 10 mins
and then lysed. The PLD was pulled down using immunoprecipitation directed against the
HA tag (1 pg/ml mouse monoclonal 12CA5 or 1 pg/ml rat monoclonal 9E10, Roche
Diagnostics). Non-immune mouse or rat IgG (1 pg/ml) was used as a negative control. The
immunoprecipitates of the HA-PLD were lysed from the beads, separated by SDS-PAGE,
Western blotted and the co-immunoprecipitated levels of 14-3-31; were detected using rabbit
polyclonal anti c-myc antibody (Upstate Biotech, Milton Keynes, UK) followed by anti-
rabbit HRP-conjugated secondary antibody (Chemicon, Hants, UK) and standard ECL
detection (Figure 5.4). The input levels of immunoprecipitated PLD were visualised with rat
anti-HA HRP-conjugated primary antibody (Roche Diagnostics) and are also shown, at top.
The 14-3-31; isoform co-immunoprecipitated specifically with both PLD1 and PLD2
above IgG control levels under basal conditions, supporting the findings of the in vitro GST-
binding assay. Upon PKC-mediated PLD activation by phorbol dibutyrate, the levels of 14-
3-31; that were co-immunoprecipitated with PLD 1 were not significantly changed from the
levels of basal association (1.33 ± 0.39 fold over basal, n=3). The levels of 14-3-31; that
were co-immunoprecipitated with PLD2 upon PKC stimulation were also not significantly
altered from basal levels (0.84 ± 0.27 fold of basal, n=3).
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PLD1 and PLD2 co-immunoprecipitate with the 14-3-3£ isoform.
COS 7 cells, transiently overexpressing 14-3-3^-myc and HA-PLD1 or HA-PLD2 were left
in a basal state or stimulated with 500 nM PDBu for 10 minutes. Immunoprecipitates were
directed against the HA tag (IP) and co-immunoprecipitated 14-3-3 visualised by blotting
for the myc tag. Non-immune IgG was used as a negative control (IgG). The stimulation of
PKC by PDBu does not appreciably affect 14-3-3£ association with PLD1 or with PLD2.
The immunoprecipitation of the HA levels is also shown (PLD1 and PLD2).
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Similar experiments were then carried out, transiently co-transfecting COS 7 cells
with HA-PLD1 or HA-PLD2 and myc-14-3-3r|. The cells were serum deprived for 16 hours
and stimulated where necessary with 500 nM PDBu for 10 mins. The HA tag of the PLDs
were immunoprecipitated from the cellular lysates using monoclonal antibodies 12CA5 or
9E10 (Roche Diagnostics) as before and co-immunoprecipitated proteins were lysed,
separated by SDS-PAGE and Western blotted. The levels of 14-3-3r] that co-
immunoprecipitated with PLD1 and PLD2 were visualised using rabbit polyclonal anti-myc
primary antibody (Upstate), followed by HRP-conjugated anti-rabbit secondary antibody
(Chemicon) and standard ECL detection (Figure 5.5). Under basal conditions, the 14-3-3r|
isoform associated with both PLD1 and PLD2 above IgG controls. The levels of !4-3-3i]
that co-immunoprecipitated with PLD1 were not affected by PKC stimulation (0.98 ±0.16
fold of basal, n=3). The levels of 14-3-3r| that were co-immunoprecipitated with PLD2 were
also not discernibly affected by PKC stimulation (1.29 ± 0.21 fold over basal, n=3).
Finally, further co-immunoprecipitation studies were carried out with the 14-3-3e
isoform and HA-PLD1 or HA-PLD2 in COS 7 cells. The cells were transfected, stimulated
with PDBu and the lysates immunoprecipitated for the HA tag as before (clone 9E10 or
12CA5, Roche). The co-immunoprecipitated proteins were separated by SDS-PAGE,
Western blotted and the 14-3-3e levels were visualised as previously (Figure 5.6). The basal
co-immunoprecipitation level of 14-3-3e with PLD1 was consistently only slightly above
the IgG control level, as was the co-immunoprecipitation level of 14-3-3e with PLD2
(indicating a relatively low level of association of 14-3-3 e with both isozymes under basal
151
Chapter :'v The in [criterion of 14-3-3 wish Pl.D
Figure 5.5
,<$ .V-'N" JP \<P sV-'




A "X ^ A -X ^
<o XV XV cP XV XV
o°
cr <r <?
« n9 >9 o° N9 N9o <?v <?v o <?v <?v kDa
If PI
14-3-3r| -►
IgG-*- mm **** * mm* mm
•P* ** i
* •*
Basal +PDBu Basal +PDBu
PLD1 PLD2
(IP-HA Blot - myc)
PLD1 and PLD2 co-immunoprecipitate with the 14-3-3t| isoform.
COS 7 cells, transiently overexpressing myc-14-3-3^ and HA-PLD1 or HA-PLD2 were left
in a basal state or stimulated with 500 nM PDBu for 10 minutes. Immunoprecipitates were
directed against the HA tag (IP) and co-immunoprecipitated 14-3-3 visualised by blotting
for the myc tag. Non immune IgG was used as a negative control (IgG). The stimulation of
PKC by PDBu does not markedly affect 14-3-3r] association with PLD1 or with PLD2.
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PLD1 and PLD2 co-immunoprecipitate with the 14-3-38 isoform.
COS 7 cells, transiently overexpressing 14-3-3£-myc and HA-PLD1 or HA-PLD2 were left
in a basal state or stimulated with 500 nM PDBu for 10 minutes. Immunoprecipitates were
directed against the HA tag (IP) and co-immunoprecipitated 14-3-3 visualised by blotting
for the myc tag. Non immune IgG was used as a negative control (IgG). The stimulation of
PKC by PDBu may enhance 14-3-3e association with PLD1, but does not affect 14-3-3e
association with PLD2.
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conditions). Upon PKC stimulation, the level of associated 14-3-3e with PLD1 appeared to
increase over basal (1.84 ± 0.55 fold over basal, n=3), compared to PLD2 where no
difference was observed (1.08 ±0.10 fold over basal, n=3) but the increase in association of
PLD1 and 14-3-3e observed upon PKC stimulation was not statistically significant.
A point to note is that the 14-3-3 dimers formed when overexpressing the isoforms
may be either homo- or heterodimers (for example 14-3-3 £ has a tendency to only form
heterodimers in vivo) (Jones et al., 1995a; Chaudhri et al., 2003). The nature of the 14-3-3
dimer itself may have implications for the isoform specificity and function, as although the
detection of the transfected isoforms are indicative of their presence in the interaction, it is
difficult to determine which other isoform may be present in the dimer formed.
Furthermore, the results make no representation about the endogenous levels of 14-3-3 that
may be docked to native PLD and whether the de novo interaction between the tagged
proteins accurately reflects the situation in the physiological system or has been able to
displace preformed native complexes. Nevertheless, a potential isoform specificity indicated
by the result suggests a possible level of regulation of interaction, the reasons for which may
be functionally important.
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The stimulation ofPKC alters colocalisation ofPLD and 14-3-3 £
To ascertain whether the subcellular localisation of PLD1 and the isoforms of 14-3-3 were
similar, HA-PLD1 and myc tagged 14-3-31; cDNAs were transfected into COS 7 cells at a
1:1 ratio. The cells were grown on coverslips and were stimulated where necessary by
activating protein kinase C with 500 nM phorbol 12,13-dibutyrate (PDBu) for 10 minutes.
They were permeabilised and fixed, and stained with mouse anti-HA primary antibody
clone 12CA5 (Roche diagnostics, East Sussex, UK) and rabbit anti-myc primary antibody
(Upstate, UK) followed by Alexa Fluor goat anti-mouse 488 nm and anti-rabbit 567 nm
secondary antibodies (Molecular Probes, Leiden, The Netherlands). The visualisations of
COS 7 cells containing PLD1 (green) and 14-3-31; (red) are shown in Figure 5.7.
In unstimulated cells, PLD1 localised to punctate structures, perinuclear
compartments and the plasma membrane as found previously. The 14-3-31; isoform
appeared to localise throughout the cells, and was present in higher levels in the cytosolic
compartment, but was also expressed in the nucleus. A small proportion of 14-3-31, was
observed at the plasma membrane. This distribution of 14-3-31; was found to be similar to
that of the live-cell investigations made by van Hemert and colleagues in variety of cell
types (van Hemert et al., 2004). Upon PKC stimulation, the majority of PLD 1 translocated
from the intracellular compartments to the plasma membrane and 14-3-31; appeared to
migrate from the nuclear compartment to the cytosolic or plasma membrane compartments.
Colocalisation was measured as in chapter 4 and the mean coefficient of correlation of both
channels in unstimulated cells was determined to be 0.12 ± 0.04 (n=4) and in PDBu
stimulated cells this value increased to 0.26 ± 0.06 (n=6) but this was not significant
(p>0.05 Unpaired Student t-test).
The experiment was repeated for PLD2 (green) and 14-3-31; (red) and the
visualisations of both basal and stimulated cells are shown in Figure 5.8. In unstimulated
cells, PLD2 was primarily localised to the plasma membrane and 14-3-31; had a similar
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distribution to that found previously. Upon PKC stimulation, 14-3-31; appeared to migrate
from the nucleus to the cytosol as before (with a small increase at the plasma membrane).
The localisation of PLD2 did not markedly change upon PKC activation, except that a small
proportion migrated into the cell. The values for the colocalisation were measured and the
mean colocalisation coefficient of correlation in unstimulated cells was determined to be
0.06 ± 0.04 (n=4) and in stimulated cells was 0.15 ± 0.10 (n=3) with no significant
difference (p>0.05, Unpaired Student t-test). These results suggest that PKC stimulation
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Chapter 5: The interaction of 14-3-3 with PLD
The effect of PKC stimulation on the localisation of PLD1 and 14-3-3^.
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
PDBu, 10 min) transiently transfected with HA-PLD1 (green) and 14-3-3'C-myc (red).
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The effect of PKC stimulation on the localisation of PLD2 and 14-3-3£.
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
PDBu, 10 min) transiently transfected with HA-PLD2 (green) and 14-3-3^-myc (red).
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The stimulation ofPKC alters colocalisation ofPLD and 14-3-3r]
COS 7 cells were transiently transfected with HA-PLD1 and myc-14-3-3r| and were
stimulated where indicated with 500 nM PDBu for 10 min. The cells were fixed and stained
exactly as before. The visualisations of PLD 1 (green) and 14-3-3r| (red) in unstimulated and
PDBu stimulated cells are shown in Figure 5.9. The PLD1 localised to many internal
structures as previously. The 14-3-3r) isoform appeared to localise primarily to the cytosol
and not to the nuclear compartment or the plasma membrane, (this was a similar distribution
to that of transfected 14-3-3a in the study by van Hemert and colleagues (van Hemert et al.,
2004)). The mean value for the colocalisation coefficient of correlation in resting cells was
determined to be 0.23 ± 0.10 (n=3). Upon PKC stimulation by PDBu, PLD1 migrated to the
plasma membrane and the 14-3-3r| localisation became more ubiquitous within the cell
(migrating into the nucleus). The mean coefficient of correlation value was 0.22 ± 0.6 (n=3),
indicating that there was no discernible difference in the levels of colocalisation of PLD 1
and 14-3-3r| due to PKC-mediated PLD1 activation.
COS 7 cells were also transiently co-transfected with HA-PLD2 and myc-14-3-
3r|, stimulated where necessary with PDBu and imaged as previously (Figure 5.10). The
PLD2 in resting cells was bound exclusively at the plasma membrane and the 14-3-3ri, was
again localised to the cytosolic compartment (not the nucleus). Upon PDBu stimulation, a
small proportion of PLD2 internalised on small punctate structures and localisation of 14-3-
3r| did not appreciably change, except there was an increase in 14-3-3r| at the plasma
membrane (most clearly visible on the upper surface of the cell). The mean coefficient of
correlation of the 14-3-3r] and PLD2 proteins in resting cells was 0.15 ± 0.05 (n=3) and in
stimulated cells was 0.32 ± 0.09 (n=4). This change was not quite significant (p=0.054,
Unpaired Student t-test), nevertheless it represented a potential increase in colocalisation of
14-3-3ri with PLD2.
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The effect of PKC stimulation on the localisation of PLD1 and 14-3-3rp
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
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The interacti. 3 with PLD
The effect of PKC stimulation on the localisation of PLD2 and 14-3-3t].
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
PDBu, 10 min) transiently transfected with HA-PLD2 (green) and myc-14-3-3r| (red).
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The stimulation ofPKC alters colocalisation ofPLD and 14-3-3 e
Imaging data was then collected for COS 7 cells transiently transfected with HA-PLD1 and
14-3-3£-myc. Unstimulated COS 7 cells were imaged as before and are shown in Figure
5.11. The localisation of PLD1 was similar, predominantly localising to the perinuclear
apparatus and forming punctate structures within the cell. The 14-3-3e isoform displayed a
localisation that appeared to be exclusively within the nucleus in most cells. This
compartmentalisation meant that there was very little colocalisation under basal conditions,
the mean coefficient of correlation was 0.02 ± 0.08 (n=3). Upon PKC stimulation, PLD1
translocated to the plasma membrane as before and 14-3-3e migrated from the nucleus to
the cytosolic compartment of the cell, with a small proportion directed to the plasma
membrane. The mean colocalisation coefficient of correlation significantly increased to 0.32
± 0.02 (n=3) (p<0.05, Unpaired student t-test) in PKC stimulated cells.
The experiment was repeated for HA-PLD2 and 14-3-3e-myc and the visualisation
of the cells is shown in Figure 5.12. Under basal conditions, as with PLD1, the distribution
of both PLD2 and 14-3-3e was discrete. PLD2 was localised to the plasma membrane as
previously indicated and 14-3-3e was predominantly localised within the nucleus. The
colocalisation coefficient of correlation was 0.13 ± 0.07 (n=3). Upon stimulation PLD2
showed a small internalisation and 14-3-3e appeared to migrate out of the nuclear
compartment, however the colocalisation coefficient was reduced to 0.02 ± 0.06 (n=2). This
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The effect of PKC stimulation on the localisation of PLD1 and 14-3-3e.
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
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Chapter 5: The interaction of 14-3-3 with PLD
The effect of PKC stimulation on the localisation of PLD2 and 14-3-3e.
The gallery (A) and mid-section (C) views of an unstimulated COS 7 cell compared with the
gallery (B) and mid-section (D) views of a phorbol ester stimulated COS 7 cell (500 nM
PDBu, 10 min) transiently transfected with HA-PLD2 (green) and 14-3-3e-myc (red).
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Taken together these values indicate that the change in colocalisation of the various
14-3-3 isoforms with PLD1 and PLD2 is isoform dependent. For PLD1, the colocalisation
of 14-3-3r] showed little difference between resting and stimulated COS 7 cells, whereas
14-3-3e showed a significant increase (n=3, p<0.05; Unpaired student t-test) (Figure 5.13).
The colocalisation of 14-3-3r| with PLD2 appeared to increase with PKC stimulation,
although not quite significantly (p=0.054; Unpaired Student t-test). The acquisition of
further data to attain a higher n number may have enabled a more explicit interpretation,
however a trend has emerged to suggest a distinct isoform specificity of interaction. It must
be noted that the values for the colocalisation of the 14-3-3 isoforms with PLD are quite low
indicating that the incidence of the two proteins colocalising, even though the interaction
may be robust, is also low. This is not totally unexpected, as the sheer abundance of 14-3-3
interactions (with other binding partners) within the cell and the relatively low levels of
PLD expression, may preclude the association from being particularly widespread.
However, the evidence using GST-fusion and co-immunoprecipitation studies suggests that
an interaction does take place in vitro and the imaging studies lend support to the idea of
this interaction occurring in vivo.
Comparing the colocalisation results with the biochemical results yields a
reasonable corroboration. The stimulation of PLD 1 by PKC leads to its colocalisation with
14-3-3e being significantly increased and leads to the co-immunoprecipitation of PLD1 with
14-3-3 e showing an increase. Furthermore, PKC stimulation does not readily affect PLD1
association with 14-3-3r|, but PLD2 colocalisation (and potential association) may be
increased. Preferential interactions of the different isoforms of 14-3-3 with the two PLD
isozymes could potentially indicate a level of molecular control within the cellular system.
It is currently unknown how 14-3-3 functions physiologically in this scheme, but there may
be indications from other 14-3-3 interactions. For example, 14-3-3 dimers have been shown
to be an important mediator in the coordination of two proteins together in an activation
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14-3-3S+PLD1 14-3-3r)+PLD1 14-3-3e+PLD1 14-3-35+PLD2 14-3-3rj+PLD2 14-3-3e+PLD2
The effect of PKC stimulation on the colocalisation of PLD and 14-3-3 isoforms.
The coefficient of correlation of voxels containing channel intensities for both PLD1 (A) or
PLD2 (B) and different 14-3-3 isoforms is shown. Unstimulated COS 7 cells (black bars)
(n> 3) and COS 7 cells that had been stimulated for 10 min with 500 nM of the phorbol
ester phorbol 12,13-dibutyrate (grey bars) (n> 3) were imaged and the resulting change in
correlation coefficient for the two channels recorded. The correlation coefficient is an
indication of the two channels colocalisation - a value of 1 indicates all voxels of both
channels are colocalised (perfect correlation), a value of 0 indicates no correlation and -1
indicates exclusive colocalisation (perfect inverse correlation) The stimulation of protein
kinase C (PKC) by phorbol dibutyrate results in a change of location of 14-3-3 isoforms and
a change in colocalisation of 14-3-3 and PLD. PKC stimulation significantly increases
colocalisation of the 14-3-3e isoform with PLD1 (*p<0.05; Unpaired Student t-test).
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process, such as c-Raf with Ras or PKC (Sozeri et al., 1992; Fantl et al., 1994; Freed et al.,
1994). The 14-3-3 isoforms could potentially fulfil the same role in this system and
preferentially facilitate direct coupling of PKC to PLD as an isoform-dependent functional
linker molecule. Alternatively, 14-3-3 may bind in an isoform specific manner to PLD
following activation (or subsequent phosphorylation) by PKC to modulate or facilitate the
phosphorylation induced attenuation of PLD activity (Hu and Exton, 2003; Chen and Exton,
2004). Furthermore, there may also be the possibility that another protein (or proteins) may
potentially be involved in the interaction.
14-3-3 alters PKC mediated activation ofPLD
To make a preliminary assessment of whether 14-3-3 association with PLD might be
physiologically relevant in vivo, PLD assays in whole COS 7 cells, transiently transfected
with 14-3-3 isoforms were performed. PLC assays were also performed as a control, to
ensure that overexpression of 14-3-3 did not affect the signalling characteristics due to
reduced cell viability. COS 7 cells, transiently transfected with empty control vector or 14-
3-3^-myc were seeded into 24 well plates and were made quiescent 16 hours before the
assay. Cells for PLC assays were radiolabelled for 16 hours with [3H]inositol and cells for
PLD assays were radiolabelled with [3H]palmitate. The cells were stimulated with either 10
mM F and 50 pM Al3+ (A1F4 ) to directly stimulate the heterotrimeric G protein and activate
PLC, assaying the [3H]inositol phosphate product as a control, or the cells were stimulated
with different concentrations of phorbol dibutyrate (PDBu) to stimulate PKC and
consequently activate PLD, assaying the [3H]phosphatidylbutanol product. The responses of
both PLC and PLD pathways to overexpression of 14-3-31; are shown in Figure 5.14.
Overexpression of 14-3-31; caused a slight decrease in the response to PLC compared to the
control vector, however this was not significant (p>0.05, Wilcoxon test; n=5) (Figure
5.14A). Furthermore, the signalling characteristics of PKC stimulated PLD were unaffected
by the overexpression of 14-3-31; (p>0.05, Wilcoxon test; n=5) (Figure 5.14B).
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The characteristics of 14-3-31; influences on receptor-independent PLC/PLD
signalling are broadly similar to those of the agonist-stimulated muscarinic receptor
responses found in Chapter 3. The small attenuation of the PLC response, although not
significant, was consistent and indicates that 14-3-31; may negatively regulate the signalling
of the heterotrimeric G protein to PLC. The close similarity of the PLD response to the
control would indicate that 14-3-3^ overexpression does not modulate this signalling
pathway to a high degree. There could be a number of reasons for this; it may be because
14-3-31; does not interact with PLD to provide any kind of functional role. Alternatively, it
may be that endogenous 14-3-3 can facilitate some aspect of the PKC-mediated stimulation
of PLD and so overexpression of the 14-3-31; isoform does not alter it. Or it may
demonstrate that interaction of the 14-3-31; with PLD may occur downstream of the PKC-
mediated activation of PLD. It was therefore determined to observe other 14-3-3 isoforms to
try and elucidate further whether there was isoform specificity involved in PKC-mediated
PLD activity.
The signalling assays were repeated to observe the effect of overexpression of the
\4-3-3r\ isoform. COS 7 cells were transiently transfected with empty control vector or
myc-14-3-3rj, made quiescent and radiolabelled with either [3H]inositol or [3H]palmitate 16
hours prior to the assay as before. The cells were then stimulated with A1F4" to activate the
PLC pathway, or different concentrations of PDBu to activate the PKC-dependent PLD
pathway, and the products of each were assayed for [3H] incorporation (Figure 5.15). The
overexpression of 14-3-3iq did not significantly affect the PLC response in COS 7 cells
compared to the control vector (p>0.05, Wilcoxon test; n=5). The PKC mediated PLD
response however, was significantly impaired with the overexpression of the \4-3-3r\
isoform (p<0.05, Wilcoxon test; n=5) at PDBu concentrations of 100 nM.
180

























Overexpression of 14-3-3£ does not affect PLC and PLD responses in COS 7 cells.
COS 7 cells, transiently transfected with empty control vector (•) or 14-3-3^-myc (A) were
stimulated for 20 minutes with either A1F4" (to directly activate the heterotrimeric G-protein
coupled PLC pathway; A) or various concentrations of the PKC activator phorbol dibutyrate
(to activate PLD; B). Although slightly reduced from those in the presence of control vector,
the PLC responses were not significantly affected by the expression of 14-3-31; (p>0.05,
Wilcoxon test; n=5). Furthermore, the phorbol ester-induced PLD responses were not
significantly different between control and 14-3-31; expressing cells (p>0.05, Wilcoxon test;
n=5).
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Figure 5.15
Overexpression of 14-3-3ri affects PLD but not PLC responses in COS 7 cells.
COS 7 cells, transiently transfected with empty control vector (•) or myc-14-3-3ri (A)
were stimulated for 20 minutes with either A1F4" (to directly activate the heterotrimeric G-
protein coupled PLC pathway; A) or various concentrations of the PKC activator phorbol
dibutyrate (to activate PLD; B). The response to A1F4" stimulation of PLC was not affected
by overexpression of 14-3-3r] (p>0.05, Wilcoxon test; n=5), however the PKC mediated
PLD response was significantly attenuated by overexpression of the 14-3-3r| isoform
(*p<0.05, Wilcoxon test; n=5).
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These data indicate that the isoform specificity of the 14-3-3 interaction with PLD
extends to a functional distinction. The attenuation of the PLD response with the
overexpression of 14-3-3r| suggests that 14-3-3 proteins do interact with PLD (or potentially
PKC) in a way that can modulate the activity of PLD in an isoform dependent manner. One
reason for this difference may be that the myc tag of 14-3-3rj is at the amino-terminus of the
protein compared to the carboxy-terminus on the 14-3-31; construct and this may impede
some aspect of the interaction that is necessary in vivo (but perhaps not the interaction in
vitro). However, this is unlikely, as the folding characteristics of the 14-3-3 dimer, coupled
with other experimental results, indicate that the carboxy-terminal myc-tag should not
interfere with 14-3-3 target association. Alternatively, the possible isoform specificity of the
14-3-3r] interaction with PLD2 compared to PLD1 may cause the functional differences
observed. It is known that in COS 7 cells, the majority of M3 receptor-stimulated PLD
activation is due to the PLD1 isozyme (Mitchell et al., 2003) and it has been proposed that
the basal activity of PLD2 is higher (Sung et al., 1999). The overexpression of the 14-3-3r]
isoform, which may preferentially couple to PLD2 rather than PLD 1, might possibly result
in the competitive inhibition of PLD1 activation by PKC. This may be due to the 14-3-3r)
coordinating the 'incorrect' PLD isozyme to PKC for activation (if the 14-3-3 proteins
generally perform such a role) or it may be due to some modulation of PLD post-activation.
Further information about the relative PLD isozyme activation by PKC (for example
mutagenesis studies) would be valuable in this cellular system.
The signalling assays were repeated for the 14-3-3e isoform in COS 7 cells. Empty
control vector or 14-3-3e-transfected COS 7 cells were assayed for the production of either
[3H]inositol phosphate (in response to A1F4" mediated PLC stimulation) or
[3H]phosphatidylbutanol (in response to PDBu-mediated, PKC-activated PLD stimulation)
(Figure 5.16). The PLC response to A1F4" in cells overexpressing 14-3-3e was moderately






































Overexpression of 14-3-3e does not affect PLC or PLD responses in COS 7 cells.
COS 7 cells, transiently transfected with empty control vector (•) or 14-3-3£-myc (A) were
stimulated for 20 minutes with either A1F4" (to directly activate the heterotrimeric G-protein
coupled PLC pathway; A) or various concentrations of the PKC activator phorbol dibutyrate
(to activate PLD; B). Although reduced from control vector expression, the PLC responses
were not significantly affected by the overexpression of 14-3-3e (p>0.05, Wilcoxon test;
n=5). Furthermore, the signalling characteristics of PLD were not significantly different
between control and 14-3-3e expressing cells (p>0.05, Wilcoxon test; n=5).
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(p>0.05, n=5). The PLD response to PDBu was unaffected by the overexpression of the 14-
3-3e isoform, similar to the lack of effect of the 14-3-31; isoform. It may be of relevance that
the myc-tag on 14-3-3 e construct is at the carboxy-terminal domain, as for 14-3-31;, which
also failed to affect functional PLD responses to PDBu (as above). The characteristics of the
signalling responses with the overexpression of 14-3-3e were thus generally quite similar to
those of the 14-3-31; isoform and this suggests that the isoform specificity may function as a
potential switch for facilitating the activation of one pathway (PLD) over another (PLC).
Summary
In this chapter, the interaction of 14-3-3 with PLD has been investigated as a result of the
novel observation that PLD isozymes contain consensus 14-3-3 interaction sequences, based
on the well characterised c-Raf RSxpSxP motif. Scansite analysis of the PLD sequences
reveals that the potential 14-3-3 recognition motif in PLD1, RSLSYP (712-717) is a high
stringency mode-1 phosphoserine based recognition sequence and that PLD2 has two lower
stringency mode-1 14-3-3 recognition motifs, RLLTMS (172-177) or KTPTYP (573-579)
(Obenauer et al., 2003). Furthermore, it has been found that isoforms of 14-3-3 may interact
with PLD isozymes in an isoform dependent manner in vitro. In addition, the 14-3-3
isoforms co-immunoprecipitate with PLD 1 and PLD2 with apparently different affinities
and the co-immunoprecipitation levels of 14-3-3 with PLD may potentially be modulated by
PKC activation. In addition, the intracellular colocalisation of the 14-3-3 isoforms with
PLDs has been investigated and it has been demonstrated that PKC stimulation appears to
alter the colocalisation characteristics of the proteins, again in an isoform dependent way.
Moreover, the overexpression of 14-3-3 isoforms has been shown to differentially modulate
the signalling characteristics of PKC-stimulated PLD responses in whole COS 7 cells, with
the unexpected finding that 14-3-3r] significantly attenuates the PKC-mediated PLD
response in COS 7 cells.
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These results suggest that 14-3-3 proteins do play an important and isoform
dependent functional role in the signalling of PLD in vivo, however the precise nature of
this role remains uncertain. Site-directed mutagenesis of the residues within PLD, thought to
be involved in the interaction with 14-3-3 (the putative consensus sequences), would be
very useful to determine whether the interaction took place at this location. Indeed, these
mutants would also yield valuable information with regard to the functional role of the
association in the PLD signalling response and whether 14-3-3 acted to facilitate the PKC
and PLD interaction (by coordinating them together as an adapter) or whether 14-3-3 acted
downstream of PLD activation (for example to facilitate the later PKC-mediated
phosphorylation and inactivation of PLD). Furthermore, determining the kinase that acts to
phosphorylate the potential 14-3-3 consensus sites on PLD would be very valuable, and the
possibility that PKC may be the kinase that phosphorylates both PLD 1 and PLD2 on these
sites, to later recruit 14-3-3 following PLD activation, remains feasible as they are all
medium stringency sites for PKC phosphorylation (Obenauer et al., 2003). Other kinases
that may potentially be responsible are Akt kinase for the domain on PLD1 and calmodulin
dependent kinase 2 for the domain on PLD2 (Obenauer et al., 2003). Moreover, the
recruitment of 14-3-3 may also perform some other function, such as facilitating the
activation of alternative intracellular signalling pathways or the facilitation of a PLD
dependent trafficking mechanism.
Additionally, it would be desirable to determine whether 14-3-3 proteins may act at
multiple stages of the signalling pathway, by investigating whether RGS proteins (by using
catalytically inactive RGS mutants) or PKC (by using specific inhibitors) were critical in the
14-3-3 modulation of any whole cell PLD signalling response. The investigation of other
14-3-3 isoforms (for example the homodimeric 14-3-3y) and their effect on the signalling of
PLD would also be of interest. Moreover, the use of live cell imaging and FRET with
fluorescently labelled PLD and 14-3-3 would be able to yield much more information with
respect to the nature of any PLD/14-3-3 interaction in vivo. It is clear that 14-3-3 may play
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an important role in GPCR signalling and that of related downstream pathways, such as







The delineation of signalling mechanisms is potentially an important route for developing
novel therapeutic targets. Traditionally, pharmacological agents have been developed that
act on cell surface receptors to modulate the intracellular environment. However, as the
complexity of signalling pathways becomes more and more apparent, it may be necessary to
investigate other, more specific, potential targets for drug design. In this study, the nature of
a novel involvement of 14-3-3 proteins in the phospholipid signalling mechanism of the M3
muscarinic receptor has been investigated. This may serve as a model for the organisation of
other G protein-coupled receptor mechanisms. It has been shown in Chapter 3 of this study
that the interaction of 14-3-3 isoforms with the M3 muscarinic receptor is similar to that of
the previous findings made by Prezeau and colleagues in the class A a2-adrenergic GPCR
and the findings made by Couve and colleagues in the class C metabotropic GABAb GPCR
(Prezeau et al., 1999; Couve et al., 2001). In those systems, the association of 14-3-3 with
the receptors was postulated to be providing a potential scaffolding or receptor localisation
function. However, the specific co-immunoprecipitation of the receptors with the 14-3-3
proteins was not demonstrated in those studies, suggesting that the affinity of the 14-3-3
interaction with the M3 receptor, in this system, is potentially higher than with those other
GPCRs (Prezeau et al., 1999; Couve et al., 2001). Furthermore, 14-3-3 proteins have been
shown to associate with other plasma membrane-associated proteins such as potassium
channels to provide a functional role in mediating the release of correctly assembled
multimeric channels from the endoplasmic reticulum (ER) or in targeting these proteins
correctly to the plasma membrane (Rajan et al., 2002; Yuan et al., 2003). The association of
14-3-3 with the M3 receptor is consistent with this type of role and it may be the case that
14-3-3 can facilitate M3 receptor trafficking from the trans-Golgi network, or 14-3-3 may
contribute to coordinating the insertion of the receptor into the plasma membrane. This role
is of interest in view of our further evidence, as demonstrated in Chapter 5, for interactions
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of PLD with 14-3-3 and the M3 receptor, since the ARF-dependent PLD activity in the
Golgi apparatus is thought to be important for vesicle budding from the trans-Golgi network
(Ktistakis et al., 1995; Ktistakis etal., 1996; Chen et al., 1997). Moreover, homologues of
14-3-3 proteins in the budding yeast Saccharomyces cerevisiae, BMH1 and BMH2, have
also been shown to be important in vesicular trafficking, where they can rescue Ache" non¬
viable strains, which are gene deletion mutants (knockouts) of the clathrin heavy chain
proteins (a coat protein involved in vesicular transport) (Gelperin et al., 1995). 14-3-3
proteins have also been shown to associate with phospholipid membranes in an isoform-
dependent manner (Roth et al., 1994; Jones et al., 1995). In view of the role of clathrin in
GPCR endocytosis (Zhang et al., 1996; Laporte et al., 1999; Oakley et al., 1999; Pierce et
al., 2000) the association of 14-3-3 with the M3 receptor indicates that 14-3-3, in addition to
providing a scaffolding role, may facilitate some type of exocytic/endocytic protein
assembly, for insertion into, or sequestration away from, the plasma membrane. It is known
that many GPCRs, including the M3 receptor, use a clathrin (and dynamin)-dependent
process for internalisation and this endocytic process may also involve PLD activity (Vogler
et al., 1999; Koch et al., 2003; Johnson et al., 2004). The potential for a role of 14-3-3 in
such mechanisms has not yet been directly investigated. However, there are thought to be
several atypical routes for GPCR endocytosis that remain mechanistically undefined (Claing
etal., 2000) and which may potentially involve 14-3-3 and PLD.
The demonstration in Chapter 4 that phospholipase D isozymes can interact with the
M3 muscarinic receptor is consistent with a potential role of PLD activation in mediating
endocytosis of GPCRs, as proposed by other groups (Koch et al., 2003; Du et al., 2004;
Koch et al., 2004). Evidence was provided to suggest that the endocytosis and recycling of
the p-opioid G protein-coupled receptor was dependent upon interaction with PLD2, but not
PLD1 (Koch et al., 2003). This may indicate that the efficient sequestration of at least some
of the receptors from the cell surface and perhaps the subsequent recycling of these
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receptors back to the plasma membrane could be dependent on PLD activity (Koch et al.,
2004). These results were supported by another group, who observed that the internalisation
of the angiotensin II (AT1a) receptor was also dependent upon PLD2 activity, although any
direct interaction between PLD2 and the AT,a receptor was not addressed (Du et al., 2004).
In the case of the angiotensin II receptor, it has been shown that PLD2 is the isozyme that is
predominantly activated upon agonist stimulation in A10 cells (Shome et al., 2000),
indicating that the preferentially coupled PLD isozyme may also mediate the internalisation
of the receptor. In other experiments performed by our group, we have shown that PLD 1 is
the isozyme that is preferentially activated by the M3 receptor in COS 7 cells (Mitchell et
al., 2003) and determined that catalytically inactive mutants of both PLD1 and PLD2
isozymes, as well as the PLD inhibitor calphostin C, can inhibit agonist mediated M3
receptor internalisation (Johnson et al., 2004). This therefore suggests that PLD1 is likely to
be able to mediate internalisation of the M3 receptor in this system. Moreover, receptor-
mediated PLD activity has been demonstrated to be important for internalisation of other
receptor classes, for example the epidermal growth factor (EGF) receptor tyrosine kinase
(Shen et al., 2001). PLD2 was shown to associate with the EGF receptor in a ligand-
independent manner (similarly to the findings within Chapter 4) and PLD1 was determined
to be the main mediator of internalisation via the activation of PKC (Slaaby et al., 1998;
Shen et al., 2001). Our findings indicate that either PLD1 or PLD2 may mediate M3 receptor
internalisation, however the implication that PLD1 is the preferred isozyme may be
supported by the evidence for a level of dissociation and subsequent re-association of PLD1
from the M3 receptor following agonist stimulation (Figures 4.6-4.7). The product of PLD
activity, phosphatidic acid, may be the bioactive species necessary for facilitating part of the
endocytic mechanism. PA has been shown to facilitate the binding of the GTPase dynamin
to lipid membranes to assist the formation of endocytic vesicles (Burger et al., 2000). The
precise mode of action is uncertain, however PA (with a small, highly polar head group)
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may alter the physical organisation of the plasma membrane to destabilise the interior
lipid:cytosolic interface and allow efficient vesicle budding (Andresen et al., 2002).
Moreover, PA has been implicated in facilitating the recruitment of the AP-2 adapter
complex and clathrin coats to lysosomal membranes, which is dependent on PIP2 synthesis
arising from the activation of phosphatidylinositol 4-phosphate 5-kinase by phosphatidic
acid (Arneson et al., 1999). The activation of PLD by the M3 receptor and subsequent
production of PA may provide a positive feedback mechanism for the necessary de novo
synthesis of PIP2 on the plasma membrane, and facilitate the sequestration of the receptor
away from the cell surface by modification of the lipid membrane or initiating the assembly
of endocytic machinery.
Evidence has been provided that EGF-induced activation of the MAPK pathway
was dependent on the PLD-mediated endocytosis of the EGF receptor (Shen et al., 2001).
Moreover, the co-activation of the MAPK cascade by some GPCRs has been shown to be
dependent upon clathrin-mediated endocytosis, whilst in other GPCRs it is not (Pierce et al.,
2000). However, several studies have revealed that inhibitors of the endocytic pathway can
act to inhibit co-activation of MAPK, regardless of whether or not the GPCR undergoes
endocytosis, as the co-activation of MAPK by agonist stimulation of the a2A-adrenergic
receptor (which is not endocytosed) could be prevented by monodansylcadaverine (a
blocker of an important endocytic protein - transglutaminase), a mutant dynamin and a
mutant beta-arrestin (Pierce et al., 2000). The M3 muscarinic receptor has been shown to
activate the MAP kinase pathway upon receptor stimulation and various reports suggest this
may or may not be dependent on internalisation (Bertram et al., 1998; Budd et al., 2000;
Budd et al., 2001). Additionally, phosphatidic acid, the product of PLD activity, has been
shown to be important for full activation of the MAPK pathway (Rizzo et al., 1999;
Andresen et al., 2002; Ghosh et al., 2003) and is produced concomitantly with M3 receptor
activation and internalisation. It is quite possible that the functional mechanisms arising
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from agonist stimulation, involving the activation of PLD, the production of phosphatidic
acid and the subsequent endocytosis of the M3 receptor, may facilitate the activation of a
signal crosstalk system that contributes to cellular MAPK pathway activation.
Furthermore, it has been previously demonstrated that 14-3-3 proteins interact with
c-Raf in the activation of the MAP kinase pathway, either by Ras or by PKCa (Kolch et al.,
1993; Fantl et al., 1994; Freed et al., 1994; Fu et al., 1994; Irie et al., 1994). 14-3-3 has
been shown to have an important trafficking and regulating role in this pathway, as it
facilitates the translocation and regulation of the cytosolic c-Raf to the membrane for
activation (and has been implicated in the activation mechanism itself) (Fantl et al., 1994;
Freed et al., 1994; Fu et al., 1994; Irie et al., 1994). Therefore the (possibly PLD dependent)
co-activation of MAPK by the M3 receptor may be facilitated by the presence of 14-3-3,
which may perform some functional adapter, trafficking or scaffolding role. The 14-3-3
dimer may act to coordinate two proteins together for activation, or it may be recruited by
regulatory modulation of another protein to facilitate the transport of that protein to another
cellular compartment. The interaction of 14-3-3 with the PLD isozymes in an isoform-
dependent manner, as presented in Chapter 5, is consistent with this type of role. The
potential 14-3-3 interaction motifs in PLD2 (KTPTYP or RLLTMS) are not as optimal for
14-3-3 interaction as that of PLD1 (RSLSYP) (Obenauer et al., 2003). The divergent nature
of the site may indicate that some isoforms of 14-3-3 are more particularly suited to
interacting with PLD2 than others (compared to the similar affinities of interaction of 14-3-3
with the more optimal, putative PLD1 motif). In this case, a candidate for specificity
conferred by the site would be the 14-3-3r| isoform, as inferred by the results in Chapter 5.
The interaction of PLD2 with 14-3-3r| appears to have a potentially higher affinity than that
between PLD2 and the other 14-3-3 isoforms. This contrasts with PLD1, which interacts
with 14-3-31; and 14-3-3r) with an apparently similar affinity (although they are not
necessarily colocalised to the same extent). The isoform specificity of 14-3-3 interaction
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with PLD may provide functional regulation of PLD localisation or activity and hence
influence downstream effects. Such a level of functional regulation, potentially provided by
the isoform specificity of interaction, is supported by the results of the whole cell PLD
signalling responses of Chapter 5. When the isoforms of 14-3-3 were overexpressed in COS
7 cells, the 14-3-31; and 14-3-3e isoforms did not markedly affect PKC-activated PLD
responses, compared to 14-3-3r], which significantly attenuated the PLD response (Figure
5.15). Whilst the modulation of the PKC-mediated PLD response with 14-3-3r| may be
attributed to conformational disruption due to the site of the tag (and this itself implies a
functional role for 14-3-3), an alternative reason for the effect of 14-3-3r| on PLD responses
could be that overexpression of 14-3-3r] may functionally inhibit the normal physiological
PKC-mediated activation of PLD (which may involve 14-3-31; or 14-3-3e, as
overexpression of these did not affect PKC-mediated PLD responses). This may be because
14-3-3r| might preferentially interact with PLD2 compared to PLD1 (and PLD2 does not
mediate the same functional role as PLD1 in this system), or it may be that 14-3-3r] has a
distinctly isoform-specific role that may facilitate inhibition of the PLD response. The
isoform specificity of the 14-3-3 association with PLD, coupled with the modulation of
interaction observed upon PKC stimulation, would suggest that 14-3-3 may mediate a
functional role during or after PLD activation rather than prior to activation. It has been
characterised previously that 14-3-3 and PKC isoforms directly interact (Meller et al., 1996;
Matto-Yelin et al., 1997). As PKC and PLD1 also associate directly in vivo (Singer et al.,
1996; Zhang et al., 1999), 14-3-3 may potentially act as an adapter or to scaffold and
stabilise the PKC/PLD interaction. The association of PKCa with both PLD1 and PLD2
isozymes is known to be increased with phorbol ester stimulation of PKC (Lee et al., 1997;
Sung et al., 1999; Chen and Exton, 2004). Furthermore, preliminary data suggest that the
interaction of 14-3-3e with PLD1 and perhaps also the interaction of 14-3-3r| with PLD2
may increase with PKC stimulation (Figures 5.4-5.6). One speculative role that 14-3-3
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might perform, may be to bind to PLD following activation by PKC and to facilitate
inhibition of the enzyme by binding to serine or threonine residues (phosphorylated by PKC
or some other unknown kinase) in the RSxpSxP-type 14-3-3 binding motif on PLD, to alter
some regulatory mechanism or to sequester PLD to another cellular compartment. Whilst a
major component of the M3 receptor-stimulated, ARF-mediated, PLD signalling pathway is
PLD 1-dependent in COS 7 cells (Mitchell el al., 2003), the PKC-stimulated PLD activity
may be potentially due to either of the isozymes. It has been proposed that PLD2 has a
higher basal activity in vivo and is not as sensitive to activation by the other intracellular
activators PKC, ARF and Rho (Jones et al., 1999). However, other groups have indicated
that PKC activates PLD2 with high potency (Chen and Exton, 2004). Determining the PLD
isozyme contribution from PKC-mediated PLD activity could indicate whether PLD2
activity represents an important component of the PKC-mediated PLD activity in COS 7
cells (and therefore whether it is more sensitive to 14-3-3 isoform overexpression). The 14-
3-3 dimer may then bind to PLD to potentially sequester PLD to another subcellular
compartment or 14-3-3 may bind to PLD to regulate or physically occlude an important site
on the enzyme (for example the catalytic HKD motif) in a similar way to the function that
14-3-3 performs with the RGS proteins.
The interaction of 14-3-3 with the regulator of G-protein signalling (RGS) proteins
(Benzing et al., 2000) has implicated 14-3-3 as providing a functional molecular switch for
the modulation of G-protein families and their downstream effectors. This study has shown
that overexpression of wild type and mutant 14-3-3 isoforms can functionally affect the
activation of M3 receptor-dependent PLC (Chapter 3) and PKC-dependent PLD (Chapter 5)
pathways in COS 7 cells. The significant attenuation of the M3 muscarinic receptor-
activated PLC responses by expression of wild type 14-3-3e (Figure 3.9) and the less
marked, but similar trend with overexpression of 14-3-31; (Figure 3.8) (but not by
overexpression of the 14-3-3 mutants) indicates that there may be a role for 14-3-3 isoform
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regulation of the PLC pathway. It has previously been shown that RGS proteins can
modulate heterotrimeric G proteins to preferentially couple the active receptor to different
intracellular effectors (Rumenapp et al., 2001). The results from the functional signalling
experiments in this study could be considered to be consistent with a potential role for 14-3-
3 in negatively regulating specific RGS subtype activity, as proposed by Benzing and
colleagues (Benzing et al., 2000). The modulation of M3 receptor-dependent (as shown in
Figures 3.8-3.9), but not A1F4" dependent (as shown in Figures 5.14-5.16), PLC responses by
overexpression of wild-type 14-3-3 isoforms would be consistent with the proposed
'molecular switch' mechanism of negative regulation of RGS proteins by 14-3-3 proteins. If
the PLC response to A1F4" stimulation potentially involves additional heterotrimeric G
proteins (and hence potentially additional RGS proteins) to those involved in mediating the
M3 receptor-induced PLC pathway, the expression of wild-type 14-3-3 and the resulting
modulation of the PLC signalling responses may specifically affect a subgroup of RGS
proteins; therefore only marginally attenuating a response to A1F4' in contrast to the greater
effect on M3 receptor responses. However, as the 14-3-3 proteins have only been
demonstrated to interact with RGS3 and RGS7 but not RGS4 (which is an RGS protein
demonstrated to act on Gq G proteins), any potential 14-3-3 isoform-specific effects may
not be attributable to this mechanism (Rumenapp et al., 2001; Benzing et al., 2002). Further
investigations would be necessary to determine more precisely the nature of 14-3-3
modulation of the M3 receptor-mediated signalling responses and any involvement of
further RGS subtypes.
Originally it was hypothesised that 14-3-3 may act as a functional linker protein to
potentially coordinate PLD to the M3 receptor for activation. The functional results of the
overexpression of the reduced affinity 14-3-3^ (T233D 14-3-31,) and dimerisation deficient
14-3-3e (A" 26 14-3-3e) mutants provided in Chapter 3 would seem to imply that this is not
the case, as they would be expected to modulate the M3 receptor-mediated PLD response if
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14-3-3 coordinated an M3 receptor:PLD interaction. However, other isoforms that have not
been investigated may have an additional functional affect on PLD responses in vivo. It has
been shown in Chapter 5 that the interaction between 14-3-3 and PLD is also modulated by
PKC stimulation and the isoform of 14-3-3 that is involved. This suggests that 14-3-3 may
possibly function to facilitate the association, activation or inactivation of PLD by PKC. In
addition, the modulation by 14-3-3 proteins of the signalling by the M3 receptor to different
effector pathways, indicates that there may potentially be two distinct functional roles for
14-3-3 in the regulation of intracellular effectors by the M3 receptor. The first role supports
the findings that 14-3-3 may regulate RGS activity (and may be consistent with the
association of 14-3-3 with the M3 receptor, as found in Chapter 3), indicating that 14-3-3
may regulate heterotrimeric G protein signalling to PLC (and possibly PLD) pathways. The
second role is suggested by evidence for the involvement of PLD in the internalisation of
the activated M3 receptor and the 14-3-3 isoform specific and PKC-modulated association
with PLD (as demonstrated in Chapters 4 and 5): This may indicate an involvement of 14-3-
3 with the potential co-activation of alternative intracellular signalling pathways following
cellular stimulation, or indeed with facilitating the potential PLD-dependent endocytic
mechanism of M3 receptor internalisation as demonstrated in Chapter 4.
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Concluding remarks
The functional and isoform specific interaction of the 14-3-3 proteins with the M3
muscarinic receptor and PLD isozymes has indicated an additional level of intracellular
regulation of GPCR signalling mechanisms that may be physiologically relevant.
The ligand recognition site for GPCRs has been one of the main targets for drug action - to
prevent or mimic the cellular influence of GPCR activation in a wide variety of
physiological systems. However, the activation of novel intracellular signalling mechanisms
(and the proteins that may potentially be a part of these mechanisms) may have important
implications for further drug therapies. Therefore further elucidating the intracellular
consequences of receptor activation is of major importance. This study has shown that the
combined techniques of biochemical analysis (GST-fusion and co-immunoprecipitation
studies) combined with confocal microscopy and functional pharmacological signalling
assays have been an important and powerful approach to determining these novel
intracellular interactions.
The involvement of the 14-3-3 proteins and PLD in the signalling by the M3
receptor has been demonstrated to be functionally important, however there remains a
dearth of information on the specific coupling mechanisms that would be valuable for future
investigation. Future studies may benefit from the use of fluorescence-tagged (for example,
enhanced cyan or yellow fluorescent protein; eCFP or eYFP) 14-3-3 and PLD isozymes in
order to determine whether they interact together in fixed or living cells with the use of
fluorescent resonance energy transfer analysis. This technique can identify whether the two
proteins are in extremely close proximity (a distance of less than 100 A) by measuring the
activation (energy emission) of an acceptor fluorophore by a donor fluorophore without the
emission of a photon. Further studies may also involve the collection of more signalling data
on the other 14-3-3 isoforms and mutants of those already investigated. In addition, site-
directed mutagenesis of the serine or threonine residues that are expected to be key elements
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within the RSxpSxP type 14-3-3 consensus domains on the PLD isozymes would be
extremely informative. These mutants could be expressed in whole cells to determine more
specifically the functional consequences of interrupting the interaction of 14-3-3 with PLD.
In addition, the difopein (dimeric 14-3-3 peptide inhibitor) plasmid construct, which can
also be heterologously expressed and which consists of two WLDLE 14-3-3 recognition-
type R18 peptides joined by a linker region (which can block both interaction sites within
the 14-3-3 amphipathic groove) would yield valuable information about the functional
interactions of 14-3-3 in GPCR signalling (Masters and Fu, 2001). Finally, the extension
and application of these experimental techniques to other members of the GPCR
superfamily would indicate whether 14-3-3 proteins provide a general functional role in the
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